=> fil reg
FILE 'REGISTRY' ENTERED AT 18:36:27 ON 14 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 DEC 2004 HIGHEST RN 796963-46-7
DICTIONARY FILE UPDATES: 13 DEC 2004 HIGHEST RN 796963-46-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d sta que l25
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
L3 10484 SEA FILE=REGISTRY SSS FUL L1
L4 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE
L6 553 SEA FILE=REGISTRY SUB=L3 SSS FUL L4
L7 STR



VAR G1=22/21/25
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 21
NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE
L8 62 SEA FILE=REGISTRY SUB=L6 SSS FUL L7
L9 46 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND 16.136.9/RID
L11 507 SEA FILE=REGISTRY ABB=ON PLU=ON L6 NOT L9
L12 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 11 3
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
L13 488 SEA FILE=REGISTRY SUB=L11 SSS FUL L12
L23 STR



```
REP G1=(1-4) A
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC  20
NUMBER OF NODES IS  17

STEREO ATTRIBUTES: NONE
L25         451 SEA FILE=REGISTRY SUB=L13 SSS FUL L23

100.0% PROCESSED    488 ITERATIONS                          451 ANSWERS
SEARCH TIME: 00.00.01


=> d his

     (FILE 'HOME' ENTERED AT 18:17:29 ON 14 DEC 2004)
               SET COST OFF

     FILE 'REGISTRY' ENTERED AT 18:20:29 ON 14 DEC 2004
L1               STR
L2             50 S L1
L3          10484 S L1 FUL
               SAV TEMP L3 ZINNA617/A
L4               STR L1
L5             28 S L4 SAM SUB=L3
L6            553 S L4 FUL SUB=L3
               SAV L6 ZINNA617A/A
L7               STR L4
L8             62 S L7 FUL SUB=L6
               SAV L8 ZINNA617B/A
L9             46 S L8 AND 16.136.9/RID
L10            16 S L8 NOT L9
L11           507 S L6 NOT L9
L12              STR L1
L13           488 S L12 FUL SUB=L11
               SAV L13 ZINNA617C/A
L14            19 S L11 NOT L13

     FILE 'HCAOLD' ENTERED AT 18:25:52 ON 14 DEC 2004
L15             0 S L13

     FILE 'HCAPLUS' ENTERED AT 18:25:56 ON 14 DEC 2004
L16            29 S L13
L17             3 S L16 AND (SCHOENAFINGER ? OR SCHONAFINGER ? OR DEFOSSA ? OR DE
L18             3 S L16 AND AVENTI?/PA,CS
L19             3 S L17,L18
```

```
L20          26 S L16 NOT L19
L21          25 S L20 AND (PD<=20020712 OR PRD<=20020712 OR AD<=20020712)
                SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 18:30:27 ON 14 DEC 2004
L22         393 S E1-E393
L23             STR L7
L24          21 S L23 SAM SUB=L13
L25         451 S L23 FUL SUB=L13
                SAV L25 ZINNA617D/A
L26          37 S L13 NOT L25
L27         362 S L25 AND L22

     FILE 'HCAPLUS' ENTERED AT 18:33:47 ON 14 DEC 2004
L28          24 S L27
L29          24 S L28 AND (PD<=20020712 OR PRD<=20020712 OR AD<=20020712)
L30           5 S L27 (L) (THU OR PKT OR PAC OR DMA)/RL
L31           8 S L27 AND (PHARMACEUT? OR PHARMACOL?)/SC,SX
L32           8 S L30,L31
L33           1 S L29 AND ?DIABET?
                E DIABETES/CT
                E E3+ALL
L34       83761 S E1+OLD,NT,PFT,RT OR E2+OLD,NT,PFT,RT OR E3+OLD,NT,PFT,RT
L35        4543 S NIDDM
L36           0 S L29 AND L34,L35
L37           8 S L32,L33
L38          16 S L29 NOT L37
L39           0 S L38 NOT AGROCHEM?/SC,SX

     FILE 'REGISTRY' ENTERED AT 18:36:27 ON 14 DEC 2004

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 18:36:44 ON 14 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 14 Dec 2004  VOL 141 ISS 25
FILE LAST UPDATED: 13 Dec 2004  (20041213/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=> d l19 all fhitstr tot

L19  ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2004 ACS on STN
AN   2004:60473  HCAPLUS
DN   140:128423
ED   Entered STN:  26 Jan 2004
TI   Preparation of heterocyclylbenzoylureas for treating type 2 diabetes
IN   Schoenafinger, Karl; Defossa, Elisabeth;
```

Kadereit, Dieter; Von Roedern, Erich; Klabunde, Thomas; Burger, Hans-Joerg; Herling, Andreas; Wendt, Karl-Ulrich
PA **Aventis Pharma Deutschland GmbH, Germany**
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA German
IC ICM C07D211-62
ICS C07D249-08; C07D257-04; C07D271-10; C07D253-06; C07D231-26; C07D307-68; C07D235-18; A61K031-17; A61P003-10
CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004007455	A1	20040122	WO 2003-EP7078	20030703
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10231627	A1	20040205	DE 2002-10231627	20020712
DE 10306503	A1	20040826	DE 2003-10306503	20030217
DE 10320326	A1	20041202	DE 2003-10320326	20030506
US 2004152743	A1	20040805	US 2003-617498	20030711
PRAI DE 2002-10231627	A	20020712		
DE 2003-10306503	A	20030217		
DE 2003-10320326	A	20030506		
US 2002-430782P	P	20021204		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004007455	ICM	C07D211-62
	ICS	C07D249-08; C07D257-04; C07D271-10; C07D253-06; C07D231-26; C07D307-68; C07D235-18; A61K031-17; A61P003-10
DE 10231627	ECLA	C07D211/60; C07D249/12; C07D253/06E1; C07D253/06E2; C07D257/04D2C4; C07D271/10B; C07D271/10D; C07D271/10D3; C07D307/68; C07D521/00B2E; C07D211/62; C07D231/26; C07D235/18; C07D249/08C3

OS MARPAT 140:128423
GI



I

AB Title compds. [I; R1, R2 = H, (substituted) A, OA, COA, CO2A, AlkCO2H, AlkCO2A; A = alkyl; Alk = alkylene; R3, R4 = F, Cl, Br, OH, NO2, CN,

(substituted) A, OA, alkenyloxy, alkynyl; R5 = H, F, Cl, Br, OH, NO2, CN, (substituted) A, OA, COA, AlkCO2H, AlkCO2A, SO2A, alkenyloxy, alkynyl; X = H, F, Cl, Br, OH, NO2, CN, (substituted) A, COA, AlkCO2H, AlkCO2A, SO2A, alkenyl, alkynyl, OA, SO1-2A, NHA, NA2, CO2H, CO2A, CONH2, CONHA, CONA2, SO2NH2, SO2NHA, SO2NA2, NHCOR6; R6 = H, A, cycloalkyl, cycloalkylalkylene, alkenyl, alkynyl, AlkCO2A, AlkCOA, AlkCO2H, AlkCONH2, aryl, Alkaryl, heteroaryl, Alkheteroaryl, heteroarylcarbonyl; het = 4-7 membered (substituted) heterocyclyl, with the exception of pyrrole; m = 1-5; n, p = 0-3], were prepared Thus, 1-(4-amino-3-fluorophenyl)-1H-[1,2,4]triazole (preparation given) and 2-chloro-4,5-difluorobenzoylisocyanate were stirred 30 min in MeCN to give 1-(2-chloro-4,5-difluorobenzoyl)-3-(2-fluor-4-[1,2,4]triazol-1-ylphenyl)urea. The latter at 10 μM gave 94% inhibition of activated glycogen phosphorylase.

ST heterocyclylbenzoylurea prepn type 2 diabetes treatment; benzoylurea azolyl prepn antidiabetic; glycogen phosphorylase inhibitor chlorofluorobenzoyltriazolylphenylurea prepn

IT Uncoupling protein
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(2, modulators coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT Uncoupling protein
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(3, modulators coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT Potassium channel
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ATP-dependent potassium channel modulators coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CART (cocaine- and amphetamine-regulated transcript), agonists coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT Histamine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(H3, H3 histamine agonists coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT Lipoprotein receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(LDL, LDL Receptor inducers coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MTP (microsomal triglyceride-exchanging protein), inhibitors coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT 5-HT reuptake inhibitors
(Serotonin reuptake inhibitors coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agonists coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT Bile acids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(bile acid resorption inhibitors coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cholesterol ester-exchanging, CETP inhibitors coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT 5-HT agonists
Antioxidants

Dopamine agonists
(coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT Sulfonylureas
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(corticotropin-releasing factor-binding, antagonists coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT Metabolism
(fat metabolism disorder treatment; preparation of heterocyclylbenzoylureas for
treating type 2 diabetes)

IT Pituitary hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(melanocortin receptor 4, agonists coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(metabolism, disorder treatment; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT Peroxisome proliferator-activated receptors
Retinoid X receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(modulators coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT Diabetes mellitus
(non-insulin-dependent, treatment; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT Antiarteriosclerotics
Antidiabetic agents
Human
(preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT Arteriosclerosis
(treatment; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α, PPAR α agonists coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT Thyroid hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β, agonists coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT Adrenoceptor agonists
(β3-, coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(γ, PPARγ agonists coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT 9027-63-8, ACAT
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ACAT inhibitors coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT 9015-71-8, CRF
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CRF- agonists coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT 57-88-5, Cholesterol, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(Cholesterol resorption inhibitors coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT 9002-79-3, Melanocyte stimulating Hormone 9011-97-6, CCK 31362-50-2, Bombesin 82785-45-3, Neuropeptide Y 169494-85-3, Leptin 193830-48-7, Urocortin 245359-74-4, Orexin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agonists coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT 24305-27-9, Thyrotropin-releasing hormone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(agonists coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT 119418-04-1, Galanin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT 300-62-9, Amphetamine 2295-31-0D, Thiazolidinedione, derivs.
9002-72-6, Growth hormone 9004-10-8, Insulin, biological studies
25614-03-3, Bromocriptin 54870-28-9, Meglitinide 129024-87-9, Doprexin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT 943-45-3D, Fibric acid, derivs.
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fibrates coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT 9000-92-4, Amylase 9001-62-1, Lipase 9004-02-8, Lipoprotein-Lipase
9027-95-6, ATP-Citrate-Lyase 9028-35-7, HMG-CoA reductase 9077-14-9, Squalene synthetase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors coadministration; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT 9035-74-9, Glycogen phosphorylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT **648916-89-6P 648917-24-2P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

IT **648916-81-8P 648916-82-9P 648916-83-0P**
648916-84-1P 648916-85-2P 648916-86-3P
648916-87-4P 648916-88-5P 648916-90-9P
648916-91-0P 648916-92-1P 648916-93-2P
648916-94-3P 648916-95-4P 648916-96-5P
648916-97-6P 648916-98-7P 648916-99-8P
648917-00-4P 648917-01-5P 648917-02-6P
648917-03-7P 648917-04-8P 648917-05-9P
648917-06-0P 648917-07-1P 648917-08-2P
648917-09-3P 648917-10-6P 648917-11-7P
648917-12-8P 648917-13-9P 648917-14-0P
648917-15-1P 648917-16-2P 648917-17-3P
648917-18-4P 648917-19-5P 648917-20-8P
648917-21-9P 648917-22-0P 648917-23-1P
648917-25-3P 648917-26-4P 648917-27-5P
648917-28-6P 648917-29-7P 648917-30-0P
648917-31-1P 648917-32-2P 648917-33-3P
648917-34-4P 648917-35-5P 648917-36-6P
648917-37-7P 648917-38-8P 648917-39-9P
648917-40-2P 648917-41-3P 648917-42-4P
648917-43-5P 648917-44-6P 648917-45-7P

648917-46-8P 648917-47-9P 648917-48-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclylbenzoylureas for treating type 2 diabetes)
IT 62-55-5, Thioacetamide 79-22-1, Methyl chloroformate 105-45-3, Methyl acetoacetate 289-96-3, 1,2,3-Triazine 364-74-9, 2,5-Difluoronitrobenzene 431-03-8, 2,3-Butanedione 448-19-1, 4-Fluoro-2-methoxynitrobenzene 498-94-2, Piperidine-4-carboxylic acid 506-68-3, Cyanogen bromide 525-76-8 541-41-3, Ethyl chloroformate 606-26-8 617-35-6, Ethyl pyruvate 1445-45-0, Trimethyl orthoacetate 2318-25-4 4138-26-5, Nipecotamide 5081-37-8 5805-39-0 21803-75-8, 4-Amino-3-chlorobenzonitrile 88578-89-6, 2-Chloro-4-fluorobenzoyl isocyanate 91527-90-1, 3-Methyl-4-nitrophenylhydrazine 175278-19-0 175278-23-6 359714-68-4, 3-Fluoro-4-nitrophenylhydrazine 634616-77-6 648917-82-2 648917-83-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocyclylbenzoylureas for treating type 2 diabetes)
IT 109060-70-0P 109060-71-1P 243984-30-7P 243984-31-8P 372192-42-2P 648917-49-1P 648917-50-4P 648917-51-5P 648917-52-6P 648917-53-7P 648917-54-8P 648917-55-9P 648917-56-0P 648917-57-1P 648917-58-2P 648917-59-3P 648917-60-6P 648917-61-7P 648917-62-8P 648917-63-9P 648917-64-0P 648917-65-1P 648917-66-2P 648917-67-3P 648917-68-4P 648917-69-5P 648917-70-8P 648917-71-9P 648917-72-0P 648917-73-1P 648917-74-2P 648917-75-3P 648917-76-4P 648917-77-5P 648917-78-6P 648917-79-7P 648917-80-0P 648917-81-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclylbenzoylureas for treating type 2 diabetes)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Aventis Pharma Gmbh; WO 0194300 A 2001 HCAPLUS
(2) Aventis Pharma Gmbh; WO 02096864 A 2002 HCAPLUS
(3) Aventis Pharma Gmbh; DE 10116768 A 2002 HCAPLUS
(4) Duphar Int Res; EP 0193249 A 1986 HCAPLUS
(5) Sandoz Ag; EP 0242322 A 1987 HCAPLUS
IT **648916-89-6P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclylbenzoylureas for treating type 2 diabetes)
RN 648916-89-6 HCAPLUS
CN Benzamide, 2-chloro-N-[[[2-chloro-4-(1H-tetrazol-5-yl)phenyl]amino]carbonyl]-4-fluoro- (9CI) (CA INDEX NAME)



L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:60456 HCAPLUS
DN 140:128158
ED Entered STN: 26 Jan 2004
TI Preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors for the treatment of diabetes
IN **Defossa, Elisabeth; Kadereit, Dieter; Klabunde, Thomas; Burger, Hans-Joerg; Herling, Andreas;**

Wendt, Karl-Ulrich; Von Roedern, Erich;
Schoenafinger, Karl
PA **Aventis Pharma Deutschland GmbH, Germany**
SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DT Patent
LA German
IC ICM C07C275-54
ICS C07D239-96; A61K031-17; A61P003-10
CC 25-21 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004007437	A1	20040122	WO 2003-EP6934	20030630
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004087659	A1	20040506	US 2003-616959	20030711
PRAI DE 2002-10231371	A	20020711		
US 2002-425600P	P	20021112		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004007437	ICM	C07C275-54
	ICS	C07D239-96; A61K031-17; A61P003-10

OS MARPAT 140:128158
GI



I



II

AB Title compds. I [W, X, Y = O, S; R9, R10, R11, R12 = H, halo, OH, etc.; R1, R2 = H, (un)substituted alkyl; R3, R4, R5, R6 = H, halo, OH, etc.; R7 = H, (un)substituted alkyl, e.g., OR13, NR14R15, etc.; R8 = NR18R19, OR20;

R13 = H, alkyl, alkenyl, etc.; R14, R15 = H, (un)substituted alkyl; R18, R19 = H, alkyl, alkenyl, etc.; R20 = alkyl, alkenyl, alkynyl, etc.] and their pharmaceutically acceptable salts were prepared For example, condensation of benzamine II (Z= H), e.g., prepared from 2-chloro-4-fluorobenzamide in 2-steps, and carbonochloridic acid Me ester afforded benzamide II (Z = COMe) in 55% yield. In glycogenphosphorylase-A (GPa) inhibition assays, 23-examples of compds. I, at 10 μM, exhibited 48-100% inhibition of GPa activity, e.g., benzamide II (Z = COMe) displayed 53% enzyme inhibition. Compds. I were claimed useful as antidiabetic agents.

ST phenylaminocarbonylbenzamide prepn glycogenphosphorylase inhibitor; antidiabetic agent phenylaminocarbonylbenzamide prepn glycogenphosphorylase inhibitor

IT 5-HT agonists
(5-HT1, medicaments with; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT 5-HT agonists
(5-HT1F, medicaments with a; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT Potassium channel
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ATP-sensitive, medicaments with agonists of; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT Lipoprotein receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(LDL, medicaments with modulators of; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Lp(a), medicaments with antagonist; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MTP (microsomal triglyceride-exchanging protein), medicaments with inhibitors of; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cholesterol ester-exchanging, medicaments with inhibitors of; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT Metabolism, animal
(disorder, treatment of; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT Neurotransmitter agonists
(histaminic H3, medicaments with; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT Cocaine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(medicaments with agonist of cocaine-amphetamine regulated transcript; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT Neuropeptide Y receptors
Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(medicaments with agonist of; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT Bile acids
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(medicaments with polymeric absorbents of; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT 5-HT reuptake inhibitors
Antidiabetic agents
Antioxidants
Peroxisome proliferators
(medicaments with; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT Sulfonylureas
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicaments with; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT Pituitary hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(melanocortin receptor 4, medicaments with agonist of; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT Lipids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(metabolic disorders, treatment of; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT Diabetes mellitus
(non-insulin-dependent, treatment of; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT Adrenoceptor agonists
(noradrenergic, medicaments with; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT Anabolic agents
Antiarteriosclerotics
Human
(preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT Arteriosclerosis
Hypoglycemia
(treatment of; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α, medicaments with agonist of; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT Adrenoceptor agonists
(β3-, medicaments with; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(δ, medicaments with agonist of; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT 31601-41-9P, N-(4-Methoxy-2-methylphenyl)acetamide 88578-89-6P, 2-Chloro-4-fluorobenzoylisocyanate 196194-97-5P 196194-98-6P 196194-99-7P, 2-Amino-5-methoxy-4-nitrobenzoic acid 634616-73-2P 634616-77-6P 648927-51-9P 648927-52-0P 648927-53-1P 648927-54-2P 648927-55-3P 648927-56-4P, 2-Amino-5-methoxy-4-nitrobenzamide 648927-57-5P, 6-Methoxy-7-nitro-1H-quinazoline-2,4-dione 648927-58-6P, 7-Amino-6-methoxy-1H-quinazoline-2,4-dione
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT 9002-79-3, Melanocyte stimulating Hormone 9011-97-6, CCK 9015-71-8, CRF 24305-27-9, Thyrotropin-Releasing Hormone 31362-50-2, Bombesin 119418-04-1, Galanin 169494-85-3, Leptin 193830-48-7, Urocortin
RL: BSU (Biological study, unclassified); BIOL (Biological study) (medicaments with agonist of; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT 245359-74-4, Orexin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (medicaments with agonist of; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT 1553-55-5, 3-Hydroxy-3-Methyl-Glutaryl Coenzyme A 9000-92-4, Amylase 9001-62-1, Lipase 9004-02-8, Lipoprotein lipase 9027-63-8, ACAT 9027-95-6, ATP citrate lyase 9077-14-9, Squalene synthetase
RL: BSU (Biological study, unclassified); BIOL (Biological study) (medicaments with inhibitors of; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT 57-88-5, Cholesterol, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (medicaments with resorption inhibitors of; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT 56-03-1, Biguanide 300-62-9, Amphetamine 943-45-3D, derivs. of 2295-31-0D, THIAZOLIDINEDIONE, derivative of 9002-72-6, Growth hormone 9004-10-8, Insulin, biological studies 25614-03-3, Bromocriptine 54870-28-9, Meglitinide 129024-87-9, Doprexin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (medicaments with; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT 9032-10-4, Glycogenphosphorylase-A
RL: BSU (Biological study, unclassified); BIOL (Biological study) (preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT 75-44-5, Phosgene 79-22-1 79-37-8, Oxalylchloride 99-59-2, 2-Methoxy-5-nitroaniline 102-50-1 108-24-7, Acetic acid anhydride 619-05-6 624-83-9, Methylisocyanate 631-61-8, Ammonium acetate 2285-12-3, 2-Trifluoromethylphenylisocyanate 7693-45-0 7757-79-1, Saltpeter, reactions 88578-90-9, 2-Chloro-4-fluorobenzamide 198151-91-6 296274-32-3, 2-Chloro-4,5-difluorobenzamide
RL: RCT (Reactant); RACT (Reactant or reagent) (preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

IT 648926-15-2P 648926-17-4P 648926-18-5P 648926-19-6P 648926-20-9P
648926-21-0P 648926-22-1P **648926-23-2P** 648926-24-3P
648926-25-4P 648926-26-5P 648926-27-6P 648926-28-7P 648926-29-8P
648926-30-1P 648926-31-2P 648926-32-3P 648926-33-4P 648926-34-5P
648926-35-6P 648926-36-7P 648926-37-8P 648926-38-9P 648926-39-0P
648926-40-3P 648926-41-4P 648926-42-5P 648926-43-6P 648926-44-7P
648926-45-8P 648926-46-9P 648926-47-0P 648926-48-1P 648926-49-2P
648926-50-5P 648926-51-6P 648926-52-7P 648926-53-8P 648926-54-9P
648926-55-0P 648926-56-1P 648926-57-2P 648926-58-3P 648926-59-4P
648926-60-7P 648926-61-8P 648926-62-9P 648926-63-0P 648926-64-1P
648926-65-2P 648926-66-3P 648926-67-4P 648926-68-5P 648926-69-6P
648926-70-9P 648926-71-0P 648926-72-1P 648926-73-2P 648926-74-3P
648926-75-4P 648926-76-5P 648926-77-6P 648926-78-7P 648926-79-8P
648926-80-1P 648926-81-2P 648926-82-3P 648926-83-4P 648926-84-5P
648926-85-6P 648926-86-7P 648926-87-8P 648926-88-9P 648926-89-0P
648926-90-3P 648926-91-4P 648926-92-5P 648926-93-6P 648926-94-7P
648926-95-8P 648926-96-9P 648926-97-0P 648926-98-1P 648926-99-2P

648927-00-8P 648927-01-9P 648927-02-0P 648927-03-1P 648927-04-2P
648927-05-3P 648927-06-4P 648927-07-5P 648927-08-6P 648927-09-7P
648927-10-0P 648927-11-1P 648927-12-2P 648927-13-3P 648927-14-4P
648927-15-5P 648927-16-6P 648927-17-7P 648927-18-8P 648927-19-9P
648927-20-2P 648927-21-3P 648927-22-4P 648927-23-5P 648927-24-6P
648927-25-7P 648927-26-8P 648927-27-9P 648927-28-0P 648927-29-1P
648927-30-4P 648927-31-5P 648927-32-6P 648927-33-7P 648927-34-8P
648927-36-0P 648927-38-2P 648927-40-6P 648927-42-8P 648927-43-9P
648927-44-0P 648927-45-1P 648927-46-2P 648927-47-3P 648927-49-5P
648927-50-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Aguro Kanesho Kk; JP 01034953 A 1989 HCAPLUS
(2) Anon; PATENT ABSTRACTS OF JAPAN 1989, V013(224), PC-599
(3) Aventis Pharma Gmbh; WO 0194300 A 2001 HCAPLUS
(4) Aventis Pharma Gmbh; WO 02096864 A 2002 HCAPLUS
(5) Ciba Geigy Ag; EP 0221847 A 1987 HCAPLUS
(6) Duphar Int Res; EP 0116729 A 1984 HCAPLUS
(7) Duphar Int Res; EP 0167197 A 1986 HCAPLUS

IT **648926-23-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphosphorylase-A inhibitors)

RN 648926-23-2 HCAPLUS

CN Benzamide, 2-chloro-N-[[[5-[[(ethylamino)carbonyl]amino]-2-(1-pyrrolidinyl)phenyl]amino]carbonyl]-4,5-difluoro- (9CI) (CA INDEX NAME)



L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:818392 HCAPLUS

DN 139:323338

ED Entered STN: 17 Oct 2003

TI Preparation of 4-(benzoylureido)benzoic acids as antidiabetics

IN **Defossa, Elisabeth; Kadereit, Dieter; Schoenafinger, Karl; Klabunde, Thomas; Burger, Hans-Joerg; Herling, Andreas; Wendt, Karl-Urlich; Von Roedern, Erich**; Enhsen, Alfons; Rieke-Zapp, Joerg

PA **Aventis Pharma Deutschland G.m.b.H., Germany**

SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2

DT Patent

LA German
IC ICM C07C275-54
ICS C07D295-12; A61K031-17; A61P007-12
CC 25-17 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003084922	A1	20031016	WO 2003-EP3251	20030328
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10215907	A1	20031106	DE 2002-10215907	20020411
US 2004077716	A1	20040422	US 2003-410601	20030410
PRAI DE 2002-10215907	A	20020411		
US 2002-402779P	P	20020812		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003084922	ICM	C07C275-54
	ICS	C07D295-12; A61K031-17; A61P007-12
DE 10215907	ECLA	C07C275/54; C07D295/14A1
US 2004077716	ECLA	C07C275/54; C07D295/14A1

OS MARPAT 139:323338
GI



I

AB Title compds. [I; R7-R10 = H, F, Cl, Br, OH, NO2, cyano, (substituted) alkoxy, alkenyloxy, alkynyloxy, alkylsulfonyloxy, alkyl, alkenyl, alkynyl; R1, R2 = H, (substituted) alkyl, alkoxy, etc.; R3-R6 = H, F, Cl, Br, NO2, cyano, OR11, OPh, SR11, CO2R11, NR12R13, (substituted) alkyl, alkenyl, alkynyl, etc.; R11 = H, (substituted) alkyl, alkenyl, alkynyl; R12, R13 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkylene, etc.] and physiol. acceptable salts thereof were prepared Thus, 2-chlorobenzoyl isocyanate (preparation given) in MeCN was refluxed with 4-amino-3-nitrobenzoic acid for 3.5 h to give 77% 4-[(2-chlorobenzoyl)ureido]-3-nitrobenzoic acid. The latter at 10 μM inhibited glycogen phosphorylase a with IC50 = 71%.
ST benzoylureidobenzoic acid prepn diabetes type 2 treatment; benzoic acid benzoylureido prepn antidiabetic
IT Diabetes mellitus
(non-insulin-dependent, treatment; preparation of (benzoylureido)benzoic acids as antidiabetics)

IT Antidiabetic agents
Human
(preparation of (benzoylureido)benzoic acids as antidiabetics)
IT 9032-10-4, Glycogen phosphorylase a
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibition of; preparation of (benzoylureido)benzoic acids as antidiabetics)
IT 613260-13-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of (benzoylureido)benzoic acids as antidiabetics)
IT 477343-25-2P 613259-63-5P 613259-64-6P 613259-65-7P 613259-66-8P
613259-67-9P 613259-68-0P 613259-69-1P 613259-70-4P 613259-71-5P
613259-72-6P 613259-73-7P 613259-74-8P 613259-75-9P 613259-76-0P
613259-77-1P 613259-78-2P 613259-79-3P 613259-80-6P 613259-81-7P
613259-82-8P 613259-83-9P 613259-84-0P 613259-85-1P 613259-86-2P
613259-87-3P 613259-88-4P 613259-89-5P 613259-90-8P 613259-91-9P
613259-92-0P 613259-93-1P 613259-94-2P 613259-95-3P 613259-96-4P
613259-97-5P 613260-00-7P 613260-02-9P 613260-04-1P 613260-05-2P
613260-06-3P 613260-07-4P 613260-08-5P 613260-09-6P 613260-10-9P
613260-11-0P 613260-12-1P 613260-14-3P 613260-15-4P 613260-16-5P
613260-17-6P 613260-18-7P 613260-19-8P 613260-20-1P 613260-21-2P
613260-22-3P 613260-23-4P 613260-24-5P 613260-25-6P 613260-26-7P
613260-27-8P 613260-28-9P 613260-29-0P 613260-30-3P 613260-31-4P
613260-32-5P 613260-33-6P 613260-34-7P 613260-35-8P 613260-36-9P
613260-37-0P **613260-38-1P** 613260-39-2P 613260-40-5P
613260-41-6P 613260-42-7P 613260-43-8P 613260-44-9P 613260-45-0P
613260-46-1P 613260-47-2P 613260-48-3P 613260-49-4P 613260-50-7P
613260-51-8P 613260-52-9P 613260-53-0P **613260-54-1P**
613260-55-2P 613260-56-3P 613260-57-4P 613260-58-5P
613260-59-6P 613260-60-9P 613260-61-0P 613260-62-1P 613260-63-2P
613260-64-3P 613260-65-4P 613260-67-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (benzoylureido)benzoic acids as antidiabetics)
IT 77-86-1, Tris 609-66-5, 2-Chlorobenzamide 1588-83-6, 4-Amino-3-nitrobenzoic acid 110877-64-0, 2-Chloro-4,5-difluorobenzoic acid 175278-22-5, 4-Amino-3-(trifluoromethoxy)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of (benzoylureido)benzoic acids as antidiabetics)
IT 4461-34-1P, 2-Chlorobenzoyl isocyanate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (benzoylureido)benzoic acids as antidiabetics)
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Aventis Pharma Deutschland Gmbh; WO 2002096864 A 2002
(2) Aventis Pharma Gmbh; WO 0194300 A 2001 HCAPLUS
(3) Basf Ag; EP 0298314 A 1989 HCAPLUS
(4) Duphar Int Res; EP 0136745 A 1985 HCAPLUS
(5) Duphar Int Res; EP 0193249 A 1986 HCAPLUS
(6) Sanwa Kaguku Kenkyusho Co Ltd; WO 02081463 A 2002 HCAPLUS
IT **613260-37-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (benzoylureido)benzoic acids as antidiabetics)
RN 613260-37-0 HCAPLUS
CN Benzoic acid, 4-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-3-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



=> d all hitstr tot l37

L37 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:20322 HCAPLUS
DN 140:87658
ED Entered STN: 11 Jan 2004
TI Peptidomimetic modulators of cell adhesion
IN Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie Denise; Wang, Shaomeng; Hu, Zengjian
PA Can.
SO U.S. Pat. Appl. Publ., 280 pp., Cont.-in-part of U.S. Ser. No. 6,982.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K038-00
NCL 514009000
CC 1-3 (**Pharmacology**)
Section cross-reference(s): 34, **63**
FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004006011	A1	20040108	US 2003-425557	20030428
	US 6031072	A	20000229	US 1997-893534	19970711
	US 6326352	B1	20011204	US 2000-507102	20000217
	US 2002168761	A1	20021114	US 2001-769145	20010124
	US 2002151475	A1	20021017	US 2001-6982	20011204
PRAI	US 1996-21612P	P	19960712		
	US 1997-893534	A1	19970711		
	US 2000-491078	B2	20000124		
	US 2000-507102	A1	20000217		
	US 2001-769145	B2	20010124		
	US 2001-6982	A2	20011204		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004006011	ICM	A61K038-00
	NCL	514009000
US 2004006011	ECLA	C07K007/06A; C07K007/56; C07K007/64; C07K014/705
US 6031072	ECLA	C07K014/705
US 2002168761	ECLA	C07K007/06A
US 2002151475	ECLA	C07K007/06A; C07K007/56; C07K007/64; C07K014/705

OS MARPAT 140:87658
AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
ST cadherin cell adhesion peptidomimetic QSAR cyclic peptide
IT Cadherins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(N-, cells bearing; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Astrocyte
(N-cadherin-bearing cell migration on; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Drug delivery systems
(carriers; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Epithelium
(cell, cadherin-mediated adhesion in; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Peptides, properties
RL: PRP (Properties)
(cyclic, conformation of; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Oligodendrocyte
Schwann cell
(demyelinating nerve diseases treatment with; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Nerve, disease
(demyelination; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Neoplasm
Skin
(drug delivery to; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Blood vessel
(endothelium, cell, cadherin-mediated adhesion in; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Synapse
(increase in stability of; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Angiogenesis
(inhibition; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Spinal cord, disease
(injury; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Eye, disease
(macula, degeneration; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Bioreactors
Membrane, biological
Microparticles
Ultrathin films
(modulator linking to; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Adhesion, biological
(modulators of; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional

structure)
IT Axon
(outgrowth, modulators of; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
IT Drug delivery systems
(patches; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
IT Angiogenesis inhibitors
Antitumor agents
Bladder, neoplasm
Bond angle
Cell migration
Combinatorial library
Conformation
Drug delivery systems
Drug screening
Electrostatic charge
Human
Hydrophobicity
Immunomodulators
Melanoma
Molecular modeling
Multiple sclerosis
Ovary, neoplasm
Peptidomimetics
Protein sequences
QSAR (structure-activity relationship)
Steric effects
Transplant and Transplantation
Wound healing
Wound healing promoters
(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
IT Cadherins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
IT Animal tissue culture
(peptidomimetics screening in; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
IT Blood vessel
(permeability increase in; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
IT Biological transport
(permeation, increase in blood vessel; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
IT Laboratory ware
(plastic dishes, modulator linking to; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
IT Laboratory ware
(plastic tubes, modulator linking to; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
IT Oligodendrocyte
(progenitor, demyelinating nerve diseases treatment with; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
IT Transplant and Transplantation

(skin; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Information systems
(storage, in structure determination; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Polymers, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(support matrixes; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Drug delivery systems
(sustained-release; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Medical goods
(sutures, modulator linking to; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Skin
(transplant; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT 57-88-5D, Cholest-5-en-3-ol (3β)-, glycoside derivs. 135-16-0, L-Glutamic acid, N-[4-[[(2-amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]- 487-49-0, Ethanone, 1-(2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)- 548-73-2, 2H-Benzimidazol-2-one, 1-[1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1,3-dihydro- 570-88-7, Cholest-4-ene-3,6-diol, (3β,6β)- 1210-66-8, 1H-Purin-6-amine, N-phenyl- 1482-74-2, 2-Propen-1-one, 3-phenyl-1-(2,3,4-trihydroxyphenyl)- 1699-40-7, Benzeneacetamide, 4-methoxy-N-[2-[3-methoxy-4-(phenylmethoxy)phenyl]ethyl]-3-(phenylmethoxy)- 1776-30-3, 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-phenyl- 2486-02-4, Benzoic acid, 3,4,5-trihydroxy-, 3-methylbutyl ester 2810-37-9, 1H-Isoindole-1,3(2H)-dione, 2-[5-(1H-benzotriazol-1-yl)propyl]- 2979-51-3, 1H-Imidazole, 1-(1-oxo-3-phenyl-2-propenyl)- 3242-68-0, L-Glutamic acid, N-[4-[[2-[(2-amino-1,4-dihydro-4-oxo-5-pyrimidinyl)amino]ethyl]amino]benzoyl]- 3257-73-6, 9H-Purin-6-amine, 9-[2,3,5-tris-O-(phenylmethyl)-β-D-arabinofuranosyl]- 3561-56-6, L-Asparagine, N2-[(phenylmethoxy)carbonyl]-, (4-nitrophenyl)methyl ester 3566-25-4, L-Glutamic acid, N-[4-[[2-(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)ethyl]amino]benzoyl]- 3575-07-3, 1H-Benzimidazole, 2,2'-(1,2-ethanediyl)bis- 3922-47-2, 1H-1,2,4-Triazol-3-amine, 5-[(phenylmethyl)thio]- 4672-96-2, Benzeneacetamide, 3-methoxy-N-[2-[4-methoxy-3-(phenylmethoxy)phenyl]ethyl]-4-(phenylmethoxy)- 5226-71-1, Benzene, 1,1'-[1,10-decanediylbis(oxy)]bis[3-nitro- 5341-00-4, 1,4-Naphthalenedione, 2-[3-(decahydro-2-naphthalenyl)propyl]-3-hydroxy- 5415-88-3, 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl-8-(4-phenylbutoxy)- 5421-95-4, Urea, (3-phenyl-1,2,4-oxadiazol-5-yl)- 5426-87-9, Benzamide, N-[(2,3,6,7-tetrahydro-1,3-dimethyl-2,6-dioxo-1H-purin-8-yl)methyl]- 5429-46-9, Benzamide, N-[2-(2,3,6,7-tetrahydro-1,3-dimethyl-2,6-dioxo-1H-purin-8-yl)ethyl]- 5446-36-6, 1H-Purin-6-amine, N-(4-methylphenyl)- 5454-50-2, Ethanone, 1-phenyl-2-(1H-purin-6-ylthio)- 5454-52-4, 1H-Purine, 6-[(2-phenoxyethyl)thio]- 5508-58-7, 2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)- 5534-95-2 5800-34-0, Pentanoic acid, 5-[[(1S)-2-[(4-nitrophenyl)amino]-2-oxo-1-(phenylmethyl)ethyl]amino]-5-oxo- 6286-57-3, 5(4H)-Isoxazolone, 4-(1,3-benzodioxol-5-ylmethylene)-3-phenyl- 6295-27-8, 7H-1,2,3-Triazolo[4,5-d]pyrimidin-7-one, 5-amino-2,6-dihydro-2-phenyl- 6300-80-7, Benzaldehyde, 4-(dimethylamino)-, 7H-purin-6-ylhydrazone 6320-71-4,

1,4-Naphthalenedione, 2-(4-cyclohexylbutyl)-3-hydroxy- 6322-09-4,
2(1H)-Quinoxalinone, 3-[2-(2-chlorophenyl)ethenyl]-7-methyl- 6323-88-2,
2(1H)-Quinoxalinone, 3-[2-(3-nitrophenyl)ethenyl]- 6323-89-3,
2(1H)-Quinoxalinone, 3-(2-phenylethenyl)- 6331-03-9, Benzaldehyde,
4-nitro-, 7H-purin-6-ylhydrazone 6338-84-7, 1H-Purine-2,6-dione,
3,7-dihydro-1,3,7-trimethyl-8-(2-phenylethyl)- 6340-76-7,
2,4-Pyrimidinediamine, 6-chloro-N4-(3-methylphenyl)- 6633-66-5,
2,4,6-Pyrimidinetriamine, N4-(4-bromophenyl)- 6807-82-5, L-Glutamic
acid, N-[4-[[(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-
L-α-glutamyl- 6962-62-5, 2-Propen-1-one, 3-(1,3-benzodioxol-5-yl)-
1-(2,4-dihydroxyphenyl)- 6975-34-4, 1H-Purine, 6-[(3-phenyl-2-
propenyl)thio]- 7781-29-5, 2,4-Pyrimidinediamine, 6-methyl-N4-phenyl-
10320-97-5, 1,2,3,4-Thiatriazol-5-amine, N-1-naphthalenyl- 13184-14-0,
L-Lysine, L-lysyl-L-lysyl- 13351-10-5, 2-Propen-1-one,
1-(2,4-dihydroxyphenyl)-3-(4-methoxyphenyl)- 13745-20-5, 2-Propen-1-one,
1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)- 15013-60-2,
Cholest-4-ene-3,6-diol, (3β,6α)- 15970-42-0,
1H-Imidazole-1,2-diamine, 4-(4-chlorophenyl)- 16856-21-6, L-Tryptophan,
N-[N-[(phenylmethoxy)carbonyl]-L-phenylalanyl]-, methyl ester
16879-84-8, L-Threonine, N-[(phenylmethoxy)carbonyl]-,
(4-nitrophenyl)methyl ester 17357-75-4, 1H-1,2,4-Triazole,
3-[[(4-methoxyphenyl)methyl]thio]- 17430-65-8, L-Tryptophan,
N-[(phenylmethoxy)carbonyl]-L-valyl-, methyl ester 17496-31-0,
1H-Imidazole, 4-[[(phenylmethyl)thio]methyl]- 18100-11-3,
1,4-Naphthalenedione, 2-(3-cyclohexylbutyl)-3-hydroxy- 18100-12-4,
1,4-Naphthalenedione, 2-[3-(4-chlorophenyl)propyl]-3-hydroxy-
18211-37-5, 1,4-Naphthalenedione, 2-hydroxy-3-[3-(4-methylphenyl)propyl]-
19312-13-1, 2-Propen-1-one, 1-(2,5-dihydroxyphenyl)-3-phenyl-
19484-75-4D, 2H-1-Benzopyran-2-one, 3,4-dihydro-7-hydroxy-4-methyl-,
furanoside derivative 19889-31-7, 1H-Imidazole-4-propanamide,
α-amino-N-2-naphthalenyl- 20621-49-2, 2-Propen-1-one,
1-(2,6-dihydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)- 20711-05-1,
L-Glutamic acid, N-[4-[[2-(2-amino-1,5,6,7-tetrahydro-4-hydroxy-6-
pteridinyl)ethyl]amino]benzoyl]- 21108-76-9, Imidazo[2,1-b]thiazol-3(2H)-
one, 5,6-dihydro-2-(3-phenyl-2-propenylidene)- 21658-45-7, Glycine,
L-arginyl-L-prolyl-L-prolyl- 23567-67-1, Phenol, 4-(1,2,3,4-thiatriazol-
5-ylamino)- 23815-88-5, 1-6-Bradykinin 24205-32-1, L-Glutamic acid,
N-[4-[[(2,4-diamino-5-methyl-6-quinazolinyl)methyl]amino]benzoyl]-
,diethylester 24386-39-8, Urea, N-1-naphthalenyl-N'-2-pyrimidinyl-
24829-12-7, Phenol, 2-[(1H-1,2,4-triazol-3-ylimino)methyl]- 26962-50-5,
2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(2-hydroxyphenyl)- 27069-81-4,
L-Glutamic acid, N-[4-[[(2-amino-1,4-dihydro-4-oxo-6-
quinazolinyl)methyl]amino]benzoyl]-, diethyl ester 27430-15-5,
4,6(1H,5H)-Pyrimidinedione, 5-[[4-(dimethylamino)phenyl]methylene]dihydro-
2-thioxo- 27430-17-7, 4,6(1H,5H)-Pyrimidinedione, dihydro-5-(3-phenyl-2-
propenylidene)-2-thioxo- 28005-33-6, Benzene, 1,1'-methylenebis[4-[(4-
nitrophenyl)thio]- 28246-23-3, Ethanone, 2-(1H-imidazol-2-ylthio)-1-
phenyl- 28772-56-7, 2H-1-Benzopyran-2-one, 3-[3-(4'-bromo[1,1'-biphenyl]-
4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy- 29654-52-2, Benzene,
1,1'-methylenebis[4-[(4-nitrophenyl)sulfonyl]- 30148-18-6, Methanone,
(4-chlorophenyl)(1-methyl-1H-imidazol-2-yl)- 30216-31-0D, Benzoxazole,
2-[2-(2-chlorophenyl)ethenyl]-, derivs. 30355-60-3, 1,3,5-Triazine-2,4-
diamine, 6-(chloromethyl)-N-phenyl- 30826-46-1, L-Glutamic acid,
N-[4-[[[5,7-bis(acetylamino)pyrido[3,4-b]pyrazin-3-
yl]methyl]methylamino]benzoyl]-, diethyl ester 30826-47-2, L-Glutamic
acid, N-[4-[[[6,8-bis(acetylamino)pyrido[2,3-b]pyrazin-2-
yl]methyl]methylamino]benzoyl]-, diethyl ester 33254-46-5,
6H-Purine-6-thione, 1,9-dihydro-9-(3-phenylpropyl)- 34396-76-4,
6H-Purin-6-one, 1,9-dihydro-9-(3-phenylpropyl)- 37664-31-6, Ethanone,
1-(4-chlorophenyl)-2-(1H-1,2,4-triazol-3-ylthio)- 40538-65-6,
5(4H)-Isoxazolone, 3-methyl-4-[(phenylamino)methylene]- 40816-36-2,
4,6-Pyrimidinediamine, 5-nitro-N-phenyl- 41266-78-8,
1H-1,2,4-Triazol-3-amine, 5-[[(4-chlorophenyl)methyl]thio]- 41600-13-9,

L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzo
yl]-L-γ-glutamyl- 42220-83-7, 2-Propen-1-one, 1-(2,4-
dihydroxyphenyl)-3-(3-hydroxyphenyl)- 46825-86-9, Pyrimidinetetramine,
N4-(4-bromophenyl)- 50602-77-2, L-Glutamic acid, N-[4-[[(2,4-diamino-6-
pteridinyl)methyl]methylamino]benzoyl]-, dibutyl ester 51646-15-2,
[1,2,4]Triazolo[1,5-a]pyrimidine, 5,7-dimethyl-2-[(phenylmethyl)thio]-
51893-98-2, Benzoic acid, 2-hydroxy-, [2-[(5-ethyl-1,4-dihydro-6-methyl-4-
oxo-2-pyrimidinyl)thio]-1-phenylethylidene]hydrazide 51934-26-0,
L-Glutamic acid, N-[4-[[(7-amino-1,5-dihydro-5-thioxopyrimido[5,4-e]-1,2,4-
triazin-3-yl)methyl]amino]benzoyl]-, diethyl ester, monohydrochloride
51934-28-2, L-Glutamic acid, N-[4-[[(5,7-diaminopyrimido[5,4-e]-1,2,4-
triazin-3-yl)methyl]amino]benzoyl]-, diethyl ester 54299-50-2,
2-Propen-1-one, 1-(2,4-dihydroxy-3,6-dimethoxyphenyl)-3-phenyl-
54395-52-7, 1H-Isoindole-1,3(2H)-dione, 5,5'-[(1-methylethylidene)bis(4,1-
phenyleneoxy)]bis[2-methyl- 56025-86-6, 1H-Purine-2,6-dione,
3,7-dihydro-3-methyl-7-(phenylmethyl)- 56307-99-4, Ethanone,
1-(2,4-dihydroxyphenyl)-2-(phenylthio)- 57710-80-2, 1H-Benzotriazole-1-
carboxylic acid, phenylmethyl ester 57808-66-9, 2H-Benzimidazol-2-one,
5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-
piperidinyl]-1,3-dihydro- 57966-42-4, L-Threonine, L-arginyl-L-tyrosyl-L-
leucyl-L-prolyl- 58677-09-1, L-Glutamic acid, N-[4-[[(2-amino-1,4-
dihydro-4-oxo-6-quinazolinyl)methyl]methylamino]benzoyl]-, diethyl ester
60045-61-6, 4,6(1H,5H)-Pyrimidinedione, dihydro-5-[(4-
methoxyphenyl)methylene]-2-thioxo- 60407-48-9, L-Isoleucine,
L-arginylglycyl-L-prolyl-L-phenylalanyl-L-prolyl- 60482-96-4, L-Leucine,
L-arginyl-L-prolyl-L-tyrosyl-L-isoleucyl- 61043-53-6,
L-Phenylalaninamide, N-(3-carboxy-1-oxopropyl)-L-alanyl-L-alanyl-N-(4-
nitrophenyl)- 64792-21-8, 2-Propenal, 3-phenyl-, (1,4-dihydro-6-methyl-4-
oxo-2-pyrimidinyl)hydrazone 64801-58-7, L-Aspartic acid,
N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-γ-
glutamyl- 65147-09-3, L-Argininamide, N-[(1,1-dimethylethoxy)carbonyl]-L-
leucylglycyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)- 65757-04-2,
L-Glutamic acid, N-[4-[[(1,2,3,4-tetrahydro-2-imino-1,3-dimethyl-4-oxo-6-
pteridinyl)methyl]amino]benzoyl]-, dimethyl ester 65757-05-3, L-Glutamic
acid, N-[4-[[(2-amino-3,4-dihydro-3-methyl-4-oxo-6-
pteridinyl)methyl]amino]benzoyl]-, dimethyl ester 65877-43-2D,
1,3-Benzenediol, 5-[2-(3-hydroxy-4-methoxyphenyl)ethenyl]-, glycoside
derivative 66048-53-1, Guanosine, 2',3',5'-tribenzoate 66147-31-7,
L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzo
yl]-, 5-butyl ester 67368-29-0, L-Alanine, L-methionyl-L-arginyl-L-
phenylalanyl- 67655-19-0, Phenol, 2,2'-[(2-hydroxy-1,3-
propanediyl)bis(oxy)]bis- 67836-16-2, Acetamide, 2-(2,4-dichlorophenoxy)-
N-1H-1,2,4-triazol-3-yl- 68047-41-6, 1,3,4-Oxadiazole,
2-(3-bromophenyl)-5-(2-naphthalenyl)- 68215-68-9, Phenol,
2-[4-amino-6-[(4-chlorophenyl)amino]-1,3,5-triazin-2-yl]-4-chloro-
68682-02-0, 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-
hydroxyphenyl)-8-(3-methyl-2-butenyl)- 68838-40-4, 1H-1,2,4-Triazole,
3-methyl-5-[(phenylmethyl)thio]- 69097-98-9, 4H-1-Benzopyran-4-one,
2,3-dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)- 69193-20-0,
4-Pyrimidinamine, 5-bromo-N-phenyl- 69480-15-5, 3H-1,2,4-Triazole-3-
thione, 5-[4-(1,1-dimethylethyl)phenyl]-1,2-dihydro- 70280-72-7,
L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl](phenylmethyl)ami
no]benzoyl]-, diethyl ester 70280-75-0, L-Glutamic acid,
N-[4-[[(2,4-diamino-6-pteridinyl)methyl]ethylamino]benzoyl]-, diethyl
ester 70539-54-7, L-Glutamic acid, N-[3,5-dichloro-4-[[(2,4-diamino-6-
pteridinyl)methyl]ethylamino]benzoyl]-, diethyl ester 70968-04-6,
L-Leucinamide, N-(3-carboxy-1-oxopropyl)-L-alanyl-L-alanyl-L-prolyl-N-(4-
nitrophenyl)- 71047-38-6, 1H-Imidazole, 1-(3,7-dimethyl-2,6-octadienyl)-
71074-46-9, Glycine, N-[N-[4-[[(2,4-diamino-6-
pteridinyl)methyl]methylamino]benzoyl]-L-γ-glutamyl]- 71074-48-1,
L-Aspartic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzo
yl]-L-α-glutamyl- 71074-49-2, L-Glutamic acid,
N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-α-

glutamyl- 71707-02-3, L-Glutamic acid, N-[N-[4-[[(2,4-diamino-6-pteridinyl)methyl]amino]benzoyl]-L-γ-glutamyl]- 72630-15-0, Glutamic acid, N-[4-[[2-(2-amino-1,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl)ethyl]amino]benzoyl]- 72682-77-0, L-Isoleucinamide, N-(3-carboxy-1-oxopropyl)-L-alanyl-L-alanyl-L-prolyl-N-(4-nitrophenyl)- 72704-76-8, 2-Propen-1-one, 3-(3,4-dihydroxyphenyl)-1-phenyl- 73554-90-2, L-Argininamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-L-seryl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)- 73572-58-4, L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-L-leucyl-L-phenylalanyl-L-leucyl- 74039-67-1, 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-8-(3-phenyl-2-propenyl)- 74405-42-8, Adenosine, N-benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-, 3'-(hydrogen butanedioate) 74405-44-0, Cytidine, N-benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-, 3'-(hydrogen butanedioate) 74853-69-3, L-Leucine, N2-acetyl-L-arginyl-L-arginyl-L-prolyl-L-tyrosyl-L-isoleucyl- 75651-68-2, L-Phenylalaninamide, N-(3-carboxy-1-oxopropyl)-L-phenylalanyl-L-prolyl-N-(4-nitrophenyl)- 75960-43-9, 1H-Imidazole-4-hexanoic acid, 5-(chloromethyl)-2,3-dihydro-ε,2-dioxo-, ethyl ester 76172-68-4, 1-Propanone, 3-(4-methoxyphenyl)-1-(2,4,6-trihydroxyphenyl)- 80032-99-1, 1H-1,2,4-Triazole, 3,3'-[1,4-butanediylbis(thio)]bis- 80360-08-3, L-Glutamic acid, N-[4-[[(2,4-diaminopyrido[2,3-d]pyrimidin-6-yl)methyl]amino]benzoyl]-,diethylester 81066-61-7, 2-Pyridinamine, 3-[[4-(1,1-dimethylethyl)phenyl]methoxy]- 81587-37-3, 3-Pyridinethiol, 2-[(2,6-diamino-4-pyrimidinyl)amino]-6-methyl- 82628-82-8, 1-Propanone, 3-(4-nitrophenyl)-1-(2,4,6-trihydroxyphenyl)- 82855-85-4, L-Glutamic acid, N-[4-[[(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido[3,2-d]pyrimidin-6-yl)methyl]amino]benzoyl]-, diethyl ester 85122-85-6, 1H-Isoindole-1,3(2H)-dione, 2,2'-[1,3-propanediylbis(4,1-piperidinediylmethylene)]bis- 86669-33-2, L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-, bis(1,1-dimethylethyl) ester 90259-60-2, Benzamide, 2-amino-N-[3-(1H-imidazol-1-yl)propyl]- 90259-61-3, Benzamide, 2-[[(4-chlorophenyl)sulfonyl]amino]-N-[3-(1H-imidazol-1-yl)propyl]- 92899-39-3, Glycine, L-valylglycyl-L-valyl-L-alanyl-L-prolyl- 92954-99-9, Glycine, 1-acetyl-L-prolyl-L-leucylglycyl-L-leucyl-L-leucyl-, ethyl ester 93515-01-6, L-Threonine, L-tyrosyl-L-prolyl-L-prolyl-L-α-glutamyl-L-prolyl-L-α-glutamyl- 93524-30-2, β-D-Glucopyranosiduronic acid, (3α,5β)-21-(acetyloxy)-20-[(aminocarbonyl)hydrazono]pregnan-3-yl, methyl ester, 2,3,4-triacetate 93674-97-6, L-Serine, L-arginylglycyl-L-α-glutamyl- 95192-21-5, L-Phenylalaninamide, N-(3-carboxy-1-oxopropyl)-L-phenylalanyl-L-alanyl-N-(4-nitrophenyl)- 95192-38-4, L-Phenylalaninamide, N-(3-carboxy-1-oxopropyl)-L-alanyl-L-valyl-L-prolyl-N-(4-nitrophenyl)- 95210-75-6, L-Proline, L-tyrosyl-L-prolyl-L-phenylalanyl-L-valyl-L-α-glutamyl-L-prolyl-L-isoleucyl- 98018-39-4, Ethanone, 2-[(2-amino-1H-purin-6-yl)thio]-1-phenyl- 98151-93-0, L-Proline, L-tyrosyl-L-prolyl-L-phenylalanyl-L-prolylglycyl-L-prolyl-L-isoleucyl- 100975-56-2, Benzaldehyde, 4-hydroxy-, (2,3,6,7-tetrahydro-1,3,7-trimethyl-2,6-dioxo-1H-purin-8-yl)hydrazone 102212-40-8, 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-8-[(2-phenylethyl)amino]- 103030-49-5, 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-5-nitro- 103398-43-2, Benzenemethanol, 2-[bis[2-[(4-nitrobenzoyl)oxy]ethyl]amino]-, 4-nitrobenzoate (ester) 105037-36-3, Benzenesulfonic acid, 4-[(7-chloro-4-quinazolinyl)amino]- 108608-63-5, Glycine, L-seryl-L-α-aspartylglycyl-L-arginyl- 110906-89-3, L-Phenylalaninamide, N-(3-carboxy-1-oxopropyl)-L-phenylalanyl-L-alanyl-L-alanyl-N-(4-nitrophenyl)- 111172-14-6, 1,3-Benzodioxole-5-carboxaldehyde, O-(2-thienylcarbonyl)oxime 112233-74-6, Carbamic acid, diphenyl-, 2-(acetylamino)-1H-purin-6-yl ester 113866-00-5, L-Argininamide, N-[(1,1-dimethylethoxy)carbonyl]-L-α-aspartyl-L-prolyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-, phenylmethyl ester 113866-16-3, L-Argininamide, N-[(1,1-dimethylethoxy)carbonyl]-L-α-glutamyl-L-alanyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-, phenylmethyl

ester 117889-48-2, 1H-Tetrazole, 5-[(2,4-dichlorophenoxy)methyl]-
118034-92-7, L-Threonine, L-histidyl-L-phenylalanyl-L-methionyl-L-prolyl-
120225-54-9, Benzenepropanoic acid, 4-[2-[[6-amino-9-(N-ethyl-β-D-
ribofuranuronamidosyl)-9H-purin-2-yl]amino]ethyl]- 121036-80-4,
1,2,4-Triazin-5(2H)-one, 6-[2-(4-methylphenyl)ethenyl]-3-phenyl-
121036-81-5, 1,2,4-Triazin-5(2H)-one, 6-[2-(4-methoxyphenyl)ethenyl]-3-
phenyl- 124485-41-2, L-Argininamide, N-[(phenylmethoxy)carbonyl]-L-valyl-
L-valyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)- 126235-09-4,
1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-8-(2-phenylethyl)-
128802-79-9, L-Phenylalaninamide, N-(3-carboxy-1-oxopropyl)-L-alanyl-L-
isoleucyl-L-prolyl-N-(4-nitrophenyl)- 131061-65-9, 7H-Purine-7-butanoic
acid, 1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-8-[(phenylmethyl)amino]-,
ethyl ester 132467-01-7, 2(1H)-Quinoxalinone, 3-[2-(2-
chlorophenyl)ethenyl]- 133061-57-1, 2,4-Pyrimidinediamine,
N4-(3,5-dichlorophenyl)-6-methyl- 134759-22-1, 1H-Thieno[3,4-d]imidazole-
4-pentanamide, N-[6-[[5-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-
1(3H),9'-[9H]xanthen]-5-yl)amino]thioxomethyl]amino]pentyl]amino]-6-
oxohexyl]hexahydro-2-oxo-, (3aS,4S,6aR)- 134796-34-2, 1H-1,2,4-Triazole,
3-[[(4-chlorophenyl)methyl]thio]- 137484-84-5, 1,3,5-Triazin-2-amine,
4-chloro-6-[3-(2-furanyl)propoxy]-N,N-dimethyl- 137833-31-9,
Myelopeptide 2 138194-56-6, 1H-Pyrrole-2,5-dione, 1-[3-[[(4-oxo-1,2,3-
benzotriazin-3(4H)-yl)oxy]carbonyl]phenyl]- 138915-75-0, L-Leucine,
N-acetyl-L-histidyl-L-tryptophyl-L-alanyl-L-valylglycyl-L-histidyl-
142206-40-4, 1H-Benzimidazole, 2,2'-(1,3-propanediyl)bis[1-methyl-
143113-41-1, L-Valine, L-Histidyl-L-Alanyl 146871-70-7,
4-Quinazolinamine, N-(3-chlorophenyl)-, monohydrochloride 148337-06-8,
Glycine, L-prolylglycyl-L-alanyl-L-isoleucyl-L-prolyl- 151358-70-2,
2-Propen-1-one, 1,1'-(2,6-pyridinediyl)bis[3-(4-hydroxyphenyl)-
152028-96-1, 1H-Imidazole, 4-[3-[(4-iodophenyl)methoxy]propyl]-
154719-25-2, L-Lysinamide, N-acetyl-L-tyrosyl-L-valyl-N-[(1S)-1-
(carboxymethyl)-3-[(2,6-dimethylbenzoyl)oxy]-2-oxopropyl]-N6-[5-
[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-
155373-59-4, 4H-1-Benzopyran-4-one, 3-[[4-(1H-tetrazol-5-yl)phenyl]methyl]-
155373-72-1, 4H-1-Benzopyran-4-one, 2-phenyl-7-[4-(1H-tetrazol-5-
yl)butoxy]- 160347-57-9D, 2(1H)-Pyrimidinone, 5-(4-pentylphenyl)-,
derivs. 185503-97-3, L-Lysine, N6-[[4-[[4-(dimethylamino)phenyl]azo]phen
yl]sulfonyl]-N2-[(9H-fluoren-9-ylmethoxy)carbonyl]- 188966-22-5D,
Phenol, 2-(2H-benzotriazol-2-yl)-4-(1,1-dimethylhexyl)-, derivs.
191411-47-9, 1H-Imidazole-5-methanol, 1-methyl-2-[(phenylmethyl)thio]-
194424-08-3, Glutamic acid, N-[4-[[3-(2-thienyl)-2-
quinoxalinyl]amino]benzoyl]-, dipropyl ester 195140-70-6, 1H-Imidazole,
1-[2-(phenylmethoxy)ethyl]- 196600-87-0, Tyrosine, N-
[(phenylmethoxy)carbonyl]norvalylglycyl-, methyl ester 197456-56-7,
1,4-Naphthalenedione, 2-[4-(decahydro-2-naphthalenyl)butyl]-3-hydroxy-
198488-04-9, Urea, N,N''-(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis[N'-(2-
methylphenyl)- 198632-08-5, L-Proline, glycyl-L-arginylglycyl-L-α-
glutamyl-L-threonyl- 199929-21-0, 1,4-Naphthalenedione,
2-hydroxy-3-[8-(4-methylphenoxy)octyl]- 200058-34-0,
1,4-Naphthalenedione, 2-(3-[1,1'-bicyclohexyl]-4-ylpropyl)-3-hydroxy-
200061-22-9, Phenol, 4,4'-(1-methylethylidene)bis-, bis(3,5-
dinitrobenzoate) 200431-98-7, 3-Pyridinemethanamine,
N-1H-1,2,4-triazol-3-yl- 200505-51-7, Decanedioic acid,
bis[[(4-ethoxy-3-methoxyphenyl)methylene]hydrazide] 200706-30-5,
4H-1,2,4-Triazol-4-amine, N-[(2,3-dihydro-1H-inden-5-yl)methylene]-
200706-45-2, 4-Imidazolidinone, 5-[(2,3-dihydro-1H-inden-5-yl)methylene]-2-
thioxo- 201997-13-9, 1,3-Benzenediol, 4-[[[2-hydroxy-2-(4-
nitrophenyl)ethyl]imino]methyl]- 202118-27-2, 1H-1,2,4-Triazol-3-amine,
N-[(2-iodophenyl)methylene]- 202118-28-3, 1H-1,2,4-Triazol-3-amine,
N-[(2-chlorophenyl)methylene]- 202332-09-0, 1,4-Benzenediol,
2-(6-methylheptyl)- 202528-15-2, Cyclo(L-alanyl-L-histidyl-L-alanyl-L-
valyl-L-α-aspartyl-L-isoleucyl) 206360-24-9, 4H-1-Benzopyran-4-
one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-3-(3-methyl-2-butenyl)-
210709-22-1, L-Alanine, N2-benzoyl-L-arginyl-L-phenylalanyl- 215434-58-5

, 1-Piperazinecarbothioamide, N-3-pyridinyl-4-[4-(trifluoromethyl)-2-pyrimidinyl]- 215655-36-0, Benzoic acid, 2-[[[2-[[4-(trifluoromethyl)-2-pyrimidinyl]amino]ethyl]amino]carbonyl]- 215657-86-6, 2-Pyrrolidinone, 1-[2-hydroxy-3-[4-[4-(trifluoromethyl)-2-pyrimidinyl]-1-piperazinyl]propyl]- 216299-43-3, 2,5-Pyrrolidinedione, 1-[[11-[(5-azido-1-naphthalenyl)oxy]-1-oxoundecyl]oxy]- RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT 216774-46-8, 4-Isoxazolecarboxamide, N-1H-benzotriazol-5-yl-5-methyl-3-phenyl- 218456-13-4, Urea, N-[2-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]-N'-phenyl- 218928-70-2, Benzamide, N-[3-(1H-imidazol-1-yl)propyl]-2-[(4-nitrobenzoyl)amino]- 218928-81-5, Benzamide, 2-[[[(2,6-dichlorophenyl)amino]carbonyl]amino]-N-[3-(1H-imidazol-1-yl)propyl]- 218929-60-3, Urea, N-(4-fluorophenyl)-N'-[4-(1,2,4-oxadiazol-3-yl)phenyl]- 219139-65-8, 4(1H)-Pyrimidinone, 2-[[[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]methyl]thio]- 219865-73-3, 2H-Isoindole-2-acetic acid, α-[3-(4H-1,3-benzodioxin-6-ylamino)-3-oxopropyl]-1,3-dihydro-1,3-dioxo- 220171-00-6, 1H-Imidazole, 2-[2-(4-methoxyphenyl)ethenyl]- 229971-59-9, L-Cysteinamide, L-cysteinyl-L-histidyl-L-alanyl-L-valyl-, cyclic (1→5)-disulfide 229971-81-7, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-L-alanyl-L-valyl-, cyclic (1→5)-disulfide 229971-83-9, L-Cysteinamide, N-acetyl-L-cysteinyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-L-isoleucyl-, cyclic (1→8)-disulfide 229971-84-0, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-L-alanyl-L-valyl-L-seryl-, cyclic (1→6)-disulfide 229971-85-1, L-Cysteinamide, N-acetyl-L-cysteinyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-, cyclic (1→7)-disulfide 229971-86-2, L-Cysteinamide, N-acetyl-L-cysteinyl-L-seryl-L-histidyl-L-alanyl-L-valyl-L-seryl-L-seryl-, cyclic (1→8)-disulfide 229971-87-3, L-Cysteinamide, N-acetyl-L-cysteinyl-L-seryl-L-histidyl-L-alanyl-L-valyl-, cyclic (1→6)-disulfide 229971-88-4, L-α-Asparagine, N2-acetyl-L-lysyl-L-histidyl-L-alanyl-L-valyl-, (5→1)-lactam 229971-89-5, L-Cysteinamide, L-cysteinyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-, cyclic (1→7)-disulfide 229971-90-8, L-Cysteinamide, L-cysteinyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-L-isoleucyl-, cyclic (1→8)-disulfide 229971-91-9, L-Cysteinamide, N-acetyl-L-cysteinyl-L-valyl-L-alanyl-L-histidyl-, cyclic (1→5)-disulfide 240799-81-9, Benzenamine, N-[2-(3-methyl-4-nitro-5-isoxazolyl)ethenyl]-4-phenoxy- 241154-06-3, 3-Furancarboxylic acid, 5-[1,1'-biphenyl]-4-yl-2-(trifluoromethyl)- 244278-78-2, Ethanone, 1-(4-chlorophenyl)-2-[(1-methyl-1H-imidazol-2-yl)thio]- 245435-74-9, 5-Pyrimidinecarbonitrile, 4-[(2,4-dichlorophenyl)amino]-2-methyl-6-(methylthio)- 252867-19-9, 1,2,4-Oxadiazole, 3-(chloromethyl)-5-(2-phenylethenyl)- 252867-33-7, 4(1H)-Pyrimidinone, 2-[[[5-(4-methyl-1,2,3-thiadiazol-5-yl)-1,2,4-oxadiazol-3-yl]methyl]thio]-6-propyl- 252914-56-0, 1,2,4-Oxadiazole, 3-[[(4-chlorophenyl)thio]methyl]-5-(4-methyl-1,2,3-thiadiazol-5-yl)- 252914-57-1, Pyridine, 2-[[[5-(4-methyl-1,2,3-thiadiazol-5-yl)-1,2,4-oxadiazol-3-yl]methyl]thio]- 254748-91-9, Urea, N-(4-chlorophenyl)-N'-[3-(1,2,4-oxadiazol-3-yl)phenyl]- 254748-92-0, Urea, N-methyl-N'-[3-(1,2,4-oxadiazol-3-yl)phenyl]- 254748-93-1, Urea, N-butyl-N'-[3-(1,2,4-oxadiazol-3-yl)phenyl]- 254748-94-2, Urea, N-[3-(1,2,4-oxadiazol-3-yl)phenyl]-N'-phenyl- 254748-97-5, Benzenamine, N-[(2-chloro-6-fluorophenyl)methylene]-3-(1,2,4-oxadiazol-3-yl)- 254749-34-3, Urea, [3-(1,2,4-oxadiazol-3-yl)phenyl]- 254753-72-5, 1,4-Benzenediol, 2-[2-methyl-5-(4-nitrophenyl)-2-oxazolidinyl]- 254880-42-7, 1,2,3-Thiadiazole, 4-[4-[(1H-1,2,4-triazol-3-ylthio)methyl]phenyl]- 254880-46-1, 1,2,3-Thiadiazole, 4-[4-[(1H-1,2,4-triazol-3-ylsulfonyl)methyl]phenyl]- 255377-83-4, Carbamic acid, [(2-oxo-2H-pyran-6-yl)carbonyl]-, phenyl ester

255378-13-3, 1,3,4-Oxadiazole-2-carboxamide, N-[[(5-methyl-3-isoxazolyl)amino]carbonyl]-5-phenyl- 255728-27-9, 1,2,4-Thiadiazole, 5-[4-[(4-fluorophenoxy)methyl]phenyl]- 255904-99-5, Pyrazinecarboxamide, N-(4-phenoxyphenyl)- 256414-57-0, 2-Thiophenecarboxamide, 4-phenyl-N-2-pyridinyl-5-(trifluoromethyl)- 256432-37-8, Ethanone, 1-[3-benzoyl-7-[(4-nitrophenyl)methyl]-1-indolizinyl]- 257287-79-9, 4-Isoxazolecarboxylic acid, 3,5-dimethyl-, 2,3-dihydro-3-oxo-6-benzofuranyl ester 258264-27-6, Thiourea, N-(2,4-dichlorophenyl)-N'-[2-(1H-imidazol-1-yl)-1-phenylethyl]- 258521-36-7, Ethanimidamide, 2-[4-(1,3,4-oxadiazol-2-yl)phenoxy]-N-[[3-(trifluoromethyl)benzoyl]oxy]- 260368-01-2, 2-Butenoic acid, 4-oxo-4-[4-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- 260555-63-3, 1,2,4-Oxadiazole, 3-(2-thienyl)-5-[2-[4-(trifluoromethoxy)phenyl]ethenyl]- 261511-13-1, 1H-1,2,4-Triazole, 3-(3,5-dichlorophenyl)-5-[[(2,4-dichlorophenyl)methyl]thio]- 261511-30-2, 1H-1,2,4-Triazole, 3-[3,5-bis(trifluoromethyl)phenyl]-5-[[(2-chloro-6-fluorophenyl)methyl]thio]- 261626-76-0, Hydrazinecarboxamide, 2-(2,6-dichlorophenyl)-N-[3-(3-methylphenyl)-1,2,4-oxadiazol-5-yl]- 261626-98-6, 1H-1,2,4-Triazole, 3-[4-(1,1-dimethylethyl)phenyl]-5-[(phenylmethyl)thio]- 261626-99-7, 1H-1,2,4-Triazole, 3-[4-(1,1-dimethylethyl)phenyl]-5-[[(4-methylphenyl)methyl]thio]- 261627-00-3, 1H-1,2,4-Triazole, 3-[[(2,4-dichlorophenyl)methyl]thio]-5-[4-(1,1-dimethylethyl)phenyl]- 261704-50-1, 1H-1,2,4-Triazole, 3-[[(2-chlorophenyl)methyl]thio]-5-(4-pentylphenyl)- 261705-07-1, 1H-1,2,4-Triazole, 3-[[(4-methylphenyl)methyl]thio]-5-(trifluoromethyl)- 261765-01-9, Benzoic acid, 2-(1,4,5,6-tetrahydro-2-pyrimidinyl)-, [(4-nitrophenyl)methylene]hydrazide 261928-97-6, 1H-1,2,4-Triazol-3-amine, 5-[[(2,6-dichlorophenyl)methyl]thio]- 261928-98-7, 1H-1,2,4-Triazol-3-amine, 5-[[(2-chloro-6-fluorophenyl)methyl]thio]- 262856-19-9, 4H-1,2,4-Triazole, 3-(1-ethyl-3-methyl-1H-pyrazol-5-yl)-4-methyl-5-[(phenylmethyl)thio]- 263160-48-1, 1,2,4-Oxadiazole-5-carboxylic acid, 3-(2-methyl-4-thiazolyl)-, 2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]hydrazide 263161-07-5, 3(2H)-Benzoxazolepropanoic acid, 2-oxo-, 4-chlorophenyl ester 263161-08-6, 3(2H)-Benzoxazolepropanoic acid, 2-oxo-, 3-(trifluoromethyl)phenyl ester 263161-09-7, 3(2H)-Benzoxazolepropanoic acid, 2-oxo-, 3-chlorophenyl ester 263563-52-6, 1,2,4-Oxadiazole-5-carboxylic acid, 3-[4-(trifluoromethoxy)phenyl]-, 2-[[(3-chlorophenyl)amino]carbonyl]hydrazide 263563-53-7, 1,2,4-Oxadiazole-5-carboxylic acid, 3-[4-(trifluoromethoxy)phenyl]-, 2-[(phenylamino)carbonyl]hydrazide 263563-54-8, 2(3H)-Benzoxazolone, 3-[2-[[[(phenylamino)carbonyl]oxy]imino]propyl]- 263563-55-9, 2(3H)-Benzoxazolone, 3-[2-[[[[(3-chlorophenyl)amino]carbonyl]oxy]imino]propyl]- 263563-75-3, Urea, N-1-piperidinyl-N'-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]- 263756-04-3, 1H-Pyrazole-1-carboxamide, 3,5-dimethyl-N-phenyl-4-(2-pyrimidinylthio)- 263756-06-5, 1H-Pyrazole, 1-(4-chlorobenzoyl)-3,5-dimethyl-4-(2-pyrimidinylthio)- 263897-82-1, Ethanone, 1-[2-(5-isoxazolyl)-4-thiazolyl]-, O-[3-(trifluoromethyl)benzoyl]oxime 263917-87-9, L-Cysteinamide, N-acetyl-L-cysteinyl-L-leucyl-L-arginyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-, cyclic (1→8)-disulfide 263917-88-0, L-Cysteinamide, N-acetyl-L-cysteinyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-, cyclic (1→6)-disulfide 263917-89-1, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-, cyclic (1→6)-disulfide 263917-90-4, L-Cysteinamide, N-acetyl-L-cysteinyl-L-arginyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-, cyclic (1→8)-disulfide 263917-92-6, L-Cysteinamide, N-acetyl-L-cysteinyl-L-seryl-L-histidyl-L-alanyl-L-valyl-L-seryl-, cyclic (1→7)-disulfide 263917-93-7, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-L-alanyl-L-valyl-L-seryl-L-seryl-, cyclic (1→7)-disulfide 264127-43-7, Ethanone, 2-[[4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]thio]-1-phenyl- 264610-37-9, Thiazolo[3,2-b][1,2,4]triazole, 2-(4-chlorophenyl)-6-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)- 265329-88-2, 1,3,5-Triazin-2-amine,

4-[[4-(1,1-dimethylethyl)phenoxy]methyl]-6-methyl- 266679-45-2D, 4(1H)-Pyrimidinone, 6-(chloromethyl)-2-[[4-(1,1-dimethylethyl)phenoxy]methyl]-, derivs. 271775-62-3, Acetamide, N-(4-cyclohexylphenyl)-2-[(1-methyl-1H-imidazol-2-yl)thio]- 273920-93-7, 4H-1-Benzopyran-4-one, 2-phenyl-7-(1H-tetrazol-5-ylmethoxy)- 280133-36-0, Benzenepropanoic acid, β-[2-[(benzo[b]thien-3-ylmethyl)amino]-2-oxoethyl]- 281211-72-1, Benzenesulfonic acid, 4-methyl-, [(2,4-dihydroxyphenyl)methylene]hydrazide 284674-47-1, 1,3,5-Triazine-2-carboxylic acid, 4-amino-6-[(2,4,6-trifluorophenyl)amino]-, methyl ester 286440-09-3, 1,3-Benzenediol, 4-(2-phenylthiazolo[3,2-b][1,2,4]triazol-6-yl)- 288161-26-2, Pyrimidine, 5-[3-(4-chlorophenyl)-5-isoxazolyl]- 289626-25-1, L-Proline, N2-benzoyl-L-arginylglycyl-L-phenylalanyl-L-phenylalanyl- 293762-17-1, Benzoic acid, 4-[4-[[2,3-dihydro-2-(3-nitrophenyl)-1,3-dioxo-1H-isoindol-5-yl]carbonyl]phenoxy]- 294878-31-2, 2-Pyrimidinamine, 4-chloro-6-(2,4-dimethylphenoxy)- 294878-32-3, 2-Pyrimidinamine, 4-(2,4-dimethylphenoxy)-6-fluoro- 296272-93-0, 1H-1,2,4-Triazole, 3-[[(4-nitrophenyl)methyl]thio]- 299461-73-7, 2-Propen-1-one, 1-(4-methylphenyl)-3-[(4-methyl-4H-1,2,4-triazol-3-yl)thio]- 301174-11-8, 4(1H)-Pyrimidinone, 2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-6-hydroxy- 301201-59-2, 1H-1,2,4-Triazol-3-amine, N-[(3-methylphenyl)methylene]- 301304-52-9, Benzaldehyde, 2,4-dimethoxy-, (1,4-dihydro-6-methyl-4-oxo-2-pyrimidinyl)hydrazone 302804-66-6, 1H-1,2,4-Triazole, 3-[[(4-methylphenyl)methyl]thio]- 303016-22-0, 1H-Benzimidazole, 2-[(imidazo[2,1-b]thiazol-6-ylmethyl)thio]- 303145-16-6, 4H-Pyrido[1,2-a]-1,3,5-triazin-4-one, 2-[[[4-(1,1-dimethylethyl)phenyl]methyl]thio]- 303147-94-6, Benzoic acid, 2-[[6-[[(4-chlorophenyl)sulfinyl]methyl]-2-(4-pyridinyl)-4-pyrimidinyl]thio]-, methyl ester 303148-00-7, Benzoic acid, 2-[[6-[[(4-chlorophenyl)sulfinyl]methyl]-2-(4-pyridinyl)-4-pyrimidinyl]oxy]-, methyl ester 303150-34-7, 1H-1,2,4-Triazol-3-amine, 5-[[(2,4-dichlorophenyl)methyl]thio]- 303150-56-3, 1H-1,2,4-Triazol-3-amine, 5-[[[3-(trifluoromethyl)phenyl]methyl]thio]- 306280-22-8, Imidazo[1,2-a]pyridine, 6-chloro-2-[[(4,6-dimethyl-2-pyrimidinyl)thio]methyl]- 306936-17-4, 1H-Pyrrole-3-carboxylic acid, 5-(1,1-dimethylethyl)-2-methyl-1-[3-(4-morpholinyl)propyl]- 306936-72-1, 1,2,4-Oxadiazole, 5-(chloromethyl)-3-[(4-nitrophenoxy)methyl]- 306936-82-3, 3H-1,2,4-Triazole-3-thione, 2,4-dihydro-5-methyl-4-[4-(phenylmethoxy)phenyl]- 307316-86-5, 2-Quinazolinecarboxylic acid, 4-[(2-chlorophenyl)amino]-, ethyl ester 307526-33-6, 1,3-Benzenediol, 4-[4-(2-benzothiazolyl)-1H-pyrazol-3-yl]-6-ethyl- 307545-27-3, 1H-1,2,4-Triazole, 3-[[(3-methylphenyl)methyl]thio]- 313493-34-4, 1H-Isoindole-1,3(2H)-dione, 2,2'-(1,4-piperazinediyldi-4,1-butanediyl)bis- 315197-15-0, L-α-Asparagine, L-lysyl-L-histidyl-L-alanyl-L-valyl-, (5→16)-lactam 317320-21-1, Cyclo(L-alanyl-L-valyl-L-seryl-L-seryl-L-seryl-L-histidyl) 317822-46-1, 4H-Pyrrolo[3,4-d]isoxazole-4,6(5H)-dione, 5-[2-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]ethyl]-3a,6a-dihydro-3-(3-methyl-5-oxo-1-phenyl-1,2,4-triazolidin-3-yl)- 317822-47-2, 4H-Pyrrolo[3,4-d]isoxazole-4,6(5H)-dione, 5-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methylamino]-3-[1-(2,4-dichlorophenyl)-3-methyl-5-oxo-1,2,4-triazolidin-3-yl]-3a,6a-dihydro- 317822-54-1, 4H-Pyrrolo[3,4-d]isoxazole-4,6(5H)-dione, 5-[2-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]ethyl]-3-[1-(2,4-dichlorophenyl)-3-methyl-5-oxo-1,2,4-triazolidin-3-yl]-3a,6a-dihydro- 319916-73-9, 1(2H)-Quinolinepropanoic acid, 6-[(4-cyanophenyl)azo]-3,4-dihydro-, methyl ester 321385-59-5, 1H-Pyrazole-1-carboxamide, 3-[4-(1H-imidazol-1-yl)phenyl]-N-phenyl- 321430-85-7, 1H-Benzimidazole, 5-chloro-2-(1H-1,2,4-triazol-1-ylmethyl)- 321432-26-2, 3-Isoxazolecarboxylic acid, 5-[[[1-[[[(4-chlorophenyl)methoxy]imino]methyl]-2-naphthalenyl]oxy]methyl]-4,5-dihydro-, ethyl ester 321433-43-6, 1,2,4-Triazolidin-3-one, 2-(2-fluorophenyl)-5-[3-(4-fluorophenyl)-2,1-benzisoxazol-5-yl]-5-methyl- 321433-44-7, 1,2,4-Triazolidin-3-one, 2-(3-fluorophenyl)-5-[3-(4-fluorophenyl)-2,1-benzisoxazol-5-yl]-5-methyl- 321576-71-0, Benzoic acid, 2-chloro-,

[4-[[(3,4,5-trimethoxybenzoyl)oxy]imino]-2,5-cyclohexadien-1-ylidene]hydrazide 321682-33-1, Benzoic acid, 4-bromo-, [4-[[(3,4,5-trimethoxybenzoyl)oxy]imino]-2,5-cyclohexadien-1-ylidene]hydrazide 321682-97-7, Benzoic acid, 2-bromo-, [4-[[(3,4,5-trimethoxybenzoyl)oxy]imino]-2,5-cyclohexadien-1-ylidene]hydrazide 321949-09-1, Benzoic acid, 4-chloro-, [4-[[(3,4,5-trimethoxybenzoyl)oxy]imino]-2,5-cyclohexadien-1-ylidene]hydrazide 321998-82-7, Pyrimidine, 2-[4-(1H-pyrazol-3-yl)phenoxy]- 321998-88-3, 1H-Pyrazole, 1-benzoyl-3-[4-(2-pyrimidinyloxy)phenyl]- 324546-09-0, 2-Thiophenecarboxamide, N-[4-[(2-pyrimidinylamino)sulfonyl]phenyl]- 328917-75-5, 1-Piperidinecarboxylic acid, 4-[(1H-imidazol-1-ylcarbonyl)oxy]-, 4-phenoxyphenyl ester 329079-25-6, Acetamide, N-(3-chlorophenyl)-2-[(4-methyl-4H-1,2,4-triazol-3-yl)thio]- 331229-47-1, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidylglycyl-L-valyl-, cyclic (1→5)-disulfide 331229-48-2, L-α-Asparagine, N2-acetyl-L-lysyl-L-histidylglycyl-L-valyl-, (5→1)-lactam 331229-49-3, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidylglycyl-L-valyl-L-α-aspartyl-, cyclic (1→6)-disulfide 331229-50-6, L-Cysteinamide, N-acetyl-L-cysteinyl-L-alanyl-L-histidylglycyl-L-valyl-, cyclic (1→6)-disulfide 331229-51-7, L-Cysteinamide, N-acetyl-L-cysteinyl-L-alanyl-L-histidylglycyl-L-valyl-L-α-aspartyl-L-isoleucyl-, cyclic (1→8)-disulfide 331229-52-8, L-Cysteinamide, N-acetyl-L-cysteinyl-L-arginyl-L-alanyl-L-histidylglycyl-L-valyl-L-α-aspartyl-, cyclic (1→8)-disulfide 331229-53-9, L-Cysteinamide, N-acetyl-L-cysteinyl-L-leucyl-L-arginyl-L-alanyl-L-histidylglycyl-L-valyl-, cyclic (1→8)-disulfide 331229-54-0, L-Cysteinamide, N-acetyl-L-cysteinyl-L-leucyl-L-arginyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-, cyclic (1→9)-disulfide 331229-55-1, L-Cysteinamide, N-acetyl-L-cysteinyl-L-leucyl-L-arginyl-L-alanyl-L-histidylglycyl-L-valyl-L-α-aspartyl-, cyclic (1→9)-disulfide 331229-56-2, L-Cysteinamide, N-acetyl-L-cysteinyl-L-seryl-L-histidylglycyl-L-valyl-, cyclic (1→6)-disulfide 331229-57-3, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidylglycyl-L-valyl-L-seryl-, cyclic (1→6)-disulfide 331229-58-4, L-Cysteinamide, N-acetyl-L-cysteinyl-L-seryl-L-histidylglycyl-L-valyl-L-seryl-, cyclic (1→7)-disulfide 331229-59-5, L-Cysteinamide, N-acetyl-L-cysteinyl-L-seryl-L-histidylglycyl-L-valyl-L-seryl-L-seryl-,cyclic(1→8)-disulfide 331229-60-8, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidylglycyl-L-valyl-L-seryl-L-seryl-, cyclic (1→7)-disulfide 331230-11-6, L-Cysteinamide, N-acetyl-L-cysteinyl-L-alanyl-L-histidylglycyl-L-valyl-L-α-aspartyl-, cyclic (1→7)-disulfide 338391-99-4, 1H-1,2,4-Triazol-3-amine, 5-[[(3,4-dichlorophenyl)methyl]thio]- 338392-61-3, Benzenemethanamine, N-[(5-chloro-2-phenyl-1H-imidazol-4-yl)methylene]-4-methyl- 338393-05-8, 1H-1,2,4-Triazole, 3-[[[3-(trifluoromethyl)phenyl]methyl]thio]- 338393-13-8, 1H-1,2,4-Triazole, 3-[[(4-methylphenyl)methyl]sulfonyl]- 338393-49-0, 5-Isoxazolepropanal, β-oxo-3-phenyl-, α-[O-[(4-nitrophenyl)methyl]oxime] 338400-95-6, 5-Isoxazolecarboxylic acid, 4,5-dihydro-3-(3-methyl-5-oxo-1-phenyl-1,2,4-triazolidin-3-yl)-, 2-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-2-methylhydrazide 338404-75-4, Imidazo[2,1-b]thiazole-5-carboxylic acid, 6-[[[3-(trifluoromethyl)phenyl]methyl]thio]- 338407-16-2, Guanidine, [3-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-1,2,4-oxadiazol-5-yl]- 338414-91-8, 1H-Imidazole-5-methanol, 1-methyl-2-[[(3-methylphenyl)methyl]thio]- 338418-54-5, 1H-Benzimidazole, 2-(1H-1,2,4-triazol-1-ylmethyl)- 338422-66-5, 1,2,4-Triazolidin-3-one, 5-[5-[[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]methyl]-4,5-dihydro-3-isoxazolyl]-5-methyl-2-phenyl- 338751-52-3, 1(3H)-Isobenzofuranone, 3-[(1H-1,2,4-triazol-3-ylamino)methylene]- 339016-03-4, 2,4-Pyrimidinediamine, 6-chloro-N4-(4-phenoxyphenyl)- 339020-51-8, Pyrido[1,2-a]indole-10-carboxylic acid, 3-[2-[[(3-nitrophenyl)methylene]hydrazino]-2-oxoethoxy]-, ethyl ester 339021-25-9, 1H-1,2,4-Triazol-3-amine, 5-[4-(diphenylmethyl)-1-piperazinyl]-

339022-11-6, 1(3H)-Isobenzofuranone, 3-[[[5-[[(2,6-dichlorophenyl)methyl]thio]-1H-1,2,4-triazol-3-yl]amino]methylene]- 339022-23-0, 1(2H)-Phthalazinone, 4-[[[5-[[(2,6-dichlorophenyl)methyl]thio]-1H-1,2,4-triazol-3-yl]amino]methyl]- 339104-83-5, 2-Propen-1-one, 3-(phenylamino)-1-[4-(2-pyrimidinyloxy)phenyl]- 339105-69-0, 1H-1,2,4-Triazole, 3-[[(4-chlorophenyl)methyl]sulfonyl]- 339105-71-4, 1H-1,2,4-Triazole, 3-[[[3-(trifluoromethyl)phenyl]methyl]sulfonyl]- 339105-73-6, 1H-1,2,4-Triazole, 3-[[(4-methoxyphenyl)methyl]sulfonyl]- 339105-78-1, 1H-1,2,4-Triazole, 3-[[(4-nitrophenyl)methyl]sulfonyl]- 339105-82-7, 1H-1,2,4-Triazole, 3-[[(2-chloro-6-fluorophenyl)methyl]thio]- 339105-84-9, 1H-1,2,4-Triazole, 3-[[(2-chloro-6-fluorophenyl)methyl]sulfonyl]- 339105-87-2, 1H-1,2,4-Triazole, 3-[[(3-methylphenyl)methyl]sulfonyl]- 339106-76-2, 1H-Imidazole, 2-[2-(4-chlorophenyl)ethenyl]- 339106-78-4, 1H-Imidazole, 2-[2-(4-bromophenyl)ethenyl]- 341944-06-7, 1H-1,2,4-Triazol-3-amine, 5-[[(2-chlorophenyl)methyl]thio]- 341965-46-6, 1H-Imidazole-5-methanol, 2-[[(4-chlorophenyl)methyl]thio]-1-methyl- 341967-46-2, 1,3-Benzenediol, 2-[(2-chloro-6-fluorophenyl)methyl]-4-[[[(4-methylphenyl)methyl]imino]methyl]- 341967-49-5, 1,3-Benzenediol, 2-[(2-chloro-6-fluorophenyl)methyl]-4-[[(4-pyridinylmethyl)imino]methyl]- 344262-76-6, 1H-1,2,4-Triazol-3-amine, 5-[[(3-chlorophenyl)methyl]thio]- 344276-82-0, 1,2,4-Triazolidin-3-one, 2-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-5-[5-[[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]methyl]-4,5-dihydro-3-isoxazolyl]-5-methyl- 344276-87-5, 1,2,4-Triazolidin-3-one, 5-[5-[[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]methyl]-4,5-dihydro-3-isoxazolyl]-2-(4-fluorophenyl)-5-methyl- 346601-39-6, 2,4-Pyrimidinediamine, N4-(2,4-difluorophenyl)-6-methyl- 351857-23-3, L-Valinamide, N-formyl-L-histidyl-3-methyl-L-valyl- 351857-24-4, 3-Pyrrolidinecarboxamide, N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(2S)-2-(formylamino)-3-(1H-imidazol-4-yl)-1-oxopropyl]- 351857-25-5, 3-Piperidinecarboxamide, N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(1H-imidazol-4-ylacetyl)- 351857-26-6, Formamide, N-[(1S)-2-[3-[[(1S)-1-acetyl-2-methylpropyl]amino]phenyl]-1-(1H-imidazol-4-ylmethyl)-2-oxoethyl]- 351857-27-7, 1-Imidazolidineacetamide, 3-[(2S)-2-(formylamino)-3-(1H-imidazol-4-yl)-1-oxopropyl]-4-methyl-α-(1-methylethyl)-2,5-dioxo-, (αS,4S)- 351857-28-8, 2,4-Imidazolidinedione, 1-(1H-imidazol-4-ylmethyl)-5-methyl-3-(1-methylethyl)-, (5S)- 351857-29-9, 2,4-Imidazolidinedione, 3-[(4-hydroxyphenyl)methyl]-1-(1H-imidazol-4-ylmethyl)-5-methyl-, (5S)- 351857-30-2, 2,4-Imidazolidinedione, 1-[2-(1H-imidazol-4-yl)ethyl]-5-methyl-3-(1-methylethyl)-, (5S)- 351857-31-3
, 2,4-Imidazolidinedione, 3-(cyclohexylmethyl)-1-(1H-imidazol-4-ylmethyl)-5-methyl-, (5S)- 351857-32-4, 1-Piperazineacetamide, 4-[(2S)-2-(acetylamino)-3-(1H-imidazol-4-yl)-1-oxopropyl]-3-methyl-α-(1-methylethyl)-2-oxo-, (αS,3S)- 351857-33-5, 1-Piperazineacetamide, 4-[(2S)-2-(acetylamino)-3-(1H-imidazol-4-yl)-1-oxopropyl]-α-[(4-hydroxyphenyl)methyl]-3-methyl-2-oxo-, (αS,3S)- 351857-34-6, L-Tyrosinamide, N-acetyl-L-histidyl-(αS,3S)-3-methyl-α-(1-methylethyl)-2-oxo-1-piperazineacetyl- 351857-35-7, Pyrazinecarboximidamide, N-[[[2-methyl-6-(trifluoromethyl)-3-pyridinyl]carbonyl]oxy]- 351857-36-8, 3H-1,2,4-Triazol-3-one, 2,4-dihydro-5-[(1-methylethyl)thio]-4-[4-(phenylmethoxy)phenyl]- 351857-37-9, Ethanone, 2-[(4-chlorophenyl)thio]-1-(6-methylthiazolo[3,2-b][1,2,4]triazol-5-yl)- 351857-38-0, Thiazolo[3,2-b][1,2,4]triazole-5-carbothioic acid, 6-methyl-, S-[3-(trifluoromethyl)phenyl] ester 351857-39-1, 1,2,4-Oxadiazole, 5-[2,2'-bithiophen]-5-yl-3-(chloromethyl)- 351857-40-4, Ethanone, 1-phenyl-2-[5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]- 351857-41-5, 2,1,3-Benzoxadiazole-5-carboxamide, N-(2-phenylethyl)- 351857-42-6, Acetamide, N-[2-[(2-furanylmethyl)thio]ethyl]-2-[(1-methyl-1H-imidazol-2-yl)thio]- 351857-43-7, Ethanone, 2,2,2-trifluoro-1-[4-[2-[3-(2-thienyl)-1,2,4-oxadiazol-5-yl]ethenyl]phenyl]- 351857-44-8, Urea, N-[4-(5-oxazolyl)phenyl]-N'-phenyl- 351857-45-9, Urea,

N-(4-chlorophenyl)-N'-[4-(5-oxazolyl)phenyl]- 351857-46-0, 2H-Imidazol-2-one, 1,3-dihydro-, [1-(4-chlorophenyl)ethylidene]hydrazone 351857-47-1, Benzenecarboximidamide, N-[[2-propyl-4-(1H-pyrazol-1-yl)benzoyl]oxy]-4-(trifluoromethyl)- 351857-48-2, 1,3,4-Oxadiazole, 2-[[(4-chlorophenyl)methyl]thio]-5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]- 351857-49-3, Urea, N-[2-[(2,1,3-benzoxadiazol-5-ylmethyl)thio]phenyl]-N'-(2,4-dichlorophenyl)- 351857-50-6, 2-Thiophenecarboxamide, N-[2-[(2,1,3-benzoxadiazol-5-ylmethyl)thio]phenyl]- 351857-51-7, L-Cysteinamide, N-(mercaptoacetyl)-L-histidyl-L-alanyl-L-valyl-, cyclic (1→4)-thioether 351857-52-8, L-Cysteinamide, N-(mercaptoacetyl)glycyl-L-histidyl-L-alanyl-L-valyl-, cyclic (1→5)-thioether 351857-53-9, L-Cysteinamide, N2-(mercaptoacetyl)-L-asparaginyl-L-histidyl-L-alanyl-L-valyl-, cyclic (1→5)-thioether 351857-54-0, Morpholine, 4-[[2-(2,1,3-benzoxadiazol-5-yl)-4-thiazolyl]carbonyl]- 351857-55-1, 4-Thiazolecarboxamide, 2-(2,1,3-benzoxadiazol-5-yl)-N-(2-pyridinylmethyl)- 351857-56-2, 4-Thiazolecarbothioic acid, 2-(2,1,3-benzoxadiazol-5-yl)-, S-(2,4-dichlorophenyl) ester 351857-57-3, 4-Thiazolecarbothioic acid, 2-(2,1,3-benzoxadiazol-5-yl)-, S-phenyl ester 351857-58-4, Piperazine, 1-(2,1,3-benzoxadiazol-5-ylcarbonyl)-4-phenyl- 351857-59-5, Ethanone, 2-(1H-imidazol-1-yl)-1-(3-methylbenzo[b]thien-2-yl)- 351857-60-8, 2-Furancarboxylic acid, 5-[[[3-[[thioxo[[4-(trifluoromethyl)-2-pyrimidinyl]amino]methyl]amino]phenyl]thio]methyl]-, methyl ester 351857-61-9, 2-Furancarboxylic acid, 5-[[[3-[[[[4-(methylthio)-2-pyrimidinyl]amino]thioxomethyl]amino]phenyl]thio]methyl]-, methyl ester 351857-62-0, 1,3-Benzodioxole-5-carboximidamide, N-[(3,4-dichlorobenzoyl)oxy]- **351857-63-1**, Benzamide, N-[[[4-(5-oxazolyl)phenyl]amino]carbonyl]- **351857-64-2**, Benzamide, 4-chloro-N-[[[4-(5-oxazolyl)phenyl]amino]carbonyl]- **351857-65-3**, Benzamide, N-[[[4-(5-oxazolyl)phenyl]amino]carbonyl]-4-(trifluoromethyl)- 351857-66-4, 1H-Pyrazole-4-carboxylic acid, 3-amino-1-[6-(1-piperidinyl)-3-pyridazinyl]-, ethyl ester 351857-67-5, 1,3-Benzodioxole-5-carboximidamide, N-(benzoyloxy)- 351857-68-6, 1,3-Benzodioxole-5-carboxaldehyde, O-(2,4-dichlorobenzoyl)oxime 351857-69-7, Benzoic acid, 4-[(1,3-benzodioxol-5-ylmethylene)hydrazino]-, ethyl ester 351857-70-0, 4-Thiazolecarboxylic acid, 2-[(2,1,3-benzoxadiazol-5-yloxy)methyl]-, 4-chlorophenyl ester 351857-71-1, Benzamide, 2,6-difluoro-N-[[[(1,5,6,7-tetrahydro-4H-inden-4-ylidene)amino]oxy]carbonyl]- 351857-72-2, Acetic acid, [(2-oxo-4-propyl-2H-1-benzopyran-7-yl)oxy]-, 2-(4-chlorophenyl)-2-oxoethyl ester 351857-73-3, Acetic acid, [(2-oxo-4-propyl-2H-1-benzopyran-7-yl)oxy]-, 2-oxo-2-phenylethyl ester 351857-74-4, 1H-Pyrrole-3-carboxylic acid, 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-(1,1-dimethylethyl)-2-methyl- 351857-75-5, Ethanone, 1-(6-methylthiazolo[3,2-b][1,2,4]triazol-5-yl)-2-[[[3-(trifluoromethyl)phenyl]methyl]thio]-

RL: BSU (Biological study, unclassified); **PAC (Pharmacological activity)**; PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT 351857-76-6, Acetamide, N-[[(2-furanylmethyl)thio]methyl]-2-[(1-methyl-1H-imidazol-2-yl)thio]- 351857-77-7, 2,4-Pyrimidinediamine, N4-(3-chloro-4-fluorophenyl)-6-methyl- 351857-78-8, 1H-Indene-1,3(2H)-dione, 2-[[[4-(1H-1,2,4-triazol-1-yl)phenyl]amino]methylene]- 351857-79-9, Pyrimidine, 4,6-dimethyl-2-[[[4-(1-methylethoxy)phenyl]methyl]thio]- 351857-80-2, Pyrazine, 2-(1H-imidazol-2-yl)-5-(1-pyrrolidinyl)- 351857-81-3D, 4H-1-Benzopyran-4-one, 7-hydroxy-2-[4-(1H-tetrazol-5-yl)phenyl]-, derivs. 351857-82-4, Ethanone, 1-(6-methylthiazolo[3,2-b][1,2,4]triazol-5-yl)-2-(phenylthio)- 351857-83-5, Pyrido[2,3-d]pyrimidin-4(3H)-one, 3-[3-(1-piperidinyl)propyl]- 351857-84-6, 1H-Imidazole, 2-[[[1-[(4-chlorophenyl)methyl]-1H-imidazol-2-yl]methyl]thio]-1-methyl- 351857-85-7, Urea, N-(2-amino-6-chloro-4-pyrimidinyl)-N'-phenyl-

351857-86-8, Ethanone, 2-(benzoyloxy)-1-(2,3-dihydroxyphenyl)-
351857-87-9, Ethanone, 2-(benzoyloxy)-1-(2,3,6-trihydroxyphenyl)-
351857-88-0D, 1,3-Benzenediol, 5-[2-(3-methoxyphenyl)ethenyl]-, glycoside
derivative 351857-89-1, 2-Butenoic acid, 3-methyl-, 4-methyl-1-(1,2,3,4-
tetrahydro-5,8-dihydroxy-1,4-dioxo-2-naphthalenyl)-3-pentenyl ester
351857-90-4, Propanoic acid, 2-methyl-, 4-methyl-1-(1,2,3,4-tetrahydro-5,8-
dihydroxy-1,4-dioxo-2-naphthalenyl)-3-pentenyl ester 351857-91-5,
Butanoic acid, 3-methyl-, 4-methyl-1-(1,2,3,4-tetrahydro-5,8-dihydroxy-1,4-
dioxo-2-naphthalenyl)-3-pentenyl ester 351857-92-6, 2-Furancarboxylic
acid, 5-[2-(2,4-dihydroxyphenyl)-2-oxoethyl]tetrahydro-, ethyl ester
351857-93-7, 2-Furancarboxylic acid, 5-[2-(2,4-dihydroxyphenyl)-2-
oxoethyl]tetrahydro-, butyl ester 351857-94-8, L-Tryptophan,
N-[(2,4-dihydroxyphenyl)methylene]-, ethyl ester 351857-95-9,
1H-Inden-1-one, 3-[[4-[[(2,4-dihydroxyphenyl)methylene]amino]phenyl]amino]-
2-phenyl- 351857-96-0, 2-Furancarboxylic acid, 5-[2-oxo-2-(2,4,5-
trihydroxyphenyl)ethyl]-, methyl ester 351857-97-1, 1-Propanone,
1-[5-[2-(3,4-dihydroxyphenyl)-2-oxoethyl]-2-furanyl]-2-methyl-
351857-98-2, 2-Furancarboxylic acid, 5-[2-(3,4-dihydroxyphenyl)-2-
oxoethyl]-, propyl ester 351857-99-3, Tryptophan, N-[(9H-fluoren-9-
ylmethoxy)carbonyl]-5-hydroxy- 351858-00-9D, Pregnane-3,6,20-trione,
21-hydroxy-, glucuronic acid derivs. 351858-01-0, Benzenemethanol,
α-[[[(4,5-dimethoxy-2-nitrophenyl)methyl]methylamino]methyl]-3-
hydroxy- 351858-02-1, 1,3-Benzenediol, 2-[(2-chloro-6-
fluorophenyl)methyl]-5-[[(1-phenylethyl)imino]methyl]- 351858-03-2,
5-Heptenoic acid, 7-[2-oxo-5-(3-oxo-5-phenylpentyl)-3-cyclopenten-1-yl]-
351858-04-3, 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-N-[2-[[2-
hydroxy-3-(1-naphthalenyloxy)propyl]amino]ethyl]-2-oxo-, (3aS,4S,6aR)-
351858-05-4, Benzenepropanoic acid, 4,4'-(1,5-dioxo-1,5-pentanediyl)bis-,
diethyl ester 351858-08-7, Benzenepropanamide, 3,4-dimethoxy-N-[2-[3-
methoxy-4-(phenylmethoxy)phenyl]-2-oxoethyl]-5-(phenylmethoxy)-
351858-09-8, Ethanone, 1-[3-(4-fluorobenzoyl)-7-[(4-nitrophenyl)methyl]-1-
indolizinyl]- 351858-10-1, Benzeneacetamide, N-[1-(4-nitrobenzoyl)-4-
piperidinyl]- 351858-11-2, Benzamide, N-[2-[[(4-
fluorophenyl)methyl]thio]-2-methylpropyl]-3-nitro- 351858-12-3,
1H-1,2,4-Triazole, 3-[[(4-bromophenyl)methyl]thio]-5-phenyl-
351858-13-4, 2H-1,4-Benzothiazin-3(4H)-one, 2-[[4-methyl-5-
[(phenylmethyl)thio]-4H-1,2,4-triazol-3-yl]methyl]- 351858-14-5,
2H-1,4-Benzothiazin-3(4H)-one, 2-[[5-[[(4-chlorophenyl)methyl]thio]-4-
methyl-4H-1,2,4-triazol-3-yl]methyl]- 351858-15-6, 1H-1,2,4-Triazole,
3-[2-[4-(1-methylethyl)phenyl]ethenyl]-5-[[[3-
(trifluoromethyl)phenyl]methyl]thio]- 351858-16-7, 2,1,3-Benzoxadiazole,
5-[[4-(4-methoxyphenyl)-2-thiazolyl]methoxy]- 351858-17-8,
4-Thiazolecarboxamide, 2-[(2,1,3-benzoxadiazol-5-yloxy)methyl]-N-(4-
chlorophenyl)- 351858-18-9, 1,2,5-Oxadiazole-3-acetamide,
N-(3-chloro-4-fluorophenyl)- 351858-19-0, Benzaldehyde,
4-(methylsulfonyl)-, 2-benzoxazolylhydrazone 351858-20-3, Urea,
N-(3-chlorophenyl)-N'-(3,5-dimethyl-4H-1,2,4-triazol-4-yl)- 351858-21-4,
1,3-Benzodioxol-5-amine, N-9H-fluoren-2-yl- 351858-22-5,
1H-Imidazo[4,5-c]pyridine, 1-(3-phenylpropyl)- 351858-23-6,
5(4H)-Oxazolone, 2-phenyl-4-(2H-1,2,3-triazol-4-ylmethylene)-
351858-24-7, Pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amine, N-phenyl-
351858-25-8, 5-Pyrimidinecarbonitrile, 2-amino-4-(1,1-dimethylethyl)-6-
(phenylamino)- 351858-26-9, 2,4-Pyrimidinediamine, 5-nitro-N4-[3-
(trifluoromethyl)phenyl]- 351858-27-0, 4-Pyrimidinamine,
N-(3,5-dichlorophenyl)-2-(4-pyridinyl)-6-(trifluoromethyl)- 351858-28-1,
4-Pyrimidinamine, 2-(2-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]-6-
(trifluoromethyl)- 351858-29-2, 4-Pyrimidinamine, N-(3-fluorophenyl)-2-
(2-pyridinyl)-6-(trifluoromethyl)- 351858-30-5, 4-Pyrimidinamine,
N-(4-methoxyphenyl)-2-(3-pyridinyl)-6-(trifluoromethyl)- 351858-31-6,
4-Pyrimidinamine, 2-[[(2,6-dichlorophenyl)methyl]thio]-N-(2,4-
difluorophenyl)-6-methyl- 351858-32-7, 4-Quinazolinamine,
N-(3,4-dimethylphenyl)-, monohydrochloride 351858-33-8,
4-Quinazolinamine, N-(4-chlorophenyl)-, monohydrochloride 351858-34-9,

4-Quinazolinamine, N-(2,4-dimethylphenyl)-, monohydrochloride
351858-35-0, 4-Quinazolinamine, N-(4-bromophenyl)-, monohydrochloride
351858-36-1, 4-Pyrimidinamine, N-(3-chlorophenyl)-2-(4-pyridinyl)-6-
(trifluoromethyl)- 351858-37-2, Acetamide, 2-[[4-methyl-5-[(3-pyrazinyl-
1,2,4-oxadiazol-5-yl)methyl]-4H-1,2,4-triazol-3-yl]thio]-N-[3-
(trifluoromethyl)phenyl]- 351858-38-3, 1,2,4-Oxadiazole-5-acetic acid,
3-pyrazinyl-, 2-[[(4-chlorophenyl)amino]carbonyl]hydrazide 351858-39-4,
1,2,4-Oxadiazole-5-acetic acid, 3-pyrazinyl-, 2-[[(3,5-
dichlorophenyl)amino]carbonyl]hydrazide 351858-40-7,
1,2,4-Oxadiazole-5-acetic acid, 3-pyrazinyl-, 2-[[[4-
(trifluoromethoxy)phenyl]amino]carbonyl]hydrazide 351858-41-8,
1,2,4-Oxadiazole-5-acetic acid, 3-pyrazinyl-, 2-
[(phenylamino)carbonyl]hydrazide 351858-42-9, 1,2,4-Oxadiazole-5-acetic
acid, 3-pyrazinyl-, 2-[(methylamino)thioxomethyl]hydrazide 351858-43-0,
1,2,4-Triazolidin-3-one, 5-[3-(4-fluorophenyl)-2,1-benzisoxazol-5-yl]-5-
methyl-2-phenyl- 351858-44-1, 4H-Pyrrolo[3,4-d]isoxazole-4,6(5H)-dione,
5-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methylamino]-3a,6a-dihydro-3-
(3-methyl-5-oxo-1-phenyl-1,2,4-triazolidin-3-yl)- 351858-45-2,
Methanesulfonamide, N-[4-[[5-[3-(2-aminoethyl)-1H-indol-5-yl-2-t]-1,2,4-
oxadiazol-3-yl]methyl]phenyl]- 351858-47-4, 2-Propenamide,
N-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-3-phenyl-N-[1-(phenylmethyl)-4-
piperidinyl]- 351858-48-5, Pentitol, 1,5-anhydro-1-C-(5-methyl-1,3,4-
oxadiazol-2-yl)-, 2,3,4-tribenzoate 351858-49-6, 3H-Pyrazol-3-one,
5-(1,1-dimethylethyl)-2,4-dihydro-2-phenyl-4-[(4-pyridinylamino)methylene]-
351858-50-9, D-erythro-Pentitol, 1,4-anhydro-2,3-dideoxy-3-[2-(4-
methylphenyl)-2-oxoethyl]-1-C-1,2,4-triazolo[4,3-a]pyrimidin-3-yl-,
5-(4-methylbenzoate), (1S)- 351858-51-0, Piperazine,
1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(1H-indol-6-ylcarbonyl)- 351858-52-1,
Piperazine, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-[[2,6-bis(dimethylamino)-4-
pyrimidinyl]carbonyl]- 351858-53-2, Spirostan-12-one, 3-(acetyloxy)-,
12-[(2,4-dinitrophenyl)hydrazone], (5α)- 351858-54-3, Phenol,
4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis-,
bis(3-nitrobenzoate) 351858-55-4, Phenol, 4,4'-(1-methylpropylidene)bis-
, bis(3-nitrobenzoate) (ester) 351858-56-5, Phenol, 4,4'-(9H-fluoren-9-
ylidene)bis-, bis(3-nitrobenzoate) 351858-57-6, Phenol,
4,4'-(diphenylmethylene)bis-, bis(4-nitrobenzoate) 351858-58-7,
L-Methioninamide, N-(4-methoxy-1,4-dioxobutyl)glycyl-L-tryptophyl-N-(4-
methyl-2-oxo-2H-1-benzopyran-6-yl)- 351858-59-8, Aspartic acid,
(βR)-3-chloro-β,5-dihydroxy-N-methyl-D-tyrosyl-3,4-didehydro-L-
valyl-3-hydroxy-L-isoleucyl-3,4-didehydro-L-prolyl-2,3-didehydroisoleucyl-
2,3-didehydro-, cyclic (15→3)-ether 351858-60-1,
19-Norpregn-5-ene-20-carboxylic acid, 3-(acetyloxy)-, 2-[[(7-nitro-2,1,3-
benzoxadiazol-4-yl)methyl]amino]ethyl ester, (3β,20S)- 351858-61-2,
L-Alaninamide, N-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-
4-yl]-1-oxopentyl]-L-threonyl-L-valyl-N-[(1S)-2-carboxy-1-formylethyl]-
351858-62-3, L-Lysinamide, N-[(phenylmethoxy)carbonyl]-L-α-glutamyl-
N-[(1S)-1-(carboxymethyl)-3-[(2,6-dimethylbenzoyl)oxy]-2-oxopropyl]-N6-[5-
[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-
351858-63-4, 1,3-Benzenediacetic acid, 5-[2-[[3-(4-aminophenyl)-1,3-
dioxopropyl]amino]-4-(methoxycarbonyl)phenoxy]- 351858-64-5,
1,3-Benzenediacetic acid, 5-[4-(methoxycarbonyl)-2-[[3-(4-nitrophenyl)-1,3-
dioxopropyl]amino]phenoxy]- 351858-65-6, 1-Propanone,
1-[2,4-dihydroxy-6-[(2,3,4,6-tetra-O-acetyl-α-D-
glucopyranosyl)oxy]phenyl]-3-(4-nitrophenyl)- 351858-66-7, 1-Propanone,
1-[2-(benzoyloxy)-6-hydroxy-4-[(2,3,4,6-tetra-O-acetyl-α-L-
glucopyranosyl)oxy]phenyl]-3-(4-nitrophenyl)- 351858-67-8,
L-Phenylalaninamide, N-(4-carboxy-1-oxobutyl)-L-phenylalanyl-L-alanyl-L-
alanyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)- 351858-68-9,
L-Asparagine, L-tyrosyl-L-alanyl-L-phenylalanyl-L-tryptophyl-
351858-69-0, 2H-Tetrazolium, 2-(2-benzothiazolyl)-3-(4-carboxy-3-
methoxyphenyl)-5-[4-[[(2-sulfoethyl)amino]carbonyl]phenyl]-, inner salt
351858-70-3, Phenylalanine, 3,3'-[phosphinicobis(methylene)]bis-
351858-71-4, 1-Propanone, 1-[2,6-dihydroxy-4-[(2,3,4,6-tetra-O-acetyl-

α-L-glucopyranosyl)oxy]phenyl]-3-(4-nitrophenyl)- 351858-72-5, 2-Propen-1-one, 3-(4-nitrophenyl)-1-[2-[(2,3,4,6-tetra-O-acetyl-α-L-glucopyranosyl)oxy]phenyl]- 351858-73-6, L-Methionine, L-phenylalanylglycylglycyl-L-phenylalanyl-N-[(1,1-dimethylethoxy)carbonyl]- 351858-74-7, L-Tryptophan, N-acetyl-L-tryptophyl-L-leucyl-L-α-aspartyl-L-isoleucyl-L-isoleucyl- 351858-76-9, Pyridinium, 1,1'-(1,6-hexanediyl)bis[4-[[(dimethylamino)carbonyl]oxy]-, compound with 2,4,6-trinitrophenol (1:1) 351858-81-6, Alanine, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]amino]benzoyl]-3-[[(2-ethoxy-2-oxoethyl)amino]sulfinyl]-, ethyl ester 351858-82-7, L-Glutamic acid, N-[4-[[[5-[3-[acetyl(6-ethoxy-6-oxohexyl)amino]-2-methyl-2-propenyl]-2-amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl]methyl]amino]benzoyl]- 351858-84-9, L-Glutamic acid, N-[4-[[2-[2-(acetylamino)-1,4-dihydro-4-oxo-6-pteridinyl]ethyl](trifluoroacetyl)amino]benzoyl]-, diethyl ester 351858-87-2, L-Glutamic acid, N-[4-[[2-(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)ethyl]amino]benzoyl]-,diethylester 351858-92-9, Histidine, 2-[[4-(aminosulfonyl)phenyl]azo]-N-(3,4-dihydro-3,4-dioxo-1-naphthalenyl)- 351858-93-0, Histidine, 2,2'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis- 351859-05-7, Glutamic acid, N-[4-[[[1,4,5,6,7,8-hexahydro-5-(3-hydroxypropyl)-2-[(3-hydroxypropyl)amino]-4-oxo-6-pteridinyl]methyl](3-hydroxypropyl)amino]benzoyl]- 351859-08-0, Pentanedioic acid, 3-[[4-[[[4-(2,4-diamino-5-pyrimidinyl)phenyl]methyl]amino]benzoyl]amino]- 351859-09-1, L-Cysteinamide, L-cysteinyl-L-histidylglycyl-L-valyl-, cyclic (1→5)-disulfide 351859-10-4, L-Lysinamide, N-acetyl-L-α-aspartyl-L-histidyl-L-alanyl-L-valyl-, (1→5)-lactam 351859-11-5, L-Lysinamide, N-acetyl-L-α-aspartyl-L-histidylglycyl-L-valyl-, (1→5)-lactam 351859-12-6, L-α-Glutamine, N2-acetyl-L-lysyl-L-histidyl-L-alanyl-L-valyl-, (5→1)-lactam 351859-13-7, L-α-Glutamine, N2-acetyl-L-lysyl-L-histidylglycyl-L-valyl-, (5→1)-lactam 351859-14-8, L-Cysteinamide, N-acetyl-L-cysteinyl-L-valylglycyl-L-histidyl-, cyclic (1→5)-disulfide 351859-15-9, L-α-Asparagine, L-lysyl-L-histidylglycyl-L-valyl-, (5→16)-lactam 351859-16-0, Cyclo(L-alanyl-L-histidylglycyl-L-valyl-L-α-aspartyl-L-isoleucyl) 351859-17-1, L-Cysteinamide, L-cysteinyl-L-alanyl-L-histidylglycyl-L-valyl-L-α-aspartyl-, cyclic (1→7)-disulfide 351859-18-2, L-Cysteinamide, L-cysteinyl-L-alanyl-L-histidylglycyl-L-valyl-L-α-aspartyl-L-isoleucyl-,cyclic(1→8)-disulfide 351859-19-3, Cyclo(glycyl-L-valyl-L-seryl-L-seryl-L-seryl-L-histidyl) 351859-20-6 351859-21-7, L-α-Asparagine, N2-acetyl-L-lysyl-L-seryl-L-histidylglycyl-L-valyl-L-seryl-L-seryl-, (8→1)-lactam 365544-54-3
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT 140039-27-6, GenBank X06340 140330-33-2, GenBank X53615 140758-02-7, GenBank X06115 384451-84-7, GenBank M34064 384464-73-7, GenBank M31131 391528-92-0, GenBank X63629 391535-27-6, GenBank Z13009
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(peptidomimetic modulators of cell adhesion)

IT 73205-86-4 110590-64-2 143304-79-4 170032-25-4 202527-94-4 202527-98-8 202528-00-5 202528-03-8 202528-07-2 202528-10-7 214684-50-1 214684-52-3 222169-86-0 222169-89-3 222169-90-6 229971-74-8 229971-80-6 231282-25-0 231282-43-2 231282-44-3 231282-45-4 231282-46-5 250271-33-1 250271-34-2 250271-35-3 250271-36-4 250271-37-5 250271-39-7 250271-41-1 250271-42-2 255369-45-0 289914-94-9 313052-61-8 317320-19-7 331474-64-7 331474-65-8 331474-66-9 331474-67-0 331474-68-1 331474-69-2 331474-70-5 331474-71-6 331474-72-7 331474-73-8 331474-74-9 331474-75-0 331474-76-1 331474-77-2 331474-78-3 331474-79-4 331474-80-7 331474-81-8 331474-82-9 331474-83-0 331474-84-1

351974-94-2 351974-95-3 351974-96-4 351974-97-5 351974-98-6
351974-99-7 351975-00-3 351975-01-4 351975-02-5 351975-03-6
351975-04-7 351975-05-8 352000-58-9 352000-59-0 352000-60-3
352335-43-4 352335-47-8 352335-49-0 352335-51-4 645000-07-3
645000-08-4 645000-09-5 645000-10-8 645000-11-9 645000-12-0
645000-13-1 645000-15-3 645000-16-4 645000-17-5 645000-18-6
645000-19-7 645000-20-0 645000-21-1 645000-22-2
RL: PRP (Properties)
(unclaimed protein sequence; peptidomimetic modulators of cell adhesion)

IT 250268-78-1
RL: PRP (Properties)
(unclaimed sequence; peptidomimetic modulators of cell adhesion)

IT **351857-63-1**, Benzamide, N-[[[4-(5-oxazolyl)phenyl]amino]carbonyl]- **351857-64-2**, Benzamide, 4-chloro-N-[[[4-(5-oxazolyl)phenyl]amino]carbonyl]- **351857-65-3**, Benzamide, N-[[[4-(5-oxazolyl)phenyl]amino]carbonyl]-4-(trifluoromethyl)-
RL: BSU (Biological study, unclassified); **PAC (Pharmacological activity)**; PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

RN 351857-63-1 HCAPLUS
CN Benzamide, N-[[[4-(5-oxazolyl)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 351857-64-2 HCAPLUS
CN Benzamide, 4-chloro-N-[[[4-(5-oxazolyl)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 351857-65-3 HCAPLUS
CN Benzamide, N-[[[4-(5-oxazolyl)phenyl]amino]carbonyl]-4-(trifluoromethyl)-
(9CI) (CA INDEX NAME)



L37 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:242317 HCAPLUS
DN 138:271533
ED Entered STN: 28 Mar 2003
TI Preparation of aminopyranone and aminopyrimidinones as selective inhibitors of DNA-dependent protein kinase
IN Griffin, Roger John; Golding, Bernard Thomas; Newell, David Richard; Calvert, Hilary Alan; Curtin, Nicola Jane; Hardcastle, Ian Robert; Martin,

Niall Morrison Barr; Smith, Graeme Cameron Murray; Rigoreau, Laurent Jean Martin; Cockcroft, Xiao-Ling Fan; Loh, Vincent Ming-Lai, Jr.; Workman, Paul; Raynaud, Florence Irene; Nutley, Bernard Paul
PA Cancer Research Technology Limited, UK
SO PCT Int. Appl., 178 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D309-38
ICS C07D311-22; C07D311-92; C07D471-04; C07D417-04; A61K031-35; A61P009-00; A61P035-00
CC 27-14 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): **1**, **63**
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003024949	A1	20030327	WO 2002-GB3781	20020814
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
GB 2393653	A1	20040407	GB 2004-1411	20020814
EP 1417196	A1	20040512	EP 2002-751439	20020814
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011889	A	20040921	BR 2002-11889	20020814
US 2004192687	A1	20040930	US 2004-486816	20040213
PRAI GB 2001-19865	A	20010814		
WO 2002-GB3781	W	20020814		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003024949	ICM	C07D309-38
	ICS	C07D311-22; C07D311-92; C07D471-04; C07D417-04; A61K031-35; A61P009-00; A61P035-00
GB 2393653	ECLA	C07D309/38; C07D311/22; C07D311/92; C07D417/04+311+277B; C07D471/04+239C+221C
US 2004192687	ECLA	C07D309/38; C07D311/22; C07D311/92; C07D417/04+311+277B; C07D471/04+239C+221C

OS MARPAT 138:271533
GI



I



II

AB The invention relates to the use of heterocyclic compds. I [R1, R2 = H,

(un)substituted C1-7 alkyl, C3-20 heterocyclyl, C5-20 aryl, or NR1R2 = (un)substituted 4-8 membered heterocyclic ring; X, Y = CR4 and O, O and CR'4, NR'4 and N where the unsatn. is in the appropriate place in the ring, and where 1 of R3 and R4 or R'4 = (un)substituted C3-20 heteroaryl or C5-20 aryl,and the other of R3 and R4 or R'4 = H; or R3 and R4 or R'4 together = -A-B-, which collectively represent a fused (un)substituted aromatic ring] and isomers, salts, solvates, chemical protected forms, and prodrugs thereof, in the preparation of a medicament for inhibiting the activity of DNA-dependent protein kinase (DNA-PK). The compds. also selectively inhibit the activity of DNA-PK compared to PI 3-kinase and/or ataxia-telangiectasia mutated (ATM) protein. Thus, condensation of acetophenone with CS2, followed by S-alkylation, substitution with morpholine, further S-alkylation, and cyclocondensation with Et bromoacetate, gave morpholine-substituted pyranone II. II inhibited DNA-PK with IC50 = 1.0 μM.

ST aminopyranone prepn DNA dependent protein kinase inhibitor; aminopyrimidinone prepn DNA dependent protein kinase inhibitor

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Ataxia-telangiectasia mutated; preparation of aminopyranone and aminopyrimidinones as selective inhibitors of DNA-dependent protein kinase)

IT Antitumor agents
Human
Neoplasm
(preparation of aminopyranone and aminopyrimidinones as selective inhibitors of DNA-dependent protein kinase)

IT Antiviral agents
(retroviral; preparation of aminopyranone and aminopyrimidinones as selective inhibitors of DNA-dependent protein kinase)

IT Infection
(viral, retroviral; preparation of aminopyranone and aminopyrimidinones as selective inhibitors of DNA-dependent protein kinase)

IT 303752-61-6, DNA-dependent protein kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(human; preparation of aminopyranone and aminopyrimidinones as selective inhibitors of DNA-dependent protein kinase)

IT 115926-52-8, PI 3-kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of aminopyranone and aminopyrimidinones as selective inhibitors of DNA-dependent protein kinase)

IT 503465-43-8P 503465-44-9P 503465-53-0P 503469-06-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of aminopyranone and aminopyrimidinones as selective inhibitors of DNA-dependent protein kinase)

IT 61035-04-9P 61035-05-0P, 2-(Piperidin-1-yl)benzo[h]chromen-4-one
69540-97-2P 116849-65-1P, 4-(Morpholin-4-yl)-6-phenylpyran-2-one
116849-66-2P, 4-(Morpholin-4-yl)-6-(4-chlorophenyl)pyran-2-one
130735-56-7P, 2-(Morpholin-4-yl)-chromen-4-one 130735-60-3P,
6-Bromo-2-(morpholin-4-yl)-chromen-4-one 130735-64-7P,
8-Methyl-2-(morpholin-4-yl)-chromen-4-one 130735-66-9P,
7-Methoxy-2-(morpholin-4-yl)-chromen-4-one 130735-92-1P,
6-Hydroxy-2-(morpholin-4-yl)-chromen-4-one 130735-93-2P,
7-Hydroxy-2-(morpholin-4-yl)-chromen-4-one 130736-41-3P,
7-(Benzyloxy)-2-(morpholin-4-yl)-chromen-4-one 130736-95-7P
130766-15-3P, 8-Methoxy-2-(morpholin-4-yl)-chromen-4-one 141106-74-3P
141106-75-4P, 2-(4-Morpholinyl)-6-phenyl-4H-pyran-4-one 141106-80-1P
141106-86-7P 141106-93-6P, 6-(4-Fluorophenyl)-2-(4-morpholinyl)-4H-pyran-4-one 154447-35-5P 154447-36-6P, 8-Phenyl-2-(morpholin-4-yl)-chromen-4-one 155906-26-6P, 6-(2-Methoxyphenyl)-2-(4-morpholinyl)-4H-pyran-4-one
155906-27-7P, 6-(3-Methoxyphenyl)-2-(4-morpholinyl)-4H-pyran-4-one

155906-28-8P, 6-(4-Methoxyphenyl)-2-(4-morpholinyl)-4H-pyran-4-one
155906-31-3P, 6-(4-Chlorophenyl)-2-(4-morpholinyl)-4H-pyran-4-one
168425-64-7P, 2-(Morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one
168425-66-9P, 2-(4-Methylpiperazin-1-yl)pyrimido[2,1-a]isoquinolin-4-one
173210-03-2P 173210-04-3P 184426-54-8P 351002-11-4P 351071-74-4P
503465-07-4P, 4-(Morpholin-4-yl)-6-(4-tert-butylphenyl)pyran-2-one
503465-09-6P, 4-(Morpholin-4-yl)-6-(4-methoxyphenyl)pyran-2-one
503465-11-0P 503465-13-2P, 2-(2,5-Dimethylpiperidin-1-yl)pyrimido[2,1-a]isoquinolin-4-one 503465-15-4P, 2-(3-Hydroxymethylpiperidin-1-yl)pyrimido[2,1-a]isoquinolin-4-one 503465-17-6P, 2-[(Tetrahydrofuran-2-ylmethyl)amino]pyrimido[2,1-a]isoquinolin-4-one 503465-19-8P, 2-[Bis-(2-hydroxyethyl)amino]pyrimido[2,1-a]isoquinolin-4-one
503465-20-1P, 2-(3-Hydroxypyrrolidin-1-yl)pyrimido[2,1-a]isoquinolin-4-one
503465-21-2P 503465-22-3P, 2-[N-Benzyl-N-(2-hydroxyethyl)amino]pyrimido[2,1-a]isoquinolin-4-one 503465-23-4P, 2-[N-(2-Hydroxyethyl)-N-methylamino]pyrimido[2,1-a]isoquinolin-4-one
503465-24-5P, 2-[N-(2-Hydroxy-2-phenylethyl)-N-methylamino]pyrimido[2,1-a]isoquinolin-4-one 503465-25-6P, 3-[N-Methyl-N-(4-oxo4H-pyrimido[2,1-a]isoquinolin-2-yl)amino]propionitrile 503465-26-7P, 2-[(2-(Thiophen-2-yl)ethyl)amino]pyrimido[2,1-a]isoquinolin-4-one
503465-27-8P, 2-[(2,3-Dihydroxypropyl)amino]pyrimido[2,1-a]isoquinolin-4-one 503465-28-9P, 2-[(2-Hydroxypropyl)amino]pyrimido[2,1-a]isoquinolin-4-one 503465-29-0P, 2-[(2-Hydroxy-2-(3-hydroxyphenyl)ethyl)amino]pyrimido[2,1-a]isoquinolin-4-one 503465-30-3P, 2-[(2-Hydroxyethyl)amino]pyrimido[2,1-a]isoquinolin-4-one 503465-31-4P
503465-32-5P 503465-33-6P 503465-34-7P 503465-35-8P 503465-36-9P
503465-37-0P 503465-38-1P 503465-39-2P 503465-40-5P 503465-41-6P
503465-42-7P 503465-45-0P 503465-46-1P 503465-47-2P 503465-48-3P
503465-49-4P 503465-50-7P 503465-51-8P 503465-52-9P 503465-54-1P
503465-55-2P 503465-56-3P 503465-57-4P 503465-58-5P 503465-59-6P
503465-60-9P 503465-61-0P 503465-62-1P 503465-63-2P 503465-64-3P
503465-65-4P 503465-66-5P 503465-67-6P 503465-68-7P 503465-69-8P
503465-70-1P 503465-71-2P 503465-72-3P 503465-73-4P 503465-74-5P
503465-75-6P 503465-76-7P 503465-77-8P 503465-78-9P 503465-79-0P
503465-80-3P 503465-81-4P 503465-82-5P 503465-83-6P 503465-84-7P
503465-85-8P 503465-86-9P 503465-87-0P 503465-88-1P 503465-89-2P
503465-90-5P 503465-91-6P 503465-92-7P 503465-93-8P 503465-94-9P
503465-95-0P 503465-96-1P 503465-97-2P 503465-98-3P 503465-99-4P
503466-00-0P 503466-01-1P 503466-02-2P 503466-03-3P 503466-04-4P
503466-05-5P 503466-06-6P 503466-07-7P 503466-08-8P 503466-09-9P
503466-10-2P 503466-11-3P 503466-12-4P 503466-13-5P 503466-14-6P
503466-15-7P 503466-16-8P 503466-17-9P 503466-18-0P 503466-19-1P
503466-20-4P 503466-21-5P 503466-22-6P 503466-23-7P 503466-24-8P
503466-25-9P 503466-26-0P 503466-27-1P 503466-28-2P 503466-29-3P
503466-30-6P 503466-31-7P 503466-32-8P 503466-33-9P 503466-34-0P
503466-35-1P 503466-36-2P 503466-37-3P 503466-38-4P 503466-39-5P
503466-40-8P 503466-41-9P 503466-42-0P 503466-44-2P 503466-46-4P
503466-47-5P 503466-48-6P 503466-49-7P 503466-50-0P 503466-51-1P
503466-52-2P 503466-53-3P 503466-54-4P 503466-55-5P 503466-56-6P
503466-57-7P 503466-58-8P 503466-59-9P 503466-60-2P 503466-61-3P
503466-62-4P 503466-63-5P 503466-64-6P 503466-65-7P 503466-66-8P
503466-67-9P 503466-68-0P 503466-69-1P 503466-70-4P 503466-71-5P
503466-72-6P 503466-73-7P 503466-74-8P 503466-75-9P 503466-76-0P
503466-77-1P 503466-78-2P 503466-79-3P 503466-80-6P 503466-81-7P
503466-82-8P 503466-83-9P 503466-84-0P 503466-85-1P 503466-86-2P
503466-87-3P 503466-88-4P 503466-89-5P 503466-90-8P 503466-91-9P
503466-92-0P 503466-93-1P 503466-94-2P 503466-95-3P 503466-96-4P
503466-97-5P 503466-98-6P 503466-99-7P 503467-00-3P 503467-01-4P
503467-02-5P 503467-03-6P 503467-04-7P 503467-05-8P 503467-06-9P
503467-07-0P 503467-08-1P 503467-09-2P 503467-10-5P 503467-11-6P
503467-12-7P 503467-13-8P 503467-14-9P 503467-15-0P 503467-16-1P
503467-17-2P 503467-18-3P 503467-20-7P 503467-21-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminopyranone and aminopyrimidinones as selective inhibitors of DNA-dependent protein kinase)

IT 503467-22-9P 503467-23-0P 503467-24-1P 503467-25-2P 503467-26-3P
503467-27-4P 503467-28-5P 503467-30-9P 503467-31-0P 503467-32-1P
503467-33-2P 503467-34-3P 503467-35-4P 503467-36-5P 503467-37-6P
503467-38-7P 503467-39-8P 503467-40-1P 503467-41-2P 503467-42-3P
503467-43-4P 503467-44-5P 503467-45-6P 503467-46-7P 503467-47-8P
503467-48-9P 503467-49-0P 503467-50-3P 503467-51-4P 503467-52-5P
503467-53-6P 503467-54-7P 503467-55-8P 503467-56-9P 503467-57-0P
503467-58-1P 503467-59-2P 503467-60-5P 503467-61-6P 503467-62-7P
503467-63-8P 503467-64-9P 503467-65-0P 503467-66-1P 503467-67-2P
503467-68-3P 503467-69-4P 503467-70-7P 503467-71-8P 503467-72-9P
503467-73-0P 503467-74-1P 503467-75-2P 503467-76-3P 503467-77-4P
503467-78-5P 503467-79-6P 503467-80-9P 503467-81-0P 503467-82-1P
503467-83-2P 503467-84-3P 503467-85-4P 503467-86-5P
503467-87-6P 503467-88-7P 503467-89-8P 503467-90-1P,
6-(4-tert-Butylphenyl)-2-(4-morpholinyl)-4H-pyran-4-one 503467-91-2P,
6-(2-Fluorophenyl)-2-(4-morpholinyl)-4H-pyran-4-one 503467-92-3P,
6-(3-Fluorophenyl)-2-(4-morpholinyl)-4H-pyran-4-one 503467-93-4P
503467-94-5P 503467-95-6P, 2-(Morpholin-4-yl)-6-phenylchromen-4-one
503467-96-7P, 7-(2,6-Dichlorobenzyloxy)-2-(morpholin-4-yl)-chromen-4-one
503467-97-8P 503467-98-9P 503467-99-0P 503468-00-6P 503468-01-7P
503468-02-8P 503468-03-9P 503468-04-0P 503468-05-1P 503468-06-2P
503468-07-3P 503468-08-4P 503468-09-5P 503468-10-8P 503468-11-9P
503468-12-0P 503468-13-1P 503468-14-2P 503468-15-3P 503468-16-4P
503468-17-5P 503468-18-6P 503468-19-7P 503468-20-0P 503468-21-1P
503468-22-2P 503468-23-3P, 7-(4-Cyanobenzyloxy)-2-(morpholin-4-yl)-chromen-4-one 503468-24-4P 503468-25-5P 503468-26-6P,
7-(3-Chlorobenzyloxy)-2-(morpholin-4-yl)-chromen-4-one 503468-27-7P,
7-(3-Methylbenzyloxy)-2-(morpholin-4-yl)-chromen-4-one 503468-28-8P,
6-(4-Cyanobenzyloxy)-2-(morpholin-4-yl)-chromen-4-one 503468-29-9P
503468-30-2P 503468-31-3P 503468-32-4P 503468-33-5P 503468-34-6P
503468-35-7P 503468-36-8P 503468-37-9P 503468-38-0P 503468-39-1P
503468-40-4P 503468-41-5P 503468-42-6P 503468-43-7P 503468-44-8P
503468-45-9P 503468-46-0P 503468-47-1P 503468-48-2P 503468-49-3P
503468-50-6P 503468-51-7P 503468-52-8P 503468-53-9P 503468-54-0P
503468-55-1P 503468-56-2P 503468-57-3P 503468-58-4P 503468-59-5P
503468-60-8P 503468-61-9P 503468-62-0P 503468-63-1P 503468-64-2P
503468-65-3P 503468-66-4P 503468-67-5P 503468-68-6P 503468-69-7P
503468-70-0P 503468-71-1P 503468-72-2P 503468-73-3P 503468-74-4P
503468-75-5P 503468-76-6P 503468-77-7P 503468-78-8P 503468-79-9P
503468-80-2P 503468-81-3P 503468-82-4P 503468-83-5P 503468-84-6P
503468-85-7P 503468-86-8P 503468-87-9P 503468-88-0P 503468-89-1P
503468-90-4P 503468-91-5P 503468-92-6P 503468-93-7P 503468-94-8P
503468-95-9P 503468-96-0P, 7-(4-Fluorobenzyloxy)-2-(morpholin-4-yl)-chromen-4-one 503468-97-1P, 7-(4-Chlorobenzyloxy)-2-(morpholin-4-yl)-chromen-4-one 503468-98-2P, 7-(4-Bromobenzyloxy)-2-(morpholin-4-yl)-chromen-4-one 503468-99-3P, 7-(2-Chlorobenzyloxy)-2-(morpholin-4-yl)-chromen-4-one 503469-00-9P, 7-(Naphthalen-2-ylmethoxy)-2-(morpholin-4-yl)-chromen-4-one 503469-01-0P, 7-(Cyclohexylmethoxy)-2-(morpholin-4-yl)-chromen-4-one 503469-02-1P, 7-Propoxy-2-(morpholin-4-yl)-chromen-4-one
503469-03-2P 503469-04-3P 503469-05-4P, 7-(Benzoyloxy)-2-(morpholin-4-yl)-chromen-4-one
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminopyranone and aminopyrimidinones as selective inhibitors of DNA-dependent protein kinase)

IT 75-56-9, Propylene oxide, reactions 86-48-6, 1-Hydroxy-2-naphthoic acid
89-55-4, 5-Bromo-2-hydroxybenzoic acid 89-84-9 95-55-6, 2-Aminophenol
98-80-6, Phenylboronic acid 98-86-2, Acetophenone, reactions 105-36-2,

Ethyl bromoacetate 105-53-3, Diethyl malonate 110-91-8, Morpholine, reactions 122-01-0, 4-Chlorobenzoyl chloride 141-43-5, Ethanolamine, reactions 303-38-8, 2,3-Dihydroxybenzoic acid 490-78-8 529-35-1, 5,6,7,8-Tetrahydro-1-naphthol 574-19-6 674-82-8, Diketene 824-94-2, 4-Methoxybenzyl chloride 1532-84-9, 1-Isoquinolinamine 1696-20-4, N-Acetylmorpholine 2605-67-6, Methyl triphenylphosphoranylideneacetate 87199-16-4, (3-Formylphenyl)boronic acid 87199-17-5, (4-Formylphenyl)boronic acid 99768-12-4, (4-Methoxycarbonylphenyl)boronic acid 99769-19-4, (3-Methoxycarbonylphenyl)boronic acid 380430-49-9 380430-68-2 503469-28-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of aminopyranone and aminopyrimidinones as selective inhibitors of DNA-dependent protein kinase)

IT 948-03-8P, Methyl 1-hydroxy-2-naphthoate 2411-83-8P, Methyl 2,3-dihydroxybenzoate 2832-98-6P, 1-Phenyl-3-(morpholin-4-yl)-3-thioxopropan-1-one 4068-76-2P, Methyl 5-bromo-2-hydroxybenzoate 5735-53-5P 6579-55-1P, 1-(2-Hydroxyethylamino)-propan-2-ol 7515-18-6P 17504-13-1P, Methyl 2-hydroxy-5-phenylbenzoate 23212-58-0P 27550-90-9P, 2-Methylmorpholine 41467-11-2P 42398-55-0P 81189-95-9P 85839-49-2P 96277-02-0P 103986-80-7P, 5,6,7,8-Tetrahydro-1-hydroxy-2-naphthoic acid 119671-47-5P 141106-96-9P 149878-72-8P, 2-Hydroxy-4-(trifluoromethylsulfonyloxy)benzoic acid methyl ester 173210-13-4DP, resin-bound 173210-13-4P 173210-14-5P 186663-74-1P 212180-23-9P 351002-09-0P, 2-Hydroxy-3-(trifluoromethylsulfonyloxy)benzoic acid methyl ester 503469-07-6P 503469-08-7P 503469-09-8P 503469-10-1P 503469-11-2P 503469-12-3P 503469-13-4P 503469-14-5P, 1-Phenyl-3-ethylsulfanyl-3-(morpholin-4-yl)propenone 503469-15-6P 503469-16-7P, 1-(1-Hydroxynaphth-2-yl)-3-(morpholin-4-yl)propan-1,3-dione 503469-17-8P, Trifluoromethanesulfonic acid 2-hydroxy-3-(3-(morpholin-4-yl)-3-oxopropionyl)phenyl ester 503469-18-9P 503469-19-0P 503469-20-3P 503469-21-4P 503469-22-5P 503469-23-6P 503469-24-7P, 2-Hydroxy-4-(4-methoxybenzyloxy)acetophenone 503469-25-8P 503469-26-9DP, resin-bound 503469-27-0DP, resin-bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminopyranone and aminopyrimidinones as selective inhibitors of DNA-dependent protein kinase)

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) DI Braccio, M; EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 1995, V30(1), P27 HCAPLUS
(2) Datta, A; SYNTHESIS 1988, V3, P248
(3) Ermili, A; FARMACO, ED SCI 1977, V32(5), P375 HCAPLUS
(4) Izzard, R; CANCER RESEARCH 1999, V59(11), P2581 HCAPLUS
(5) Morris, J; JOURNAL OF MEDICINAL CHEMISTRY 1993, V36, P2026 HCAPLUS
(6) Thrombogenix; WO 0153266 A 2001 HCAPLUS
(7) Upjohn; WO 9006921 A 1990 HCAPLUS
(8) Upjohn; WO 9119707 A 1991 HCAPLUS
(9) Upjohn; WO 9200290 A 1992 HCAPLUS

IT **503467-87-6P**
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminopyranone and aminopyrimidinones as selective inhibitors of DNA-dependent protein kinase)

RN 503467-87-6 HCAPLUS

CN Benzamide, N-[[[4-[6-(4-morpholinyl)-4-oxo-4H-pyran-2-yl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



L37 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:869496 HCAPLUS
DN 137:363033
ED Entered STN: 15 Nov 2002
TI Peptidomimetic modulators of cell adhesion
IN Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie D.; Wang, Shoameng; Hu, Zenjian
PA Can.
SO U.S. Pat. Appl. Publ., 309 pp., Cont.-in-part of U.S. Ser. No. 491,078.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K038-17
ICS C07K014-435; C12N005-02
NCL 435325000
CC 1-3 (**Pharmacology**)
Section cross-reference(s): 34, **63**
FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002168761	A1	20021114	US 2001-769145	20010124
	US 2004058864	A1	20040325	US 2003-412701	20030410
	US 2004006011	A1	20040108	US 2003-425557	20030428
PRAI	US 2000-491078	A2	20000124		
	US 1996-21612P	P	19960712		
	US 1997-893534	A1	19970711		
	US 2000-507102	A1	20000217		
	US 2001-769145	B1	20010124		
	US 2001-6982	A2	20011204		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2002168761	ICM	A61K038-17
	ICS	C07K014-435; C12N005-02
	NCL	435325000
US 2002168761	ECLA	C07K007/06A
US 2004058864	ECLA	C07K007/06A
US 2004006011	ECLA	C07K007/06A; C07K007/56; C07K007/64; C07K014/705

OS MARPAT 137:363033
AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
ST cadherin cell adhesion peptidomimetic QSAR cyclic peptide
IT Cadherins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(N-, cells bearing; peptidomimetic modulators of cadherin-mediated cell

adhesion for therapeutic use in relation to three-dimensional structure)

IT Astrocyte
(N-cadherin-bearing cell migration on; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Antitumor agents
(bladder; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Drug delivery systems
(carriers; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Epithelium
(cell, cadherin-mediated adhesion in; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Peptides, properties
RL: PRP (Properties)
(cyclic, conformation of; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Oligodendrocyte
Schwann cell
(demyelinating nerve diseases treatment with; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Nerve, disease
(demyelination; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Neoplasm
Skin
(drug delivery to; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Blood vessel
(endothelium, cell, cadherin-mediated adhesion in; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Synapse
(increase in stability of; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Angiogenesis
(inhibition; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Spinal cord, disease
(injury; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Eye, disease
(macula, degeneration; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Antitumor agents
(melanoma; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Bioreactors
Membrane, biological
Microparticles
Ultrathin films
(modulator linking to; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional

structure)
IT Adhesion, biological
(modulators of; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
IT Axon
(outgrowth, modulators of; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
IT Antitumor agents
(ovary; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
IT Drug delivery systems
(patches; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
IT Angiogenesis inhibitors
Antitumor agents
Bladder, neoplasm
Bond angle
Cell migration
Combinatorial library
Conformation
Drug delivery systems
Drug delivery systems
Drug screening
Electrostatic charge
Human
Hydrophobicity
Immunomodulators
Melanoma
Molecular modeling
Multiple sclerosis
Ovary, neoplasm
Peptidomimetics
Protein sequences
QSAR (structure-activity relationship)
Steric effects
Transplant and Transplantation
Wound healing
Wound healing promoters
(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
IT Cadherins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
IT Animal tissue culture
(peptidomimetics screening in; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
IT Blood vessel
(permeability increase in; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
IT Biological transport
(permeation, increase in blood vessel; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
IT Laboratory ware
(plastic dishes, modulator linking to; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
IT Laboratory ware

(plastic tubes, modulator linking to; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Oligodendrocyte
(progenitor, demyelinating nerve diseases treatment with; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Transplant and Transplantation
(skin; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Information systems
(storage, in structure determination; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Polymers, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(support matrixes; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Drug delivery systems
(sustained-release; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Medical goods
(sutures, modulator linking to; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT Skin
(transplant; peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT 57-88-5D, Cholest-5-en-3-ol (3β)-, glycoside derivs. 135-16-0, L-Glutamic acid, N-[4-[[(2-amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]- 487-49-0, Ethanone, 1-(2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)- 548-73-2, 2H-Benzimidazol-2-one, 1-[1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1,3-dihydro- 570-88-7, Cholest-4-ene-3,6-diol, (3β,6β)- 1210-66-8, 1H-Purin-6-amine, N-phenyl- 1482-74-2, 2-Propen-1-one, 3-phenyl-1-(2,3,4-trihydroxyphenyl)- 1699-40-7, Benzeneacetamide, 4-methoxy-N-[2-[3-methoxy-4-(phenylmethoxy)phenyl]ethyl]-3-(phenylmethoxy)- 1776-30-3, 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-phenyl- 2486-02-4, Benzoic acid, 3,4,5-trihydroxy-, 3-methylbutyl ester 2810-37-9, 1H-Isoindole-1,3(2H)-dione, 2-[5-(1H-benzotriazol-1-yl)propyl]- 2979-51-3, 1H-Imidazole, 1-(1-oxo-3-phenyl-2-propenyl)- 3242-68-0, L-Glutamic acid, N-[4-[[2-[(2-amino-1,4-dihydro-4-oxo-5-pyrimidinyl)amino]ethyl]amino]benzoyl]- 3257-73-6, 9H-Purin-6-amine, 9-[2,3,5-tris-O-(phenylmethyl)-β-D-arabinofuranosyl]- 3561-56-6, L-Asparagine, N2-[(phenylmethoxy)carbonyl]-, (4-nitrophenyl)methyl ester 3566-25-4, L-Glutamic acid, N-[4-[[2-(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)ethyl]amino]benzoyl]- 3575-07-3, 1H-Benzimidazole, 2,2'-(1,2-ethanediyl)bis- 3922-47-2, 1H-1,2,4-Triazol-3-amine, 5-[(phenylmethyl)thio]- 4672-96-2, Benzeneacetamide, 3-methoxy-N-[2-[4-methoxy-3-(phenylmethoxy)phenyl]ethyl]-4-(phenylmethoxy)- 5226-71-1, Benzene, 1,1'-[1,10-decanediylbis(oxy)]bis[3-nitro- 5341-00-4, 1,4-Naphthalenedione, 2-[3-(decahydro-2-naphthalenyl)propyl]-3-hydroxy- 5415-88-3, 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl-8-(4-phenylbutoxy)- 5421-95-4, Urea, (3-phenyl-1,2,4-oxadiazol-5-yl)- 5426-87-9, Benzamide, N-[(2,3,6,7-tetrahydro-1,3-dimethyl-2,6-dioxo-1H-purin-8-yl)methyl]- 5429-46-9, Benzamide, N-[2-(2,3,6,7-tetrahydro-1,3-dimethyl-2,6-dioxo-1H-purin-8-yl)ethyl]- 5446-36-6, 1H-Purin-6-amine, N-(4-methylphenyl)- 5454-50-2, Ethanone, 1-phenyl-2-(1H-purin-6-ylthio)- 5454-52-4, 1H-Purine, 6-[(2-phenoxyethyl)thio]- 5508-58-7,

2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)- 5534-95-2 5800-34-0, Pentanoic acid, 5-[[(1S)-2-[(4-nitrophenyl)amino]-2-oxo-1-(phenylmethyl)ethyl]amino]-5-oxo- 6286-57-3, 5(4H)-Isoxazolone, 4-(1,3-benzodioxol-5-ylmethylene)-3-phenyl- 6295-27-8, 7H-1,2,3-Triazolo[4,5-d]pyrimidin-7-one, 5-amino-2,6-dihydro-2-phenyl- 6300-80-7, Benzaldehyde, 4-(dimethylamino)-, 7H-purin-6-ylhydrazone 6320-71-4, 1,4-Naphthalenedione, 2-(4-cyclohexylbutyl)-3-hydroxy- 6322-09-4, 2(1H)-Quinoxalinone, 3-[2-(2-chlorophenyl)ethenyl]-7-methyl- 6323-88-2, 2(1H)-Quinoxalinone, 3-[2-(3-nitrophenyl)ethenyl]- 6323-89-3, 2(1H)-Quinoxalinone, 3-(2-phenylethenyl)- 6331-03-9, Benzaldehyde, 4-nitro-, 7H-purin-6-ylhydrazone 6338-84-7, 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl-8-(2-phenylethyl)- 6340-76-7, 2,4-Pyrimidinediamine, 6-chloro-N4-(3-methylphenyl)- 6633-66-5, 2,4,6-Pyrimidinetriamine, N4-(4-bromophenyl)- 6807-82-5, L-Glutamic acid, N-[4-[[(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-α-glutamyl- 6962-62-5, 2-Propen-1-one, 3-(1,3-benzodioxol-5-yl)-1-(2,4-dihydroxyphenyl)- 6975-34-4, 1H-Purine, 6-[(3-phenyl-2-propenyl)thio]- 7781-29-5, 2,4-Pyrimidinediamine, 6-methyl-N4-phenyl- 10320-97-5, 1,2,3,4-Thiatriazol-5-amine, N-1-naphthalenyl- 13184-14-0, L-Lysine, L-lysyl-L-lysyl- 13351-10-5, 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-methoxyphenyl)- 13745-20-5, 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)- 15013-60-2, Cholest-4-ene-3,6-diol, (3β,6α)- 15970-42-0, 1H-Imidazole-1,2-diamine, 4-(4-chlorophenyl)- 16856-21-6, L-Tryptophan, N-[N-[(phenylmethoxy)carbonyl]-L-phenylalanyl]-, methyl ester 16879-84-8, L-Threonine, N-[(phenylmethoxy)carbonyl]-, (4-nitrophenyl)methyl ester 17357-75-4, 1H-1,2,4-Triazole, 3-[[(4-methoxyphenyl)methyl]thio]- 17430-65-8, L-Tryptophan, N-[(phenylmethoxy)carbonyl]-L-valyl-, methyl ester 17496-31-0, 1H-Imidazole, 4-[[(phenylmethyl)thio]methyl]- 18100-11-3, 1,4-Naphthalenedione, 2-(3-cyclohexylbutyl)-3-hydroxy- 18100-12-4, 1,4-Naphthalenedione, 2-[3-(4-chlorophenyl)propyl]-3-hydroxy- 18211-37-5, 1,4-Naphthalenedione, 2-hydroxy-3-[3-(4-methylphenyl)propyl]- 19312-13-1, 2-Propen-1-one, 1-(2,5-dihydroxyphenyl)-3-phenyl- 19484-75-4D, 2H-1-Benzopyran-2-one, 3,4-dihydro-7-hydroxy-4-methyl-, furanoside derivative 19889-31-7, 1H-Imidazole-4-propanamide, α-amino-N-2-naphthalenyl- 20621-49-2, 2-Propen-1-one, 1-(2,6-dihydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)- 20711-05-1, L-Glutamic acid, N-[4-[[2-(2-amino-1,5,6,7-tetrahydro-4-hydroxy-6-pteridinyl)ethyl]amino]benzoyl]- 21108-76-9, Imidazo[2,1-b]thiazol-3(2H)-one, 5,6-dihydro-2-(3-phenyl-2-propenylidene)- 21658-45-7, Glycine, L-arginyl-L-prolyl-L-prolyl- 23567-67-1, Phenol, 4-(1,2,3,4-thiatriazol-5-ylamino)- 23815-88-5, 1-6-Bradykinin 24205-32-1, L-Glutamic acid, N-[4-[[(2,4-diamino-5-methyl-6-quinazolinyl)methyl]amino]benzoyl]-,diethylester 24386-39-8, Urea, N-1-naphthalenyl-N'-2-pyrimidinyl- 24829-12-7, Phenol, 2-[(1H-1,2,4-triazol-3-ylimino)methyl]- 26962-50-5, 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(2-hydroxyphenyl)- 27069-81-4, L-Glutamic acid, N-[4-[[(2-amino-1,4-dihydro-4-oxo-6-quinazolinyl)methyl]amino]benzoyl]-, diethyl ester 27430-15-5, 4,6(1H,5H)-Pyrimidinedione, 5-[[4-(dimethylamino)phenyl]methylene]dihydro-2-thioxo- 27430-17-7, 4,6(1H,5H)-Pyrimidinedione, dihydro-5-(3-phenyl-2-propenylidene)-2-thioxo- 28005-33-6, Benzene, 1,1'-methylenebis[4-[(4-nitrophenyl)thio]- 28246-23-3, Ethanone, 2-(1H-imidazol-2-ylthio)-1-phenyl- 28772-56-7, 2H-1-Benzopyran-2-one, 3-[3-(4'-bromo[1,1'-biphenyl]-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy- 29654-52-2, Benzene, 1,1'-methylenebis[4-[(4-nitrophenyl)sulfonyl]- 30148-18-6, Methanone, (4-chlorophenyl)(1-methyl-1H-imidazol-2-yl)- 30216-31-0D, Benzoxazole, 2-[2-(2-chlorophenyl)ethenyl]-, derivs. 30355-60-3, 1,3,5-Triazine-2,4-diamine, 6-(chloromethyl)-N-phenyl- 30826-46-1, L-Glutamic acid, N-[4-[[[5,7-bis(acetylamino)pyrido[3,4-b]pyrazin-3-yl]methyl]methylamino]benzoyl]-, diethyl ester 30826-47-2, L-Glutamic

acid, N-[4-[[[6,8-bis(acetylamino)pyrido[2,3-b]pyrazin-2-yl]methyl]methylamino]benzoyl]-, diethyl ester 33254-46-5, 6H-Purine-6-thione, 1,9-dihydro-9-(3-phenylpropyl)- 34396-76-4, 6H-Purin-6-one, 1,9-dihydro-9-(3-phenylpropyl)- 37664-31-6, Ethanone, 1-(4-chlorophenyl)-2-(1H-1,2,4-triazol-3-ylthio)- 40538-65-6, 5(4H)-Isoxazolone, 3-methyl-4-[(phenylamino)methylene]- 40816-36-2, 4,6-Pyrimidinediamine, 5-nitro-N-phenyl- 41266-78-8, 1H-1,2,4-Triazol-3-amine, 5-[[(4-chlorophenyl)methyl]thio]- 41600-13-9, L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-γ-glutamyl- 42220-83-7, 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(3-hydroxyphenyl)- 46825-86-9, Pyrimidinetetramine, N4-(4-bromophenyl)- 50602-77-2, L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-, dibutyl ester 51646-15-2, [1,2,4]Triazolo[1,5-a]pyrimidine, 5,7-dimethyl-2-[(phenylmethyl)thio]- 51893-98-2, Benzoic acid, 2-hydroxy-, [2-[(5-ethyl-1,4-dihydro-6-methyl-4-oxo-2-pyrimidinyl)thio]-1-phenylethylidene]hydrazide 51934-26-0, L-Glutamic acid, N-[4-[[(7-amino-1,5-dihydro-5-thioxopyrimido[5,4-e]-1,2,4-triazin-3-yl)methyl]amino]benzoyl]-, diethyl ester, monohydrochloride 51934-28-2, L-Glutamic acid, N-[4-[[(5,7-diaminopyrimido[5,4-e]-1,2,4-triazin-3-yl)methyl]amino]benzoyl]-, diethyl ester 54299-50-2, 2-Propen-1-one, 1-(2,4-dihydroxy-3,6-dimethoxyphenyl)-3-phenyl- 54395-52-7, 1H-Isoindole-1,3(2H)-dione, 5,5'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[2-methyl- 56025-86-6, 1H-Purine-2,6-dione, 3,7-dihydro-3-methyl-7-(phenylmethyl)- 56307-99-4, Ethanone, 1-(2,4-dihydroxyphenyl)-2-(phenylthio)- 57710-80-2, 1H-Benzotriazole-1-carboxylic acid, phenylmethyl ester 57808-66-9, 2H-Benzimidazol-2-one, 5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro- 57966-42-4, L-Threonine, L-arginyl-L-tyrosyl-L-leucyl-L-prolyl- 58677-09-1, L-Glutamic acid, N-[4-[[(2-amino-1,4-dihydro-4-oxo-6-quinazolinyl)methyl]methylamino]benzoyl]-, diethyl ester 60045-61-6, 4,6(1H,5H)-Pyrimidinedione, dihydro-5-[(4-methoxyphenyl)methylene]-2-thioxo- 60407-48-9, L-Isoleucine, L-arginylglycyl-L-prolyl-L-phenylalanyl-L-prolyl- 60482-96-4, L-Leucine, L-arginyl-L-prolyl-L-tyrosyl-L-isoleucyl- 61043-53-6, L-Phenylalaninamide, N-(3-carboxy-1-oxopropyl)-L-alanyl-L-alanyl-N-(4-nitrophenyl)- 64792-21-8, 2-Propenal, 3-phenyl-, (1,4-dihydro-6-methyl-4-oxo-2-pyrimidinyl)hydrazone 64801-58-7, L-Aspartic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-γ-glutamyl- 65147-09-3, L-Argininamide, N-[(1,1-dimethylethoxy)carbonyl]-L-leucylglycyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)- 65757-04-2, L-Glutamic acid, N-[4-[[(1,2,3,4-tetrahydro-2-imino-1,3-dimethyl-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, dimethyl ester 65757-05-3, L-Glutamic acid, N-[4-[[(2-amino-3,4-dihydro-3-methyl-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, dimethyl ester 65877-43-2D, 1,3-Benzenediol, 5-[2-(3-hydroxy-4-methoxyphenyl)ethenyl]-, glycoside derivative 66048-53-1, Guanosine, 2',3',5'-tribenzoate 66147-31-7, L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-, 5-butyl ester 67368-29-0, L-Alanine, L-methionyl-L-arginyl-L-phenylalanyl- 67655-19-0, Phenol, 2,2'-[(2-hydroxy-1,3-propanediyl)bis(oxy)]bis- 67836-16-2, Acetamide, 2-(2,4-dichlorophenoxy)-N-1H-1,2,4-triazol-3-yl- 68047-41-6, 1,3,4-Oxadiazole, 2-(3-bromophenyl)-5-(2-naphthalenyl)- 68215-68-9, Phenol, 2-[4-amino-6-[(4-chlorophenyl)amino]-1,3,5-triazin-2-yl]-4-chloro- 68682-02-0, 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methyl-2-butenyl)- 68838-40-4, 1H-1,2,4-Triazole, 3-methyl-5-[(phenylmethyl)thio]- 69097-98-9, 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)- 69193-20-0, 4-Pyrimidinamine, 5-bromo-N-phenyl- 69480-15-5, 3H-1,2,4-Triazole-3-thione, 5-[4-(1,1-dimethylethyl)phenyl]-1,2-dihydro- 70280-72-7, L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl](phenylmethyl)amino]benzoyl]-, diethyl ester 70280-75-0, L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]ethylamino]benzoyl]-, diethyl ester 70539-54-7, L-Glutamic acid, N-[3,5-dichloro-4-[[(2,4-diamino-6-

pteridinyl)methyl]ethylamino]benzoyl]-, diethyl ester 70968-04-6, L-Leucinamide, N-(3-carboxy-1-oxopropyl)-L-alanyl-L-alanyl-L-prolyl-N-(4-nitrophenyl)- 71047-38-6, 1H-Imidazole, 1-(3,7-dimethyl-2,6-octadienyl)- 71074-46-9, Glycine, N-[N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-γ-glutamyl]- 71074-48-1, L-Aspartic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-α-glutamyl- 71074-49-2, L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-α-glutamyl- 71707-02-3, L-Glutamic acid, N-[N-[4-[[(2,4-diamino-6-pteridinyl)methyl]amino]benzoyl]-L-γ-glutamyl]- 72630-15-0, Glutamic acid, N-[4-[[2-(2-amino-1,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl)ethyl]amino]benzoyl]- 72682-77-0, L-Isoleucinamide, N-(3-carboxy-1-oxopropyl)-L-alanyl-L-alanyl-L-prolyl-N-(4-nitrophenyl)- 72704-76-8, 2-Propen-1-one, 3-(3,4-dihydroxyphenyl)-1-phenyl- 73554-90-2, L-Argininamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-L-seryl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)- 73572-58-4, L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-L-leucyl-L-phenylalanyl-L-leucyl- 74039-67-1, 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-8-(3-phenyl-2-propenyl)- 74405-42-8, Adenosine, N-benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-, 3'-(hydrogen butanedioate) 74405-44-0, Cytidine, N-benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-, 3'-(hydrogen butanedioate) 74853-69-3, L-Leucine, N2-acetyl-L-arginyl-L-arginyl-L-prolyl-L-tyrosyl-L-isoleucyl- 75651-68-2, L-Phenylalaninamide, N-(3-carboxy-1-oxopropyl)-L-phenylalanyl-L-prolyl-N-(4-nitrophenyl)- 75960-43-9, 1H-Imidazole-4-hexanoic acid, 5-(chloromethyl)-2,3-dihydro-ε,2-dioxo-, ethyl ester 76172-68-4, 1-Propanone, 3-(4-methoxyphenyl)-1-(2,4,6-trihydroxyphenyl)- 80032-99-1, 1H-1,2,4-Triazole, 3,3'-[1,4-butanediylbis(thio)]bis- 80360-08-3, L-Glutamic acid, N-[4-[[(2,4-diaminopyrido[2,3-d]pyrimidin-6-yl)methyl]amino]benzoyl]-, diethyl ester 81066-61-7, 2-Pyridinamine, 3-[[4-(1,1-dimethylethyl)phenyl]methoxy]- 81587-37-3, 3-Pyridinethiol, 2-[(2,6-diamino-4-pyrimidinyl)amino]-6-methyl- 82628-82-8, 1-Propanone, 3-(4-nitrophenyl)-1-(2,4,6-trihydroxyphenyl)- 82855-85-4, L-Glutamic acid, N-[4-[[(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido[3,2-d]pyrimidin-6-yl)methyl]amino]benzoyl]-, diethyl ester 85122-85-6, 1H-Isoindole-1,3(2H)-dione, 2,2'-[1,3-propanediylbis(4,1-piperidinediylmethylene)]bis- 86669-33-2, L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-, bis(1,1-dimethylethyl) ester 90259-60-2, Benzamide, 2-amino-N-[3-(1H-imidazol-1-yl)propyl]- 90259-61-3, Benzamide, 2-[[(4-chlorophenyl)sulfonyl]amino]-N-[3-(1H-imidazol-1-yl)propyl]- 92899-39-3, Glycine, L-valylglycyl-L-valyl-L-alanyl-L-prolyl- 92954-99-9, Glycine, 1-acetyl-L-prolyl-L-leucylglycyl-L-leucyl-L-leucyl-, ethyl ester 93515-01-6, L-Threonine, L-tyrosyl-L-prolyl-L-prolyl-L-α-glutamyl-L-prolyl-L-α-glutamyl- 93524-30-2, β-D-Glucopyranosiduronic acid, (3α,5β)-21-(acetyloxy)-20-[(aminocarbonyl)hydrazono]pregnan-3-yl, methyl ester, 2,3,4-triacetate 93674-97-6, L-Serine, L-arginylglycyl-L-α-glutamyl- 95192-21-5, L-Phenylalaninamide, N-(3-carboxy-1-oxopropyl)-L-phenylalanyl-L-alanyl-N-(4-nitrophenyl)- 95192-38-4, L-Phenylalaninamide, N-(3-carboxy-1-oxopropyl)-L-alanyl-L-valyl-L-prolyl-N-(4-nitrophenyl)- 95210-75-6, L-Proline, L-tyrosyl-L-prolyl-L-phenylalanyl-L-valyl-L-α-glutamyl-L-prolyl-L-isoleucyl- 98018-39-4, Ethanone, 2-[(2-amino-1H-purin-6-yl)thio]-1-phenyl- 98151-93-0, L-Proline, L-tyrosyl-L-prolyl-L-phenylalanyl-L-prolylglycyl-L-prolyl-L-isoleucyl- 100975-56-2, Benzaldehyde, 4-hydroxy-, (2,3,6,7-tetrahydro-1,3,7-trimethyl-2,6-dioxo-1H-purin-8-yl)hydrazone 102212-40-8, 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-8-[(2-phenylethyl)amino]- 103030-49-5, 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-5-nitro- 103398-43-2, Benzenemethanol, 2-[bis[2-[(4-nitrobenzoyl)oxy]ethyl]amino]-, 4-nitrobenzoate (ester) 105037-36-3, Benzenesulfonic acid, 4-[(7-chloro-4-quinazolinyl)amino]- 108608-63-5, Glycine, L-seryl-L-α-aspartylglycyl-L-arginyl-

110906-89-3, L-Phenylalaninamide, N-(3-carboxy-1-oxopropyl)-L-phenylalanyl-L-alanyl-L-alanyl-N-(4-nitrophenyl)- 111172-14-6, 1,3-Benzodioxole-5-carboxaldehyde, O-(2-thienylcarbonyl)oxime 112233-74-6, Carbamic acid, diphenyl-, 2-(acetylamino)-1H-purin-6-yl ester 113866-00-5, L-Argininamide, N-[(1,1-dimethylethoxy)carbonyl]-L-α-aspartyl-L-prolyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-, phenylmethyl ester 113866-16-3, L-Argininamide, N-[(1,1-dimethylethoxy)carbonyl]-L-α-glutamyl-L-alanyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-, phenylmethyl ester 117889-48-2, 1H-Tetrazole, 5-[(2,4-dichlorophenoxy)methyl]- 118034-92-7, L-Threonine, L-histidyl-L-phenylalanyl-L-methionyl-L-prolyl- 120225-54-9, Benzenepropanoic acid, 4-[2-[[6-amino-9-(N-ethyl-β-D-ribofuranuronamidosyl)-9H-purin-2-yl]amino]ethyl]- 121036-80-4, 1,2,4-Triazin-5(2H)-one, 6-[2-(4-methylphenyl)ethenyl]-3-phenyl- 121036-81-5, 1,2,4-Triazin-5(2H)-one, 6-[2-(4-methoxyphenyl)ethenyl]-3-phenyl- 124485-41-2, L-Argininamide, N-[(phenylmethoxy)carbonyl]-L-valyl-L-valyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)- 126235-09-4, 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-8-(2-phenylethyl)- 128802-79-9, L-Phenylalaninamide, N-(3-carboxy-1-oxopropyl)-L-alanyl-L-isoleucyl-L-prolyl-N-(4-nitrophenyl)- 131061-65-9, 7H-Purine-7-butanoic acid, 1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-8-[(phenylmethyl)amino]-, ethyl ester 132467-01-7, 2(1H)-Quinoxalinone, 3-[2-(2-chlorophenyl)ethenyl]- 133061-57-1, 2,4-Pyrimidinediamine, N4-(3,5-dichlorophenyl)-6-methyl- 134759-22-1, 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[5-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]thioxomethyl]amino]pentyl]amino]-6-oxohexyl]hexahydro-2-oxo-, (3aS,4S,6aR)- 134796-34-2, 1H-1,2,4-Triazole, 3-[[(4-chlorophenyl)methyl]thio]- 137484-84-5, 1,3,5-Triazin-2-amine, 4-chloro-6-[3-(2-furanyl)propoxy]-N,N-dimethyl- 137833-31-9, Myelopeptide 2 138194-56-6, 1H-Pyrrole-2,5-dione, 1-[3-[[(4-oxo-1,2,3-benzotriazin-3(4H)-yl)oxy]carbonyl]phenyl]- 138915-75-0, L-Leucine, N-acetyl-L-histidyl-L-tryptophyl-L-alanyl-L-valylglycyl-L-histidyl- 142206-40-4, 1H-Benzimidazole, 2,2'-(1,3-propanediyl)bis[1-methyl- 143113-41-1, L-Valine, L-Histidyl-L-Alanyl 146871-70-7, 4-Quinazolinamine, N-(3-chlorophenyl)-, monohydrochloride 148337-06-8, Glycine, L-prolylglycyl-L-alanyl-L-isoleucyl-L-prolyl- 151358-70-2, 2-Propen-1-one, 1,1'-(2,6-pyridinediyl)bis[3-(4-hydroxyphenyl)- 152028-96-1, 1H-Imidazole, 4-[3-[(4-iodophenyl)methoxy]propyl]- 154719-25-2, L-Lysinamide, N-acetyl-L-tyrosyl-L-valyl-N-[(1S)-1-(carboxymethyl)-3-[(2,6-dimethylbenzoyl)oxy]-2-oxopropyl]-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]- 155373-59-4, 4H-1-Benzopyran-4-one, 3-[[4-(1H-tetrazol-5-yl)phenyl]methyl]- 155373-72-1, 4H-1-Benzopyran-4-one, 2-phenyl-7-[4-(1H-tetrazol-5-yl)butoxy]- 160347-57-9D, 2(1H)-Pyrimidinone, 5-(4-pentylphenyl)-, derivs. 185503-97-3, L-Lysine, N6-[[4-[[4-(dimethylamino)phenyl]azo]phenyl]sulfonyl]-N2-[(9H-fluoren-9-ylmethoxy)carbonyl]- 188966-22-5D, Phenol, 2-(2H-benzotriazol-2-yl)-4-(1,1-dimethylhexyl)-, derivs. 191411-47-9, 1H-Imidazole-5-methanol, 1-methyl-2-[(phenylmethyl)thio]- 194424-08-3, Glutamic acid, N-[4-[[3-(2-thienyl)-2-quinoxalinyl]amino]benzoyl]-, dipropyl ester 195140-70-6, 1H-Imidazole, 1-[2-(phenylmethoxy)ethyl]- 196600-87-0, Tyrosine, N-[(phenylmethoxy)carbonyl]norvalylglycyl-, methyl ester 197456-56-7, 1,4-Naphthalenedione, 2-[4-(decahydro-2-naphthalenyl)butyl]-3-hydroxy- 198488-04-9, Urea, N,N''-(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis[N'-(2-methylphenyl)- 198632-08-5, L-Proline, glycyl-L-arginylglycyl-L-α-glutamyl-L-threonyl- 199929-21-0, 1,4-Naphthalenedione, 2-hydroxy-3-[8-(4-methylphenoxy)octyl]- 200058-34-0, 1,4-Naphthalenedione, 2-(3-[1,1'-bicyclohexyl]-4-ylpropyl)-3-hydroxy- 200061-22-9, Phenol, 4,4'-(1-methylethylidene)bis-, bis(3,5-dinitrobenzoate) 200431-98-7, 3-Pyridinemethanamine, N-1H-1,2,4-triazol-3-yl- 200505-51-7, Decanedioic acid, bis[[(4-ethoxy-3-methoxyphenyl)methylene]hydrazide] 200706-30-5, 4H-1,2,4-Triazol-4-amine, N-[(2,3-dihydro-1H-inden-5-yl)methylene]- 200706-45-2, 4-Imidazolidinone, 5-[(2,3-dihydro-1H-inden-5-yl)methylene]-2-

thioxo- 201997-13-9, 1,3-Benzenediol, 4-[[[2-hydroxy-2-(4-nitrophenyl)ethyl]imino]methyl]- 202118-27-2, 1H-1,2,4-Triazol-3-amine, N-[(2-iodophenyl)methylene]- 202118-28-3, 1H-1,2,4-Triazol-3-amine, N-[(2-chlorophenyl)methylene]- 202332-09-0, 1,4-Benzenediol, 2-(6-methylheptyl)- 202528-15-2, Cyclo(L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-L-isoleucyl) 206360-24-9
, 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-3-(3-methyl-2-butenyl)- 210709-22-1, L-Alanine, N2-benzoyl-L-arginyl-L-phenylalanyl- 215434-58-5, 1-Piperazinecarbothioamide, N-3-pyridinyl-4-[4-(trifluoromethyl)-2-pyrimidinyl]- 215655-36-0, Benzoic acid, 2-[[[2-[[4-(trifluoromethyl)-2-pyrimidinyl]amino]ethyl]amino]carbonyl]- 215657-86-6, 2-Pyrrolidinone, 1-[2-hydroxy-3-[4-[4-(trifluoromethyl)-2-pyrimidinyl]-1-piperazinyl]propyl]- 216299-43-3, 2,5-Pyrrolidinedione, 1-[[11-[(5-azido-1-naphthalenyl)oxy]-1-oxoundecyl]oxy]-
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT 216774-46-8, 4-Isoxazolecarboxamide, N-1H-benzotriazol-5-yl-5-methyl-3-phenyl- 218456-13-4, Urea, N-[2-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]-N'-phenyl- 218928-70-2, Benzamide, N-[3-(1H-imidazol-1-yl)propyl]-2-[(4-nitrobenzoyl)amino]- 218928-81-5, Benzamide, 2-[[[(2,6-dichlorophenyl)amino]carbonyl]amino]-N-[3-(1H-imidazol-1-yl)propyl]- 218929-60-3, Urea, N-(4-fluorophenyl)-N'-[4-(1,2,4-oxadiazol-3-yl)phenyl]- 219139-65-8, 4(1H)-Pyrimidinone, 2-[[[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]methyl]thio]- 219865-73-3, 2H-Isoindole-2-acetic acid, α-[3-(4H-1,3-benzodioxin-6-ylamino)-3-oxopropyl]-1,3-dihydro-1,3-dioxo- 220171-00-6, 1H-Imidazole, 2-[2-(4-methoxyphenyl)ethenyl]- 229971-59-9, L-Cysteinamide, L-cysteinyl-L-histidyl-L-alanyl-L-valyl-, cyclic (1→5)-disulfide 229971-81-7, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-L-alanyl-L-valyl-, cyclic (1→5)-disulfide 229971-83-9, L-Cysteinamide, N-acetyl-L-cysteinyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-L-isoleucyl-, cyclic (1→8)-disulfide 229971-84-0, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-L-alanyl-L-valyl-L-seryl-, cyclic (1→6)-disulfide 229971-85-1, L-Cysteinamide, N-acetyl-L-cysteinyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-, cyclic (1→7)-disulfide 229971-86-2, L-Cysteinamide, N-acetyl-L-cysteinyl-L-seryl-L-histidyl-L-alanyl-L-valyl-L-seryl-L-seryl-, cyclic (1→8)-disulfide 229971-87-3, L-Cysteinamide, N-acetyl-L-cysteinyl-L-seryl-L-histidyl-L-alanyl-L-valyl-, cyclic (1→6)-disulfide 229971-88-4, L-α-Asparagine, N2-acetyl-L-lysyl-L-histidyl-L-alanyl-L-valyl-, (5→1)-lactam 229971-89-5, L-Cysteinamide, L-cysteinyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-, cyclic (1→7)-disulfide 229971-90-8, L-Cysteinamide, L-cysteinyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-L-isoleucyl-, cyclic (1→8)-disulfide 229971-91-9, L-Cysteinamide, N-acetyl-L-cysteinyl-L-valyl-L-alanyl-L-histidyl-, cyclic (1→5)-disulfide 240799-81-9, Benzenamine, N-[2-(3-methyl-4-nitro-5-isoxazolyl)ethenyl]-4-phenoxy- 241154-06-3, 3-Furancarboxylic acid, 5-[1,1'-biphenyl]-4-yl-2-(trifluoromethyl)- 244278-78-2, Ethanone, 1-(4-chlorophenyl)-2-[(1-methyl-1H-imidazol-2-yl)thio]- 245435-74-9, 5-Pyrimidinecarbonitrile, 4-[(2,4-dichlorophenyl)amino]-2-methyl-6-(methylthio)- 252867-19-9, 1,2,4-Oxadiazole, 3-(chloromethyl)-5-(2-phenylethenyl)- 252867-33-7, 4(1H)-Pyrimidinone, 2-[[[5-(4-methyl-1,2,3-thiadiazol-5-yl)-1,2,4-oxadiazol-3-yl]methyl]thio]-6-propyl- 252914-56-0, 1,2,4-Oxadiazole, 3-[[(4-chlorophenyl)thio]methyl]-5-(4-methyl-1,2,3-thiadiazol-5-yl)- 252914-57-1, Pyridine, 2-[[[5-(4-methyl-1,2,3-thiadiazol-5-yl)-1,2,4-oxadiazol-3-yl]methyl]thio]- 254748-91-9, Urea, N-(4-chlorophenyl)-N'-[3-(1,2,4-oxadiazol-3-yl)phenyl]- 254748-92-0, Urea, N-methyl-N'-[3-(1,2,4-oxadiazol-3-yl)phenyl]-

254748-93-1, Urea, N-butyl-N'-[3-(1,2,4-oxadiazol-3-yl)phenyl]-
254748-94-2, Urea, N-[3-(1,2,4-oxadiazol-3-yl)phenyl]-N'-phenyl-
254748-97-5, Benzenamine, N-[(2-chloro-6-fluorophenyl)methylene]-3-(1,2,4-
oxadiazol-3-yl)- 254749-34-3, Urea, [3-(1,2,4-oxadiazol-3-yl)phenyl]-
254753-72-5, 1,4-Benzenediol, 2-[2-methyl-5-(4-nitrophenyl)-2-
oxazolidinyl]- 254880-42-7, 1,2,3-Thiadiazole, 4-[4-[(1H-1,2,4-triazol-3-
ylthio)methyl]phenyl]- 254880-46-1, 1,2,3-Thiadiazole,
4-[4-[(1H-1,2,4-triazol-3-ylsulfonyl)methyl]phenyl]- 255377-83-4,
Carbamic acid, [(2-oxo-2H-pyran-6-yl)carbonyl]-, phenyl ester
255378-13-3, 1,3,4-Oxadiazole-2-carboxamide, N-[[(5-methyl-3-
isoxazolyl)amino]carbonyl]-5-phenyl- 255728-27-9, 1,2,4-Thiadiazole,
5-[4-[(4-fluorophenoxy)methyl]phenyl]- 255904-99-5, Pyrazinecarboxamide,
N-(4-phenoxyphenyl)- 256414-57-0, 2-Thiophenecarboxamide,
4-phenyl-N-2-pyridinyl-5-(trifluoromethyl)- 256432-37-8, Ethanone,
1-[3-benzoyl-7-[(4-nitrophenyl)methyl]-1-indolizinyl]- 257287-79-9,
4-Isoxazolecarboxylic acid, 3,5-dimethyl-, 2,3-dihydro-3-oxo-6-
benzofuranyl ester 258264-27-6, Thiourea, N-(2,4-dichlorophenyl)-N'-[2-
(1H-imidazol-1-yl)-1-phenylethyl]- 258521-36-7, Ethanimidamide,
2-[4-(1,3,4-oxadiazol-2-yl)phenoxy]-N-[[3-(trifluoromethyl)benzoyl]oxy]-
260368-01-2, 2-Butenoic acid, 4-oxo-4-[4-[5-(trifluoromethyl)-2-pyridinyl]-
1-piperazinyl]- 260555-63-3, 1,2,4-Oxadiazole, 3-(2-thienyl)-5-[2-[4-
(trifluoromethoxy)phenyl]ethenyl]- 261511-13-1, 1H-1,2,4-Triazole,
3-(3,5-dichlorophenyl)-5-[[(2,4-dichlorophenyl)methyl]thio]-
261511-30-2, 1H-1,2,4-Triazole, 3-[3,5-bis(trifluoromethyl)phenyl]-5-[[(2-
chloro-6-fluorophenyl)methyl]thio]- 261626-76-0, Hydrazinecarboxamide,
2-(2,6-dichlorophenyl)-N-[3-(3-methylphenyl)-1,2,4-oxadiazol-5-yl]-
261626-98-6, 1H-1,2,4-Triazole, 3-[4-(1,1-dimethylethyl)phenyl]-5-
[(phenylmethyl)thio]- 261626-99-7, 1H-1,2,4-Triazole,
3-[4-(1,1-dimethylethyl)phenyl]-5-[[(4-methylphenyl)methyl]thio]-
261627-00-3, 1H-1,2,4-Triazole, 3-[[(2,4-dichlorophenyl)methyl]thio]-5-[4-
(1,1-dimethylethyl)phenyl]- 261704-50-1, 1H-1,2,4-Triazole,
3-[[(2-chlorophenyl)methyl]thio]-5-(4-pentylphenyl)- 261705-07-1,
1H-1,2,4-Triazole, 3-[[(4-methylphenyl)methyl]thio]-5-(trifluoromethyl)-
261765-01-9, Benzoic acid, 2-(1,4,5,6-tetrahydro-2-pyrimidinyl)-,
[(4-nitrophenyl)methylene]hydrazide 261928-97-6, 1H-1,2,4-Triazol-3-
amine, 5-[[(2,6-dichlorophenyl)methyl]thio]- 261928-98-7,
1H-1,2,4-Triazol-3-amine, 5-[[(2-chloro-6-fluorophenyl)methyl]thio]-
262856-19-9, 4H-1,2,4-Triazole, 3-(1-ethyl-3-methyl-1H-pyrazol-5-yl)-4-
methyl-5-[(phenylmethyl)thio]- 263160-48-1, 1,2,4-Oxadiazole-5-
carboxylic acid, 3-(2-methyl-4-thiazolyl)-, 2-[[[3-
(trifluoromethyl)phenyl]amino]carbonyl]hydrazide 263161-07-5,
3(2H)-Benzoxazolepropanoic acid, 2-oxo-, 4-chlorophenyl ester
263161-08-6, 3(2H)-Benzoxazolepropanoic acid, 2-oxo-, 3-
(trifluoromethyl)phenyl ester 263161-09-7, 3(2H)-Benzoxazolepropanoic
acid, 2-oxo-, 3-chlorophenyl ester 263563-52-6, 1,2,4-Oxadiazole-5-
carboxylic acid, 3-[4-(trifluoromethoxy)phenyl]-, 2-[[(3-
chlorophenyl)amino]carbonyl]hydrazide 263563-53-7, 1,2,4-Oxadiazole-5-
carboxylic acid, 3-[4-(trifluoromethoxy)phenyl]-, 2-
[(phenylamino)carbonyl]hydrazide 263563-54-8, 2(3H)-Benzoxazolone,
3-[2-[[[(phenylamino)carbonyl]oxy]imino]propyl]- 263563-55-9,
2(3H)-Benzoxazolone, 3-[2-[[[[(3-chlorophenyl)amino]carbonyl]oxy]imino]pro
pyl]- 263563-75-3, Urea, N-1-piperidinyl-N'-[3-[4-
(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]- 263756-04-3,
1H-Pyrazole-1-carboxamide, 3,5-dimethyl-N-phenyl-4-(2-pyrimidinylthio)-
263756-06-5, 1H-Pyrazole, 1-(4-chlorobenzoyl)-3,5-dimethyl-4-(2-
pyrimidinylthio)- 263897-82-1, Ethanone, 1-[2-(5-isoxazolyl)-4-
thiazolyl]-, O-[3-(trifluoromethyl)benzoyl]oxime 263917-87-9,
L-Cysteinamide, N-acetyl-L-cysteinyl-L-leucyl-L-arginyl-L-alanyl-L-
histidyl-L-alanyl-L-valyl-, cyclic (1→8)-disulfide 263917-88-0,
L-Cysteinamide, N-acetyl-L-cysteinyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-
, cyclic (1→6)-disulfide 263917-89-1, L-Cysteinamide,
N-acetyl-L-cysteinyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-,
cyclic (1→6)-disulfide 263917-90-4, L-Cysteinamide,

N-acetyl-L-cysteinyl-L-arginyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-, cyclic (1→8)-disulfide 263917-92-6, L-Cysteinamide, N-acetyl-L-cysteinyl-L-seryl-L-histidyl-L-alanyl-L-valyl-L-seryl-, cyclic (1→7)-disulfide 263917-93-7, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-L-alanyl-L-valyl-L-seryl-L-seryl-, cyclic (1→7)-disulfide 264127-43-7, Ethanone, 2-[[4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]thio]-1-phenyl- 264610-37-9, Thiazolo[3,2-b][1,2,4]triazole, 2-(4-chlorophenyl)-6-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)- 265329-88-2, 1,3,5-Triazin-2-amine, 4-[[4-(1,1-dimethylethyl)phenoxy]methyl]-6-methyl- 266679-45-2D, 4(1H)-Pyrimidinone, 6-(chloromethyl)-2-[[4-(1,1-dimethylethyl)phenoxy]methyl]-, derivs. 271775-62-3, Acetamide, N-(4-cyclohexylphenyl)-2-[(1-methyl-1H-imidazol-2-yl)thio]- 273920-93-7, 4H-1-Benzopyran-4-one, 2-phenyl-7-(1H-tetrazol-5-ylmethoxy)- 280133-36-0, Benzenepropanoic acid, β-[2-[(benzo[b]thien-3-ylmethyl)amino]-2-oxoethyl]- 281211-72-1, Benzenesulfonic acid, 4-methyl-, [(2,4-dihydroxyphenyl)methylene]hydrazide 284674-47-1, 1,3,5-Triazine-2-carboxylic acid, 4-amino-6-[(2,4,6-trifluorophenyl)amino]-, methyl ester 286440-09-3, 1,3-Benzenediol, 4-(2-phenylthiazolo[3,2-b][1,2,4]triazol-6-yl)- 288161-26-2, Pyrimidine, 5-[3-(4-chlorophenyl)-5-isoxazolyl]- 289626-25-1, L-Proline, N2-benzoyl-L-arginylglycyl-L-phenylalanyl-L-phenylalanyl- 293762-17-1, Benzoic acid, 4-[4-[[2,3-dihydro-2-(3-nitrophenyl)-1,3-dioxo-1H-isoindol-5-yl]carbonyl]phenoxy]- 294878-31-2, 2-Pyrimidinamine, 4-chloro-6-(2,4-dimethylphenoxy)- 294878-32-3, 2-Pyrimidinamine, 4-(2,4-dimethylphenoxy)-6-fluoro- 296272-93-0, 1H-1,2,4-Triazole, 3-[[(4-nitrophenyl)methyl]thio]- 299461-73-7, 2-Propen-1-one, 1-(4-methylphenyl)-3-[(4-methyl-4H-1,2,4-triazol-3-yl)thio]- 301174-11-8, 4(1H)-Pyrimidinone, 2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-6-hydroxy- 301201-59-2, 1H-1,2,4-Triazol-3-amine, N-[(3-methylphenyl)methylene]- 301304-52-9, Benzaldehyde, 2,4-dimethoxy-, (1,4-dihydro-6-methyl-4-oxo-2-pyrimidinyl)hydrazone 302804-66-6, 1H-1,2,4-Triazole, 3-[[(4-methylphenyl)methyl]thio]- 303016-22-0, 1H-Benzimidazole, 2-[(imidazo[2,1-b]thiazol-6-ylmethyl)thio]- 303145-16-6, 4H-Pyrido[1,2-a]-1,3,5-triazin-4-one, 2-[[[4-(1,1-dimethylethyl)phenyl]methyl]thio]- 303147-94-6, Benzoic acid, 2-[[6-[[(4-chlorophenyl)sulfinyl]methyl]-2-(4-pyridinyl)-4-pyrimidinyl]thio]-, methyl ester 303148-00-7, Benzoic acid, 2-[[6-[[(4-chlorophenyl)sulfinyl]methyl]-2-(4-pyridinyl)-4-pyrimidinyl]oxy]-, methyl ester 303150-34-7, 1H-1,2,4-Triazol-3-amine, 5-[[(2,4-dichlorophenyl)methyl]thio]- 303150-56-3, 1H-1,2,4-Triazol-3-amine, 5-[[[3-(trifluoromethyl)phenyl]methyl]thio]- 306280-22-8, Imidazo[1,2-a]pyridine, 6-chloro-2-[[(4,6-dimethyl-2-pyrimidinyl)thio]methyl]- 306936-17-4, 1H-Pyrrole-3-carboxylic acid, 5-(1,1-dimethylethyl)-2-methyl-1-[3-(4-morpholinyl)propyl]- 306936-72-1, 1,2,4-Oxadiazole, 5-(chloromethyl)-3-[(4-nitrophenoxy)methyl]- 306936-82-3, 3H-1,2,4-Triazole-3-thione, 2,4-dihydro-5-methyl-4-[4-(phenylmethoxy)phenyl]- 307316-86-5, 2-Quinazolinecarboxylic acid, 4-[(2-chlorophenyl)amino]-, ethyl ester 307526-33-6, 1,3-Benzenediol, 4-[4-(2-benzothiazolyl)-1H-pyrazol-3-yl]-6-ethyl- 307545-27-3, 1H-1,2,4-Triazole, 3-[[(3-methylphenyl)methyl]thio]- 313493-34-4, 1H-Isoindole-1,3(2H)-dione, 2,2'-(1,4-piperazinediyldi-4,1-butanediyl)bis- 315197-15-0, L-α-Asparagine, L-lysyl-L-histidyl-L-alanyl-L-valyl-, (5→16)-lactam 317320-21-1, Cyclo(L-alanyl-L-valyl-L-seryl-L-seryl-L-seryl-L-histidyl) 317822-46-1, 4H-Pyrrolo[3,4-d]isoxazole-4,6(5H)-dione, 5-[2-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]ethyl]-3a,6a-dihydro-3-(3-methyl-5-oxo-1-phenyl-1,2,4-triazolidin-3-yl)- 317822-47-2, 4H-Pyrrolo[3,4-d]isoxazole-4,6(5H)-dione, 5-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methylamino]-3-[1-(2,4-dichlorophenyl)-3-methyl-5-oxo-1,2,4-triazolidin-3-yl]-3a,6a-dihydro- 317822-54-1, 4H-Pyrrolo[3,4-d]isoxazole-4,6(5H)-dione, 5-[2-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]ethyl]-3-[1-(2,4-dichlorophenyl)-3-methyl-5-oxo-1,2,4-triazolidin-3-yl]-3a,6a-dihydro- 319916-73-9, 1(2H)-Quinolinepropanoic

acid, 6-[(4-cyanophenyl)azo]-3,4-dihydro-, methyl ester 321385-59-5, 1H-Pyrazole-1-carboxamide, 3-[4-(1H-imidazol-1-yl)phenyl]-N-phenyl- 321430-85-7, 1H-Benzimidazole, 5-chloro-2-(1H-1,2,4-triazol-1-ylmethyl)- 321432-26-2, 3-Isoxazolecarboxylic acid, 5-[[[1-[[[(4-chlorophenyl)methoxy]imino]methyl]-2-naphthalenyl]oxy]methyl]-4,5-dihydro-, ethyl ester 321433-43-6, 1,2,4-Triazolidin-3-one, 2-(2-fluorophenyl)-5-[3-(4-fluorophenyl)-2,1-benzisoxazol-5-yl]-5-methyl- 321433-44-7, 1,2,4-Triazolidin-3-one, 2-(3-fluorophenyl)-5-[3-(4-fluorophenyl)-2,1-benzisoxazol-5-yl]-5-methyl- 321576-71-0, Benzoic acid, 2-chloro-, [4-[[(3,4,5-trimethoxybenzoyl)oxy]imino]-2,5-cyclohexadien-1-ylidene]hydrazide 321682-33-1, Benzoic acid, 4-bromo-, [4-[[(3,4,5-trimethoxybenzoyl)oxy]imino]-2,5-cyclohexadien-1-ylidene]hydrazide 321682-97-7, Benzoic acid, 2-bromo-, [4-[[(3,4,5-trimethoxybenzoyl)oxy]imino]-2,5-cyclohexadien-1-ylidene]hydrazide 321949-09-1, Benzoic acid, 4-chloro-, [4-[[(3,4,5-trimethoxybenzoyl)oxy]imino]-2,5-cyclohexadien-1-ylidene]hydrazide 321998-82-7, Pyrimidine, 2-[4-(1H-pyrazol-3-yl)phenoxy]- 321998-88-3, 1H-Pyrazole, 1-benzoyl-3-[4-(2-pyrimidinyloxy)phenyl]- 324546-09-0, 2-Thiophenecarboxamide, N-[4-[(2-pyrimidinylamino)sulfonyl]phenyl]- 328917-75-5, 1-Piperidinecarboxylic acid, 4-[(1H-imidazol-1-ylcarbonyl)oxy]-, 4-phenoxyphenyl ester 329079-25-6, Acetamide, N-(3-chlorophenyl)-2-[(4-methyl-4H-1,2,4-triazol-3-yl)thio]- 331229-47-1, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidylglycyl-L-valyl-, cyclic (1→5)-disulfide 331229-48-2, L-α-Asparagine, N2-acetyl-L-lysyl-L-histidylglycyl-L-valyl-, (5→1)-lactam 331229-49-3, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidylglycyl-L-valyl-L-α-aspartyl-, cyclic (1→6)-disulfide 331229-50-6, L-Cysteinamide, N-acetyl-L-cysteinyl-L-alanyl-L-histidylglycyl-L-valyl-, cyclic (1→6)-disulfide 331229-51-7, L-Cysteinamide, N-acetyl-L-cysteinyl-L-alanyl-L-histidylglycyl-L-valyl-L-α-aspartyl-L-isoleucyl-, cyclic (1→8)-disulfide 331229-52-8, L-Cysteinamide, N-acetyl-L-cysteinyl-L-arginyl-L-alanyl-L-histidylglycyl-L-valyl-L-α-aspartyl-, cyclic (1→8)-disulfide 331229-53-9, L-Cysteinamide, N-acetyl-L-cysteinyl-L-leucyl-L-arginyl-L-alanyl-L-histidylglycyl-L-valyl-, cyclic (1→8)-disulfide 331229-54-0, L-Cysteinamide, N-acetyl-L-cysteinyl-L-leucyl-L-arginyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-α-aspartyl-, cyclic (1→9)-disulfide 331229-55-1, L-Cysteinamide, N-acetyl-L-cysteinyl-L-leucyl-L-arginyl-L-alanyl-L-histidylglycyl-L-valyl-L-α-aspartyl-, cyclic (1→9)-disulfide 331229-56-2, L-Cysteinamide, N-acetyl-L-cysteinyl-L-seryl-L-histidylglycyl-L-valyl-, cyclic (1→6)-disulfide 331229-57-3, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidylglycyl-L-valyl-L-seryl-, cyclic (1→6)-disulfide 331229-58-4, L-Cysteinamide, N-acetyl-L-cysteinyl-L-seryl-L-histidylglycyl-L-valyl-L-seryl-, cyclic (1→7)-disulfide 331229-59-5, L-Cysteinamide, N-acetyl-L-cysteinyl-L-seryl-L-histidylglycyl-L-valyl-L-seryl-L-seryl-, cyclic (1→8)-disulfide 331229-60-8, L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidylglycyl-L-valyl-L-seryl-L-seryl-, cyclic (1→7)-disulfide 331230-11-6, L-Cysteinamide, N-acetyl-L-cysteinyl-L-alanyl-L-histidylglycyl-L-valyl-L-α-aspartyl-, cyclic (1→7)-disulfide 338391-99-4, 1H-1,2,4-Triazol-3-amine, 5-[[(3,4-dichlorophenyl)methyl]thio]- 338392-61-3, Benzenemethanamine, N-[(5-chloro-2-phenyl-1H-imidazol-4-yl)methylene]-4-methyl- 338393-05-8, 1H-1,2,4-Triazole, 3-[[[3-(trifluoromethyl)phenyl]methyl]thio]- 338393-13-8, 1H-1,2,4-Triazole, 3-[[(4-methylphenyl)methyl]sulfonyl]- 338393-49-0, 5-Isoxazolepropanal, β-oxo-3-phenyl-, α-[O-[(4-nitrophenyl)methyl]oxime] 338400-95-6, 5-Isoxazolecarboxylic acid, 4,5-dihydro-3-(3-methyl-5-oxo-1-phenyl-1,2,4-triazolidin-3-yl)-, 2-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-2-methylhydrazide 338404-75-4, Imidazo[2,1-b]thiazole-5-carboxylic acid, 6-[[[3-(trifluoromethyl)phenyl]methyl]thio]- 338407-16-2, Guanidine, [3-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-1,2,4-oxadiazol-5-yl]- 338414-91-8, 1H-Imidazole-5-methanol, 1-methyl-2-[[(3-

methylphenyl)methyl]thio]- 338418-54-5, 1H-Benzimidazole, 2-(1H-1,2,4-triazol-1-ylmethyl)- 338422-66-5, 1,2,4-Triazolidin-3-one, 5-[5-[[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]methyl]-4,5-dihydro-3-isoxazolyl]-5-methyl-2-phenyl- 338751-52-3, 1(3H)-Isobenzofuranone, 3-[(1H-1,2,4-triazol-3-ylamino)methylene]- 339016-03-4, 2,4-Pyrimidinediamine, 6-chloro-N4-(4-phenoxyphenyl)- 339020-51-8, Pyrido[1,2-a]indole-10-carboxylic acid, 3-[2-[[(3-nitrophenyl)methylene]hydrazino]-2-oxoethoxy]-, ethyl ester 339021-25-9, 1H-1,2,4-Triazol-3-amine, 5-[4-(diphenylmethyl)-1-piperazinyl]- 339022-11-6, 1(3H)-Isobenzofuranone, 3-[[[5-[[(2,6-dichlorophenyl)methyl]thio]-1H-1,2,4-triazol-3-yl]amino]methylene]- 339022-23-0, 1(2H)-Phthalazinone, 4-[[[5-[[(2,6-dichlorophenyl)methyl]thio]-1H-1,2,4-triazol-3-yl]amino]methyl]- 339104-83-5, 2-Propen-1-one, 3-(phenylamino)-1-[4-(2-pyrimidinyloxy)phenyl]- 339105-69-0, 1H-1,2,4-Triazole, 3-[[(4-chlorophenyl)methyl]sulfonyl]- 339105-71-4, 1H-1,2,4-Triazole, 3-[[[3-(trifluoromethyl)phenyl]methyl]sulfonyl]- 339105-73-6, 1H-1,2,4-Triazole, 3-[[(4-methoxyphenyl)methyl]sulfonyl]- 339105-78-1, 1H-1,2,4-Triazole, 3-[[(4-nitrophenyl)methyl]sulfonyl]- 339105-82-7, 1H-1,2,4-Triazole, 3-[[(2-chloro-6-fluorophenyl)methyl]thio]- 339105-84-9, 1H-1,2,4-Triazole, 3-[[(2-chloro-6-fluorophenyl)methyl]sulfonyl]- 339105-87-2, 1H-1,2,4-Triazole, 3-[[(3-methylphenyl)methyl]sulfonyl]- 339106-76-2, 1H-Imidazole, 2-[2-(4-chlorophenyl)ethenyl]- 339106-78-4, 1H-Imidazole, 2-[2-(4-bromophenyl)ethenyl]- 341944-06-7, 1H-1,2,4-Triazol-3-amine, 5-[[(2-chlorophenyl)methyl]thio]- 341965-46-6, 1H-Imidazole-5-methanol, 2-[[(4-chlorophenyl)methyl]thio]-1-methyl- 341967-46-2, 1,3-Benzenediol, 2-[(2-chloro-6-fluorophenyl)methyl]-4-[[[(4-methylphenyl)methyl]imino]methyl]- 341967-49-5, 1,3-Benzenediol, 2-[(2-chloro-6-fluorophenyl)methyl]-4-[[(4-pyridinylmethyl)imino]methyl]- 344262-76-6, 1H-1,2,4-Triazol-3-amine, 5-[[(3-chlorophenyl)methyl]thio]- 344276-82-0, 1,2,4-Triazolidin-3-one, 2-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-5-[5-[[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]methyl]-4,5-dihydro-3-isoxazolyl]-5-methyl- 344276-87-5, 1,2,4-Triazolidin-3-one, 5-[5-[[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]methyl]-4,5-dihydro-3-isoxazolyl]-2-(4-fluorophenyl)-5-methyl- 346601-39-6, 2,4-Pyrimidinediamine, N4-(2,4-difluorophenyl)-6-methyl- 351857-23-3, L-Valinamide, N-formyl-L-histidyl-3-methyl-L-valyl- 351857-24-4, 3-Pyrrolidinecarboxamide, N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(2S)-2-(formylamino)-3-(1H-imidazol-4-yl)-1-oxopropyl]- 351857-25-5, 3-Piperidinecarboxamide, N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(1H-imidazol-4-ylacetyl)- 351857-26-6, Formamide, N-[(1S)-2-[3-[[(1S)-1-acetyl-2-methylpropyl]amino]phenyl]-1-(1H-imidazol-4-ylmethyl)-2-oxoethyl]- 351857-27-7, 1-Imidazolidineacetamide, 3-[(2S)-2-(formylamino)-3-(1H-imidazol-4-yl)-1-oxopropyl]-4-methyl-α-(1-methylethyl)-2,5-dioxo-, (αS,4S)- 351857-28-8, 2,4-Imidazolidinedione, 1-(1H-imidazol-4-ylmethyl)-5-methyl-3-(1-methylethyl)-, (5S)- 351857-29-9, 2,4-Imidazolidinedione, 3-[(4-hydroxyphenyl)methyl]-1-(1H-imidazol-4-ylmethyl)-5-methyl-, (5S)- 351857-30-2, 2,4-Imidazolidinedione, 1-[2-(1H-imidazol-4-yl)ethyl]-5-methyl-3-(1-methylethyl)-, (5S)- 351857-31-3, 2,4-Imidazolidinedione, 3-(cyclohexylmethyl)-1-(1H-imidazol-4-ylmethyl)-5-methyl-, (5S)- 351857-32-4, 1-Piperazineacetamide, 4-[(2S)-2-(acetylamino)-3-(1H-imidazol-4-yl)-1-oxopropyl]-3-methyl-α-(1-methylethyl)-2-oxo-, (αS,3S)- 351857-33-5, 1-Piperazineacetamide, 4-[(2S)-2-(acetylamino)-3-(1H-imidazol-4-yl)-1-oxopropyl]-α-[(4-hydroxyphenyl)methyl]-3-methyl-2-oxo-, (αS,3S)- 351857-34-6, L-Tyrosinamide, N-acetyl-L-histidyl-(αS,3S)-3-methyl-α-(1-methylethyl)-2-oxo-1-piperazineacetyl- 351857-35-7, Pyrazinecarboximidamide, N-[[[2-methyl-6-(trifluoromethyl)-3-pyridinyl]carbonyl]oxy]- 351857-36-8, 3H-1,2,4-Triazol-3-one, 2,4-dihydro-5-[(1-methylethyl)thio]-4-[4-(phenylmethoxy)phenyl]- 351857-37-9, Ethanone, 2-[(4-chlorophenyl)thio]-1-(6-methylthiazolo[3,2-b][1,2,4]triazol-5-yl)- 351857-38-0, Thiazolo[3,2-b][1,2,4]triazole-5-

carbothioic acid, 6-methyl-, S-[3-(trifluoromethyl)phenyl] ester
351857-39-1, 1,2,4-Oxadiazole, 5-[2,2'-bithiophen]-5-yl-3-(chloromethyl)-
351857-40-4, Ethanone, 1-phenyl-2-[5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]-
351857-41-5, 2,1,3-Benzoxadiazole-5-carboxamide, N-(2-phenylethyl)-
351857-42-6, Acetamide, N-[2-[(2-furanylmethyl)thio]ethyl]-2-[(1-methyl-1H-
imidazol-2-yl)thio]- 351857-43-7, Ethanone, 2,2,2-trifluoro-1-[4-[2-[3-
(2-thienyl)-1,2,4-oxadiazol-5-yl]ethenyl]phenyl]- 351857-44-8, Urea,
N-[4-(5-oxazolyl)phenyl]-N'-phenyl- 351857-45-9, Urea,
N-(4-chlorophenyl)-N'-[4-(5-oxazolyl)phenyl]- 351857-46-0,
2H-Imidazol-2-one, 1,3-dihydro-, [1-(4-chlorophenyl)ethylidene]hydrazone
351857-47-1, Benzenecarboximidamide, N-[[2-propyl-4-(1H-pyrazol-1-
yl)benzoyl]oxy]-4-(trifluoromethyl)- 351857-48-2, 1,3,4-Oxadiazole,
2-[[(4-chlorophenyl)methyl]thio]-5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-
351857-49-3, Urea, N-[2-[(2,1,3-benzoxadiazol-5-ylmethyl)thio]phenyl]-
N'-(2,4-dichlorophenyl)- 351857-50-6, 2-Thiophenecarboxamide,
N-[2-[(2,1,3-benzoxadiazol-5-ylmethyl)thio]phenyl]- 351857-51-7,
L-Cysteinamide, N-(mercaptoacetyl)-L-histidyl-L-alanyl-L-valyl-, cyclic
(1→4)-thioether 351857-52-8, L-Cysteinamide, N-
(mercaptoacetyl)glycyl-L-histidyl-L-alanyl-L-valyl-, cyclic
(1→5)-thioether 351857-53-9, L-Cysteinamide, N2-(mercaptoacetyl)-
L-asparaginyl-L-histidyl-L-alanyl-L-valyl-, cyclic (1→5)-thioether
351857-54-0, Morpholine, 4-[[2-(2,1,3-benzoxadiazol-5-yl)-4-
thiazolyl]carbonyl]- 351857-55-1, 4-Thiazolecarboxamide,
2-(2,1,3-benzoxadiazol-5-yl)-N-(2-pyridinylmethyl)- 351857-56-2,
4-Thiazolecarbothioic acid, 2-(2,1,3-benzoxadiazol-5-yl)-,
S-(2,4-dichlorophenyl) ester 351857-57-3, 4-Thiazolecarbothioic acid,
2-(2,1,3-benzoxadiazol-5-yl)-, S-phenyl ester 351857-58-4, Piperazine,
1-(2,1,3-benzoxadiazol-5-ylcarbonyl)-4-phenyl- 351857-59-5, Ethanone,
2-(1H-imidazol-1-yl)-1-(3-methylbenzo[b]thien-2-yl)- 351857-60-8,
2-Furancarboxylic acid, 5-[[[3-[[thioxo[[4-(trifluoromethyl)-2-
pyrimidinyl]amino]methyl]amino]phenyl]thio]methyl]-, methyl ester
351857-61-9, 2-Furancarboxylic acid, 5-[[[3-[[[[4-(methylthio)-2-
pyrimidinyl]amino]thioxomethyl]amino]phenyl]thio]methyl]-, methyl ester
351857-62-0, 1,3-Benzodioxole-5-carboximidamide, N-[(3,4-
dichlorobenzoyl)oxy]- **351857-63-1**, Benzamide,
N-[[[4-(5-oxazolyl)phenyl]amino]carbonyl]- **351857-64-2**,
Benzamide, 4-chloro-N-[[[4-(5-oxazolyl)phenyl]amino]carbonyl]-
351857-65-3, Benzamide, N-[[[4-(5-oxazolyl)phenyl]amino]carbonyl]-
4-(trifluoromethyl)- 351857-66-4, 1H-Pyrazole-4-carboxylic acid,
3-amino-1-[6-(1-piperidinyl)-3-pyridazinyl]-, ethyl ester 351857-67-5,
1,3-Benzodioxole-5-carboximidamide, N-(benzoyloxy)- 351857-68-6,
1,3-Benzodioxole-5-carboxaldehyde, O-(2,4-dichlorobenzoyl)oxime
351857-69-7, Benzoic acid, 4-[(1,3-benzodioxol-5-ylmethylene)hydrazino]-,
ethyl ester 351857-70-0, 4-Thiazolecarboxylic acid, 2-[(2,1,3-
benzoxadiazol-5-yloxy)methyl]-, 4-chlorophenyl ester 351857-71-1,
Benzamide, 2,6-difluoro-N-[[[(1,5,6,7-tetrahydro-4H-inden-4-
ylidene)amino]oxy]carbonyl]- 351857-72-2, Acetic acid,
[(2-oxo-4-propyl-2H-1-benzopyran-7-yl)oxy]-, 2-(4-chlorophenyl)-2-oxoethyl
ester 351857-73-3, Acetic acid, [(2-oxo-4-propyl-2H-1-benzopyran-7-
yl)oxy]-, 2-oxo-2-phenylethyl ester 351857-74-4, 1H-Pyrrole-3-carboxylic
acid, 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-(1,1-dimethylethyl)-2-methyl-
351857-75-5, Ethanone, 1-(6-methylthiazolo[3,2-b][1,2,4]triazol-5-yl)-2-
[[[3-(trifluoromethyl)phenyl]methyl]thio]-
RL: BSU (Biological study, unclassified); **PAC (Pharmacological activity)**; PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT 351857-76-6, Acetamide, N-[[(2-furanylmethyl)thio]methyl]-2-[(1-methyl-1H-
imidazol-2-yl)thio]- 351857-77-7, 2,4-Pyrimidinediamine,
N4-(3-chloro-4-fluorophenyl)-6-methyl- 351857-78-8, 1H-Indene-1,3(2H)-
dione, 2-[[[4-(1H-1,2,4-triazol-1-yl)phenyl]amino]methylene]-
351857-79-9, Pyrimidine, 4,6-dimethyl-2-[[[4-(1-

methylethoxy)phenyl]methyl]thio]- 351857-80-2, Pyrazine, 2-(1H-imidazol-2-yl)-5-(1-pyrrolidinyl)- 351857-81-3D, 4H-1-Benzopyran-4-one, 7-hydroxy-2-[4-(1H-tetrazol-5-yl)phenyl]-, derivs. 351857-82-4, Ethanone, 1-(6-methylthiazolo[3,2-b][1,2,4]triazol-5-yl)-2-(phenylthio)- 351857-83-5, Pyrido[2,3-d]pyrimidin-4(3H)-one, 3-[3-(1-piperidinyl)propyl]- 351857-84-6, 1H-Imidazole, 2-[[[1-[(4-chlorophenyl)methyl]-1H-imidazol-2-yl]methyl]thio]-1-methyl- 351857-85-7, Urea, N-(2-amino-6-chloro-4-pyrimidinyl)-N'-phenyl- 351857-86-8, Ethanone, 2-(benzoyloxy)-1-(2,3-dihydroxyphenyl)- 351857-87-9, Ethanone, 2-(benzoyloxy)-1-(2,3,6-trihydroxyphenyl)- 351857-88-0D, 1,3-Benzenediol, 5-[2-(3-methoxyphenyl)ethenyl]-, glycoside derivative 351857-89-1, 2-Butenoic acid, 3-methyl-, 4-methyl-1-(1,2,3,4-tetrahydro-5,8-dihydroxy-1,4-dioxo-2-naphthalenyl)-3-pentenyl ester 351857-90-4, Propanoic acid, 2-methyl-, 4-methyl-1-(1,2,3,4-tetrahydro-5,8-dihydroxy-1,4-dioxo-2-naphthalenyl)-3-pentenyl ester 351857-91-5, Butanoic acid, 3-methyl-, 4-methyl-1-(1,2,3,4-tetrahydro-5,8-dihydroxy-1,4-dioxo-2-naphthalenyl)-3-pentenyl ester 351857-92-6, 2-Furancarboxylic acid, 5-[2-(2,4-dihydroxyphenyl)-2-oxoethyl]tetrahydro-, ethyl ester 351857-93-7, 2-Furancarboxylic acid, 5-[2-(2,4-dihydroxyphenyl)-2-oxoethyl]tetrahydro-, butyl ester 351857-94-8, L-Tryptophan, N-[(2,4-dihydroxyphenyl)methylene]-, ethyl ester 351857-95-9, 1H-Inden-1-one, 3-[[4-[[(2,4-dihydroxyphenyl)methylene]amino]phenyl]amino]-2-phenyl- 351857-96-0, 2-Furancarboxylic acid, 5-[2-oxo-2-(2,4,5-trihydroxyphenyl)ethyl]-, methyl ester 351857-97-1, 1-Propanone, 1-[5-[2-(3,4-dihydroxyphenyl)-2-oxoethyl]-2-furanyl]-2-methyl- 351857-98-2, 2-Furancarboxylic acid, 5-[2-(3,4-dihydroxyphenyl)-2-oxoethyl]-, propyl ester 351857-99-3, Tryptophan, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-5-hydroxy- 351858-00-9D, Pregnane-3,6,20-trione, 21-hydroxy-, glucuronic acid derivs. 351858-01-0, Benzenemethanol, α-[[[(4,5-dimethoxy-2-nitrophenyl)methyl]methylamino]methyl]-3-hydroxy- 351858-02-1, 1,3-Benzenediol, 2-[(2-chloro-6-fluorophenyl)methyl]-5-[[(1-phenylethyl)imino]methyl]- 351858-03-2, 5-Heptenoic acid, 7-[2-oxo-5-(3-oxo-5-phenylpentyl)-3-cyclopenten-1-yl]- 351858-04-3, 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-N-[2-[[2-hydroxy-3-(1-naphthalenyloxy)propyl]amino]ethyl]-2-oxo-, (3aS,4S,6aR)- 351858-05-4, Benzenepropanoic acid, 4,4'-(1,5-dioxo-1,5-pentanediyl)bis-, diethyl ester 351858-08-7, Benzenepropanamide, 3,4-dimethoxy-N-[2-[3-methoxy-4-(phenylmethoxy)phenyl]-2-oxoethyl]-5-(phenylmethoxy)- 351858-09-8, Ethanone, 1-[3-(4-fluorobenzoyl)-7-[(4-nitrophenyl)methyl]-1-indolizinyl]- 351858-10-1, Benzeneacetamide, N-[1-(4-nitrobenzoyl)-4-piperidinyl]- 351858-11-2, Benzamide, N-[2-[[(4-fluorophenyl)methyl]thio]-2-methylpropyl]-3-nitro- 351858-12-3, 1H-1,2,4-Triazole, 3-[[(4-bromophenyl)methyl]thio]-5-phenyl- 351858-13-4, 2H-1,4-Benzothiazin-3(4H)-one, 2-[[4-methyl-5-[(phenylmethyl)thio]-4H-1,2,4-triazol-3-yl]methyl]- 351858-14-5, 2H-1,4-Benzothiazin-3(4H)-one, 2-[[5-[[(4-chlorophenyl)methyl]thio]-4-methyl-4H-1,2,4-triazol-3-yl]methyl]- 351858-15-6, 1H-1,2,4-Triazole, 3-[2-[4-(1-methylethyl)phenyl]ethenyl]-5-[[[3-(trifluoromethyl)phenyl]methyl]thio]- 351858-16-7, 2,1,3-Benzoxadiazole, 5-[[4-(4-methoxyphenyl)-2-thiazolyl]methoxy]- 351858-17-8, 4-Thiazolecarboxamide, 2-[(2,1,3-benzoxadiazol-5-yloxy)methyl]-N-(4-chlorophenyl)- 351858-18-9, 1,2,5-Oxadiazole-3-acetamide, N-(3-chloro-4-fluorophenyl)- 351858-19-0, Benzaldehyde, 4-(methylsulfonyl)-, 2-benzoxazolylhydrazone 351858-20-3, Urea, N-(3-chlorophenyl)-N'-(3,5-dimethyl-4H-1,2,4-triazol-4-yl)- 351858-21-4, 1,3-Benzodioxol-5-amine, N-9H-fluoren-2-yl- 351858-22-5, 1H-Imidazo[4,5-c]pyridine, 1-(3-phenylpropyl)- 351858-23-6, 5(4H)-Oxazolone, 2-phenyl-4-(2H-1,2,3-triazol-4-ylmethylene)- 351858-24-7, Pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amine, N-phenyl- 351858-25-8, 5-Pyrimidinecarbonitrile, 2-amino-4-(1,1-dimethylethyl)-6-(phenylamino)- 351858-26-9, 2,4-Pyrimidinediamine, 5-nitro-N4-[3-(trifluoromethyl)phenyl]- 351858-27-0, 4-Pyrimidinamine, N-(3,5-dichlorophenyl)-2-(4-pyridinyl)-6-(trifluoromethyl)- 351858-28-1,

4-Pyrimidinamine, 2-(2-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]-6-(trifluoromethyl)- 351858-29-2, 4-Pyrimidinamine, N-(3-fluorophenyl)-2-(2-pyridinyl)-6-(trifluoromethyl)- 351858-30-5, 4-Pyrimidinamine, N-(4-methoxyphenyl)-2-(3-pyridinyl)-6-(trifluoromethyl)- 351858-31-6, 4-Pyrimidinamine, 2-[[(2,6-dichlorophenyl)methyl]thio]-N-(2,4-difluorophenyl)-6-methyl- 351858-32-7, 4-Quinazolinamine, N-(3,4-dimethylphenyl)-, monohydrochloride 351858-33-8, 4-Quinazolinamine, N-(4-chlorophenyl)-, monohydrochloride 351858-34-9, 4-Quinazolinamine, N-(2,4-dimethylphenyl)-, monohydrochloride 351858-35-0, 4-Quinazolinamine, N-(4-bromophenyl)-, monohydrochloride 351858-36-1, 4-Pyrimidinamine, N-(3-chlorophenyl)-2-(4-pyridinyl)-6-(trifluoromethyl)- 351858-37-2, Acetamide, 2-[[4-methyl-5-[(3-pyrazinyl-1,2,4-oxadiazol-5-yl)methyl]-4H-1,2,4-triazol-3-yl]thio]-N-[3-(trifluoromethyl)phenyl]- 351858-38-3, 1,2,4-Oxadiazole-5-acetic acid, 3-pyrazinyl-, 2-[[(4-chlorophenyl)amino]carbonyl]hydrazide 351858-39-4, 1,2,4-Oxadiazole-5-acetic acid, 3-pyrazinyl-, 2-[[(3,5-dichlorophenyl)amino]carbonyl]hydrazide 351858-40-7, 1,2,4-Oxadiazole-5-acetic acid, 3-pyrazinyl-, 2-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]hydrazide 351858-41-8, 1,2,4-Oxadiazole-5-acetic acid, 3-pyrazinyl-, 2-[(phenylamino)carbonyl]hydrazide 351858-42-9, 1,2,4-Oxadiazole-5-acetic acid, 3-pyrazinyl-, 2-[(methylamino)thioxomethyl]hydrazide 351858-43-0, 1,2,4-Triazolidin-3-one, 5-[3-(4-fluorophenyl)-2,1-benzisoxazol-5-yl]-5-methyl-2-phenyl- 351858-44-1, 4H-Pyrrolo[3,4-d]isoxazole-4,6(5H)-dione, 5-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methylamino]-3a,6a-dihydro-3-(3-methyl-5-oxo-1-phenyl-1,2,4-triazolidin-3-yl)- 351858-45-2, Methanesulfonamide, N-[4-[[5-[3-(2-aminoethyl)-1H-indol-5-yl-2-t]-1,2,4-oxadiazol-3-yl]methyl]phenyl]- 351858-47-4, 2-Propenamide, N-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-3-phenyl-N-[1-(phenylmethyl)-4-piperidinyl]- 351858-48-5, Pentitol, 1,5-anhydro-1-C-(5-methyl-1,3,4-oxadiazol-2-yl)-, 2,3,4-tribenzoate 351858-49-6, 3H-Pyrazol-3-one, 5-(1,1-dimethylethyl)-2,4-dihydro-2-phenyl-4-[(4-pyridinylamino)methylene]- 351858-50-9, D-erythro-Pentitol, 1,4-anhydro-2,3-dideoxy-3-[2-(4-methylphenyl)-2-oxoethyl]-1-C-1,2,4-triazolo[4,3-a]pyrimidin-3-yl-, 5-(4-methylbenzoate), (1S)- 351858-51-0, Piperazine, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(1H-indol-6-ylcarbonyl)- 351858-52-1, Piperazine, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-[[2,6-bis(dimethylamino)-4-pyrimidinyl]carbonyl]- 351858-53-2, Spirostan-12-one, 3-(acetyloxy)-, 12-[(2,4-dinitrophenyl)hydrazone], (5α)- 351858-54-3, Phenol, 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis-, bis(3-nitrobenzoate) 351858-55-4, Phenol, 4,4'-(1-methylpropylidene)bis-, bis(3-nitrobenzoate) (ester) 351858-56-5, Phenol, 4,4'-(9H-fluoren-9-ylidene)bis-, bis(3-nitrobenzoate) 351858-57-6, Phenol, 4,4'-(diphenylmethylene)bis-, bis(4-nitrobenzoate) 351858-58-7, L-Methioninamide, N-(4-methoxy-1,4-dioxobutyl)glycyl-L-tryptophyl-N-(4-methyl-2-oxo-2H-1-benzopyran-6-yl)- 351858-59-8, Aspartic acid, (βR)-3-chloro-β,5-dihydroxy-N-methyl-D-tyrosyl-3,4-didehydro-L-valyl-3-hydroxy-L-isoleucyl-3,4-didehydro-L-prolyl-2,3-didehydroisoleucyl-2,3-didehydro-, cyclic (15→3)-ether 351858-60-1, 19-Norpregn-5-ene-20-carboxylic acid, 3-(acetyloxy)-, 2-[[(7-nitro-2,1,3-benzoxadiazol-4-yl)methyl]amino]ethyl ester, (3β,20S)- 351858-61-2, L-Alaninamide, N-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-L-threonyl-L-valyl-N-[(1S)-2-carboxy-1-formylethyl]- 351858-62-3, L-Lysinamide, N-[(phenylmethoxy)carbonyl]-L-α-glutamyl-N-[(1S)-1-(carboxymethyl)-3-[(2,6-dimethylbenzoyl)oxy]-2-oxopropyl]-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]- 351858-63-4, 1,3-Benzenediacetic acid, 5-[2-[[3-(4-aminophenyl)-1,3-dioxopropyl]amino]-4-(methoxycarbonyl)phenoxy]- 351858-64-5, 1,3-Benzenediacetic acid, 5-[4-(methoxycarbonyl)-2-[[3-(4-nitrophenyl)-1,3-dioxopropyl]amino]phenoxy]- 351858-65-6, 1-Propanone, 1-[2,4-dihydroxy-6-[(2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl)oxy]phenyl]-3-(4-nitrophenyl)- 351858-66-7, 1-Propanone, 1-[2-(benzoyloxy)-6-hydroxy-4-[(2,3,4,6-tetra-O-acetyl-α-L-

glucopyranosyl)oxy]phenyl]-3-(4-nitrophenyl)- 351858-67-8, L-Phenylalaninamide, N-(4-carboxy-1-oxobutyl)-L-phenylalanyl-L-alanyl-L-alanyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)- 351858-68-9, L-Asparagine, L-tyrosyl-L-alanyl-L-phenylalanyl-L-tryptophyl- 351858-69-0, 2H-Tetrazolium, 2-(2-benzothiazolyl)-3-(4-carboxy-3-methoxyphenyl)-5-[4-[[(2-sulfoethyl)amino]carbonyl]phenyl]-, inner salt 351858-70-3, Phenylalanine, 3,3'-[phosphinicobis(methylene)]bis- 351858-71-4, 1-Propanone, 1-[2,6-dihydroxy-4-[(2,3,4,6-tetra-O-acetyl-α-L-glucopyranosyl)oxy]phenyl]-3-(4-nitrophenyl)- 351858-72-5, 2-Propen-1-one, 3-(4-nitrophenyl)-1-[2-[(2,3,4,6-tetra-O-acetyl-α-L-glucopyranosyl)oxy]phenyl]- 351858-73-6, L-Methionine, L-phenylalanylglycylglycyl-L-phenylalanyl-N-[(1,1-dimethylethoxy)carbonyl]- 351858-74-7, L-Tryptophan, N-acetyl-L-tryptophyl-L-leucyl-L-α-aspartyl-L-isoleucyl-L-isoleucyl- 351858-76-9, Pyridinium, 1,1'-(1,6-hexanediyl)bis[4-[[(dimethylamino)carbonyl]oxy]-, compound with 2,4,6-trinitrophenol (1:1) 351858-81-6, Alanine, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]amino]benzoyl]-3-[[(2-ethoxy-2-oxoethyl)amino]sulfinyl]-, ethyl ester 351858-82-7, L-Glutamic acid, N-[4-[[[5-[3-[acetyl(6-ethoxy-6-oxohexyl)amino]-2-methyl-2-propenyl]-2-amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl]methyl]amino]benzoyl]- 351858-84-9, L-Glutamic acid, N-[4-[[2-[2-(acetylamino)-1,4-dihydro-4-oxo-6-pteridinyl]ethyl](trifluoroacetyl)amino]benzoyl]-, diethyl ester 351858-87-2, L-Glutamic acid, N-[4-[[2-(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)ethyl]amino]benzoyl]-, diethyl ester 351858-92-9, Histidine, 2-[[4-(aminosulfonyl)phenyl]azo]-N-(3,4-dihydro-3,4-dioxo-1-naphthalenyl)- 351858-93-0, Histidine, 2,2'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis- 351859-05-7, Glutamic acid, N-[4-[[[1,4,5,6,7,8-hexahydro-5-(3-hydroxypropyl)-2-[(3-hydroxypropyl)amino]-4-oxo-6-pteridinyl]methyl](3-hydroxypropyl)amino]benzoyl]- 351859-08-0, Pentanedioic acid, 3-[[4-[[[4-(2,4-diamino-5-pyrimidinyl)phenyl]methyl]amino]benzoyl]amino]- 351859-09-1, L-Cysteinamide, L-cysteinyl-L-histidylglycyl-L-valyl-, cyclic (1→5)-disulfide 351859-10-4, L-Lysinamide, N-acetyl-L-α-aspartyl-L-histidyl-L-alanyl-L-valyl-, (1→5)-lactam 351859-11-5, L-Lysinamide, N-acetyl-L-α-aspartyl-L-histidylglycyl-L-valyl-, (1→5)-lactam 351859-12-6, L-α-Glutamine, N2-acetyl-L-lysyl-L-histidyl-L-alanyl-L-valyl-, (5→1)-lactam 351859-13-7, L-α-Glutamine, N2-acetyl-L-lysyl-L-histidylglycyl-L-valyl-, (5→1)-lactam 351859-14-8, L-Cysteinamide, N-acetyl-L-cysteinyl-L-valylglycyl-L-histidyl-, cyclic (1→5)-disulfide 351859-15-9, L-α-Asparagine, L-lysyl-L-histidylglycyl-L-valyl-, (5→16)-lactam 351859-16-0, Cyclo(L-alanyl-L-histidylglycyl-L-valyl-L-α-aspartyl-L-isoleucyl) 351859-17-1, L-Cysteinamide, L-cysteinyl-L-alanyl-L-histidylglycyl-L-valyl-L-α-aspartyl-, cyclic (1→7)-disulfide 351859-18-2, L-Cysteinamide, L-cysteinyl-L-alanyl-L-histidylglycyl-L-valyl-L-α-aspartyl-L-isoleucyl-, cyclic (1→8)-disulfide 351859-19-3, Cyclo(glycyl-L-valyl-L-seryl-L-seryl-L-seryl-L-histidyl) 351859-20-6, L-α-Asparagine, N2-acetyl-L-lysyl-L-seryl-L-histidyl-L-alanyl-L-valyl-L-seryl-L-seryl-, (8→1)-lactam 351859-21-7, L-α-Asparagine, N2-acetyl-L-lysyl-L-seryl-L-histidylglycyl-L-valyl-L-seryl-L-seryl-, (8→1)-lactam

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT 475228-42-3 475228-43-4 475228-44-5 475228-45-6 475228-46-7 475228-47-8 475228-48-9 475228-49-0 475228-50-3 475228-51-4 475228-52-5 475228-53-6 475228-54-7 475228-55-8 475228-56-9 475228-57-0

RL: PRP (Properties)

(unclaimed protein sequence; peptidomimetic modulators of cell adhesion)

IT 73205-86-4 110590-64-2 143304-79-4 170032-25-4 202527-94-4
202527-98-8 202528-00-5 202528-03-8 202528-07-2 202528-10-7
214684-50-1 214684-52-3 222169-86-0 222169-89-3 222169-90-6
229971-74-8 229971-80-6 231282-25-0 231282-43-2 231282-44-3
231282-45-4 231282-46-5 250268-78-1 250271-33-1 250271-34-2
250271-35-3 250271-36-4 250271-37-5 250271-39-7 250271-41-1
250271-42-2 255369-45-0 289914-94-9 313052-61-8 317320-19-7
331474-64-7 331474-65-8 331474-66-9 331474-67-0 331474-68-1
331474-69-2 331474-70-5 331474-71-6 331474-72-7 331474-73-8
331474-74-9 331474-75-0 331474-76-1 331474-77-2 331474-78-3
331474-79-4 331474-80-7 331474-81-8 331474-82-9 331474-83-0
331474-84-1 351974-94-2 351974-95-3 351974-96-4 351974-97-5
351974-98-6 351974-99-7 351975-00-3 351975-01-4 351975-02-5
351975-03-6 351975-04-7 351975-05-8 352000-58-9 352000-59-0
352000-60-3 352335-43-4 352335-47-8 352335-49-0 352335-51-4
RL: PRP (Properties)
(unclaimed sequence; peptidomimetic modulators of cell adhesion)

IT **351857-63-1**, Benzamide, N-[[[4-(5-oxazolyl)phenyl]amino]carbonyl]-
351857-64-2, Benzamide, 4-chloro-N-[[[4-(5-oxazolyl)phenyl]amino]carbonyl]- **351857-65-3**, Benzamide, N-[[[4-(5-oxazolyl)phenyl]amino]carbonyl]-4-(trifluoromethyl)-
RL: BSU (Biological study, unclassified); **PAC (Pharmacological activity)**; PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

RN 351857-63-1 HCAPLUS
CN Benzamide, N-[[[4-(5-oxazolyl)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 351857-64-2 HCAPLUS
CN Benzamide, 4-chloro-N-[[[4-(5-oxazolyl)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 351857-65-3 HCAPLUS
CN Benzamide, N-[[[4-(5-oxazolyl)phenyl]amino]carbonyl]-4-(trifluoromethyl)-
(9CI) (CA INDEX NAME)



L37 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:657513 HCAPLUS
DN 135:227005
ED Entered STN: 07 Sep 2001
TI Preparation of 6-(4-acylaminophenyl)-5-methyldihydropyridazinones for
treatment of anemia
IN Braeunlich, Gabriele; Loegers, Michael; Stoltefuss, Juergen; Schmeck,
Carsten; Nielsch, Ulrich; Stuermer, Werner; Gerdes, Christian; Lustig,

Klemens; Sperzel, Michael
PA Bayer A.-G., Germany
SO Ger. Offen., 52 pp.
CODEN: GWXXBX
DT Patent
LA German
IC ICM C07D401-12
ICS C07D237-14; C07D403-12; C07D405-12; C07D409-12; C07D413-12; C07D417-12; A61K031-501; A61P007-06
CC 28-15 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 10010425	A1	20010906	DE 2000-10010425	20000303
WO 2001064652	A1	20010907	WO 2001-EP1873	20010220
WO 2001064652	C2	20020704		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1272474	A1	20030108	EP 2001-925339	20010220

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRAI DE 2000-10010425	A	20000303
WO 2001-EP1873	W	20010220

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
DE 10010425	ICM	C07D401-12
	ICS	C07D237-14; C07D403-12; C07D405-12; C07D409-12; C07D413-12; C07D417-12; A61K031-501; A61P007-06

OS MARPAT 135:227005
GI



I

AB Use of title compds. [I; A, D, E, G = H, alkyl, OH, halo, alkoxy; R1 = H, alkyl; R2 = (substituted) heterocyclyl, Ph, cycloalkyl, aryl, aryloxy, arylthio, dihydropyridinone, alkyl, alkoxycarbonyl, alkoxy, alkenyl, etc.], for preparation of drugs or drug formulations for treatment of anemia, is claimed. Thus, 6-(4-aminophenyl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one in DMF was stirred for 16 h at 20° with 4-methoxyphenyl isocyanate and 1 drop Et3N to give 92% 1-(4-methoxyphenyl)-3-[4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-

yl)phenyl]urea. I were said to show erythropoiesis stimulating effects (no data).

ST acylaminophenylmethyldihydropyridazinone prepn erythropoiesis stimulator; pyridazinone acylaminophenyl methyl prepn erythropoiesis stimulator; anemia treatment acylaminophenylmethyldihydropyridazinone prepn

IT Erythropoiesis
(stimulators; preparation of acylaminophenylmethyldihydropyridazinones for treatment of anemia)

IT Anemia (disease)
(treatment; preparation of acylaminophenylmethyldihydropyridazinones for treatment of anemia)

IT 36725-27-6P 69635-63-8P 81005-74-5P 81005-75-6P 81005-85-8P
81005-88-1P 81228-48-0P 86800-29-5P 86800-30-8P 86800-31-9P
86800-32-0P 86800-33-1P 86800-36-4P 86800-41-1P 88012-32-2P
160698-99-7P 160699-00-3P 160699-01-4P 214758-60-8P 214758-63-1P
214758-66-4P 214758-70-0P 214758-72-2P 214758-74-4P 214758-76-6P
215930-68-0P 224961-76-6P 224961-79-9P 227464-76-8P 227764-85-4P
227764-86-5P 300362-10-1P 358780-33-3P 358780-34-4P 358780-35-5P
358780-36-6P 358780-37-7P 358780-38-8P 358780-39-9P 358780-40-2P
358780-41-3P 358780-42-4P 358780-43-5P 358780-44-6P 358780-45-7P
358780-46-8P 358780-47-9P 358780-48-0P 358780-49-1P 358780-50-4P
358780-51-5P 358780-52-6P 358780-53-7P 358780-54-8P 358780-55-9P
358780-56-0P 358780-57-1P 358780-58-2P 358780-59-3P 358780-60-6P
358780-61-7P 358780-62-8P 358780-63-9P 358780-64-0P 358780-65-1P
358780-66-2P 358780-67-3P 358780-68-4P 358780-69-5P 358780-70-8P
358780-71-9P 358780-72-0P 358780-73-1P 358780-74-2P 358780-75-3P
358780-76-4P 358780-77-5P 358780-78-6P 358780-79-7P 358780-80-0P
358780-81-1P 358780-82-2P 358780-83-3P 358780-84-4P 358780-85-5P
358780-86-6P 358780-87-7P 358780-88-8P 358780-89-9P 358780-90-2P
358780-91-3P 358780-92-4P 358780-93-5P 358780-94-6P 358780-95-7P
358780-96-8P 358780-97-9P 358780-98-0P 358780-99-1P 358781-00-7P
358781-01-8P 358781-02-9P 358781-03-0P 358781-04-1P 358781-05-2P
358781-06-3P 358781-07-4P 358781-08-5P 358781-09-6P 358781-10-9P
358781-11-0P 358781-12-1P 358781-13-2P 358781-14-3P 358781-15-4P
358781-16-5P 358781-17-6P 358781-18-7P 358781-19-8P 358781-20-1P
358781-21-2P 358781-22-3P 358781-23-4P 358781-24-5P 358781-25-6P
358781-26-7P 358781-27-8P 358781-28-9P 358781-29-0P 358781-32-5P
358781-34-7P 358781-37-0P 358781-39-2P 358781-40-5P 358781-41-6P
358781-42-7P 358781-43-8P 358781-44-9P 358781-45-0P 358781-46-1P
358781-47-2P 358781-48-3P 358781-49-4P 358781-50-7P 358781-51-8P
358781-52-9P 358781-53-0P 358781-54-1P 358781-55-2P 358781-56-3P
358781-57-4P 358781-58-5P 358781-59-6P 358781-60-9P 358781-61-0P
358781-62-1P 358781-63-2P 358781-64-3P 358781-65-4P
358781-66-5P 358781-67-6P 358781-68-7P 358781-69-8P
358781-70-1P 358781-71-2P 358781-72-3P 358781-73-4P 358781-74-5P
358781-75-6P 358781-76-7P 358781-77-8P 358781-78-9P 358781-79-0P
358781-80-3P 358781-81-4P 358781-82-5P 358781-83-6P 358781-84-7P
358781-85-8P 358781-86-9P 358781-87-0P 358781-88-1P 358781-89-2P
358781-90-5P 358781-91-6P 358781-92-7P 358781-93-8P 358781-94-9P
358781-95-0P 358781-96-1P 358781-97-2P 358781-98-3P 358781-99-4P
358782-00-0P 358782-01-1P 358782-02-2P 358782-03-3P 358782-04-4P
358782-05-5P 358782-06-6P 358782-07-7P 358782-08-8P 358782-09-9P
358782-10-2P 358782-11-3P 358782-12-4P 358782-13-5P 358782-14-6P
358782-15-7P 358782-16-8P 358782-17-9P 358782-18-0P 358782-19-1P
358782-20-4P 358782-21-5P 358782-22-6P 358782-23-7P 358782-24-8P
358782-25-9P 358782-26-0P 358782-27-1P 358782-28-2P 358782-29-3P
358782-30-6P 358782-31-7P 358782-32-8P 358782-33-9P 358782-34-0P
358782-35-1P 358782-36-2P 358782-37-3P 358782-38-4P 358782-39-5P
358782-40-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylaminophenylmethyldihydropyridazinones for treatment of

anemia)

IT 358782-41-9P 358782-42-0P 358782-43-1P 358782-44-2P 358782-45-3P
358782-46-4P 358782-47-5P 358782-48-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylaminophenylmethyldihydropyridazinones for treatment of anemia)

IT 65-45-2, Salicylamide 98-89-5, Cyclohexanecarboxylic acid 530-62-1
618-46-2, 3-Chlorobenzoyl chloride 5416-93-3, 4-Methoxyphenylisocyanate
36725-28-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of acylaminophenylmethyldihydropyridazinones for treatment of anemia)

IT 358780-32-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of acylaminophenylmethyldihydropyridazinones for treatment of anemia)

IT **358781-66-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylaminophenylmethyldihydropyridazinones for treatment of anemia)

RN 358781-66-5 HCAPLUS
CN Benzamide, N-[[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



L37 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:545724 HCAPLUS
DN 135:147398
ED Entered STN: 27 Jul 2001
TI Peptidomimetic modulators of cell adhesion
IN Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie Denise; Wang, Shoameng; Hu, Zengjian
PA Adherex Technologies, Inc., Can.
SO PCT Int. Appl., 416 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07K007-00
CC 1-3 (**Pharmacology**)
Section cross-reference(s): 34, **63**

FAN.CNT 15

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001053331	A2	20010726	WO 2001-US2508	20010124
WO 2001053331	A3	20020711		
WO 2001053331	C2	20021031		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-491078 A 20000124

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001053331	ICM	C07K007-00

OS MARPAT 135:147398

AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.

ST cadherin cell adhesion peptidomimetic QSAR cyclic peptide

IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(-mediated cell adhesion; peptidomimetic modulators of cell adhesion)

IT Cadherins
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(N-, cells bearing; peptidomimetic modulators of cell adhesion)

IT Astrocyte
(N-cadherin-bearing cell migration on; peptidomimetic modulators of cell adhesion)

IT Antitumor agents
(bladder; peptidomimetic modulators of cell adhesion)

IT Drug delivery systems
(carriers; peptidomimetic modulators of cell adhesion)

IT Peptides, properties
RL: PRP (Properties)
(cyclic, conformation of; peptidomimetic modulators of cell adhesion)

IT Nerve, disease
(demyelination; peptidomimetic modulators of cell adhesion)

IT Neoplasm
Skin
(drug delivery to; peptidomimetic modulators of cell adhesion)

IT Blood vessel
(endothelium; peptidomimetic modulators of cell adhesion)

IT Ovary, neoplasm
(inhibitors; peptidomimetic modulators of cell adhesion)

IT Spinal cord
(injury; peptidomimetic modulators of cell adhesion)

IT Antitumor agents
(melanoma; peptidomimetic modulators of cell adhesion)

IT Cell adhesion
(modulators of; peptidomimetic modulators of cell adhesion)

IT Bladder
(neoplasm, inhibitors; peptidomimetic modulators of cell adhesion)

IT Bladder
(neoplasm; peptidomimetic modulators of cell adhesion)

IT Axon
(outgrowth; peptidomimetic modulators of cell adhesion)

IT Antitumor agents
(ovary; peptidomimetic modulators of cell adhesion)

IT Drug delivery systems
(patches; peptidomimetic modulators of cell adhesion)
IT Antitumor agents
Bioreactors
Bond angle
Cell migration
Combinatorial library
Drug delivery systems
Drug screening
Drug targeting
Electrostatic charge
Epithelium
Hydrophobicity
Melanoma
Membrane, biological
Microparticles
Molecular modeling
Multiple sclerosis
Oligodendrocyte
Ovary, neoplasm
Peptidomimetics
Protein sequences
QSAR (structure-activity relationship)
Schwann cell
Steric effects
Transplant and Transplantation
Transplant and Transplantation
Ultrathin films
Wound healing
Wound healing promoters
(peptidomimetic modulators of cell adhesion)
IT Laboratory ware
(plastic dishes; peptidomimetic modulators of cell adhesion)
IT Laboratory ware
(plastic tubes; peptidomimetic modulators of cell adhesion)
IT Oligodendrocyte
(progenitor; peptidomimetic modulators of cell adhesion)
IT Transplant and Transplantation
(skin; peptidomimetic modulators of cell adhesion)
IT Information systems
(storage; peptidomimetic modulators of cell adhesion)
IT Polymers, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(support matrixes; peptidomimetic modulators of cell adhesion)
IT Drug delivery systems
(sustained-release; peptidomimetic modulators of cell adhesion)
IT Medical goods
(sutures; peptidomimetic modulators of cell adhesion)
IT Skin
(transplant; peptidomimetic modulators of cell adhesion)
IT 57-88-5D, Cholest-5-en-3-ol (3β)-, glycoside derivs. 135-16-0
487-49-0 548-73-2 570-88-7 1210-66-8 1482-74-2 1699-40-7
1776-30-3 2486-02-4 2810-37-9 2979-51-3 3242-68-0 3257-73-6
3561-56-6 3566-25-4 3575-07-3 3922-47-2 4672-96-2 5226-71-1
5341-00-4 5415-88-3 5421-95-4 5426-87-9 5429-46-9 5446-36-6
5454-50-2 5454-52-4 5508-58-7 5534-95-2 5800-34-0 6286-57-3
6295-27-8 6300-80-7 6320-71-4 6322-09-4 6323-88-2 6323-89-3
6331-03-9 6338-84-7 6340-76-7 6633-66-5 6807-82-5 6962-62-5
6975-34-4 7781-29-5 10320-97-5 13184-14-0 13351-10-5 13745-20-5
15013-60-2 15970-42-0 16856-21-6 16879-84-8 17357-75-4
17430-65-8 17496-31-0 18100-11-3 18100-12-4 18211-37-5
19312-13-1 19484-75-4D, furanoside derivative 19889-31-7 20621-49-2

20711-05-1 21108-76-9 21658-45-7 23567-67-1 23815-88-5,
1-6-Bradykinin 24205-32-1 24386-39-8 24829-12-7 26962-50-5
27069-81-4 27430-15-5 27430-17-7 28005-33-6 28246-23-3
28772-56-7 29654-52-2 30148-18-6 30216-31-0D, derivs. 30355-60-3
30826-46-1 30826-47-2 33254-46-5 34396-76-4 37664-31-6
40538-65-6 40816-36-2 41266-78-8 41600-13-9 42220-83-7
46825-86-9 50602-77-2 51646-15-2 51893-98-2 51934-26-0
51934-28-2 54299-50-2 54395-52-7 56025-86-6 56307-99-4
57710-80-2 57808-66-9 57966-42-4 58677-09-1 60045-61-6
60407-48-9 60482-96-4 61043-53-6 64792-21-8 64801-58-7
65147-09-3 65757-04-2 65757-05-3 65877-43-2D, glycoside derivative
66048-53-1 66147-31-7 67368-29-0 67655-19-0 67836-16-2
68047-41-6 68215-68-9 68682-02-0 68838-40-4 69097-98-9
69193-20-0 69480-15-5 70280-72-7 70280-75-0 70539-54-7
70968-04-6 71047-38-6 71074-46-9 71074-48-1 71074-49-2
71707-02-3 72630-15-0 72682-77-0 72704-76-8 73554-90-2
73572-58-4 74039-67-1 74405-42-8 74405-44-0 74853-69-3
75651-68-2 75960-43-9 76172-68-4 80032-99-1 80360-08-3
81066-61-7 81587-37-3 82628-82-8 82855-85-4 85122-85-6
86669-33-2 90259-60-2 90259-61-3 92899-39-3 92954-99-9
93515-01-6 93524-30-2 93674-97-6 95192-21-5 95192-38-4
95210-75-6 98018-39-4 98151-93-0 100975-56-2 102212-40-8
103030-49-5 103398-43-2 105037-36-3 108608-63-5 110906-89-3
111172-14-6 112233-74-6 113866-00-5 113866-16-3 117889-48-2
118034-92-7 120225-54-9 121036-80-4 121036-81-5 124485-41-2
126235-09-4 128802-79-9 131061-65-9 132467-01-7 133061-57-1
134759-22-1 134796-34-2 137484-84-5 137833-31-9, Myelopeptide 2
138194-56-6 138915-75-0 142206-40-4 146871-70-7 148337-06-8
151358-70-2 152028-96-1 154719-25-2 155373-59-4 155373-72-1
160347-57-9D, derivs. 185503-97-3 188966-22-5D, derivs. 191411-47-9
194424-08-3 195140-70-6 196600-87-0 197456-56-7 198488-04-9
198632-08-5 199929-21-0 200058-34-0 200061-22-9 200431-98-7
200505-51-7 200706-30-5 200706-45-2 201997-13-9 202118-27-2
202118-28-3 202332-09-0 202528-15-2 206360-24-9 210709-22-1
215434-58-5 215655-36-0 215657-86-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptidomimetic modulators of cell adhesion)

IT 216299-43-3 216774-46-8 218456-13-4 218928-70-2 218928-81-5
218929-60-3 219139-65-8 219865-73-3 220171-00-6 229971-59-9
229971-81-7 229971-83-9 229971-84-0 229971-85-1 229971-86-2
229971-87-3 229971-88-4 229971-89-5 229971-90-8 229971-91-9
240799-81-9 241154-06-3 244278-78-2 245435-74-9 252867-19-9
252867-33-7 252914-56-0 252914-57-1 254748-91-9 254748-92-0
254748-93-1 254748-94-2 254748-97-5 254749-34-3 254753-72-5
254880-42-7 254880-46-1 255377-83-4 255378-13-3 255728-27-9
255904-99-5 256414-57-0 256432-37-8 257287-79-9 258264-27-6
258521-36-7 260368-01-2 260555-63-3 261511-13-1 261511-30-2
261626-76-0 261626-98-6 261626-99-7 261627-00-3 261704-50-1
261705-07-1 261765-01-9 261928-97-6 261928-98-7 262856-19-9
263160-48-1 263161-07-5 263161-08-6 263161-09-7 263563-52-6
263563-53-7 263563-54-8 263563-55-9 263563-75-3 263756-04-3
263756-06-5 263897-82-1 263917-87-9 263917-88-0 263917-89-1
263917-90-4 263917-92-6 263917-93-7 264127-43-7 264610-37-9
265329-88-2 266679-45-2D, derivs. 271775-62-3 273920-93-7
280133-36-0 281211-72-1 284674-47-1 286440-09-3 288161-26-2
289626-25-1 293762-17-1 294878-31-2 294878-32-3 296272-93-0
299461-73-7 301174-11-8 301201-59-2 301304-52-9 302804-66-6
303016-22-0 303145-16-6 303147-94-6 303148-00-7 303150-34-7
303150-56-3 306280-22-8 306936-17-4 306936-72-1 306936-82-3
307316-86-5 307526-33-6 307545-27-3 313493-34-4 315197-15-0

317320-21-1 317822-46-1 317822-47-2 317822-54-1 319916-73-9
321385-59-5 321430-85-7 321432-26-2 321433-43-6 321433-44-7
321576-71-0 321682-33-1 321682-97-7 321949-09-1 321998-82-7
321998-88-3 324546-09-0 328917-75-5 329079-25-6 331229-47-1
331229-48-2 331229-49-3 331229-50-6 331229-51-7 331229-52-8
331229-53-9 331229-54-0 331229-55-1 331229-56-2 331229-57-3
331229-58-4 331229-59-5 331229-60-8 331230-11-6 338391-99-4
338392-61-3 338393-05-8 338393-13-8 338393-49-0 338400-95-6
338404-75-4 338407-16-2 338414-91-8 338418-54-5 338422-66-5
338751-52-3 339016-03-4 339020-51-8 339021-25-9 339022-11-6
339022-23-0 339104-83-5 339105-69-0 339105-71-4 339105-73-6
339105-78-1 339105-82-7 339105-84-9 339105-87-2 339106-76-2
339106-78-4 341944-06-7 341965-46-6 341967-46-2 341967-49-5
344262-76-6 344276-82-0 344276-87-5 346601-39-6 351857-23-3
351857-24-4 351857-25-5 351857-26-6 351857-27-7 351857-28-8
351857-29-9 351857-30-2 351857-31-3 351857-32-4 351857-33-5
351857-34-6 351857-35-7 351857-36-8 351857-37-9 351857-38-0
351857-39-1 351857-40-4 351857-41-5 351857-42-6 351857-43-7
351857-44-8 351857-45-9 351857-46-0 351857-47-1 351857-48-2
351857-49-3 351857-50-6 351857-51-7 351857-52-8 351857-53-9
351857-54-0 351857-55-1 351857-56-2 351857-57-3 351857-58-4
351857-59-5 351857-60-8 351857-61-9 351857-62-0 **351857-63-1**
351857-64-2 **351857-65-3** 351857-66-4 351857-67-5
351857-68-6 351857-69-7 351857-70-0 351857-71-1 351857-72-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(peptidomimetic modulators of cell adhesion)

IT 351857-73-3 351857-74-4 351857-75-5 351857-76-6 351857-77-7
351857-78-8 351857-79-9 351857-80-2 351857-81-3D, derivs.
351857-82-4 351857-83-5 351857-84-6 351857-85-7 351857-86-8
351857-87-9 351857-88-0D, glycoside derivative 351857-89-1 351857-90-4
351857-91-5 351857-92-6 351857-93-7 351857-94-8 351857-95-9
351857-96-0 351857-97-1 351857-98-2 351857-99-3 351858-00-9D, glucuronic acid derivs. 351858-01-0 351858-02-1 351858-03-2
351858-04-3 351858-05-4 351858-08-7 351858-09-8 351858-10-1
351858-11-2 351858-12-3 351858-13-4 351858-14-5 351858-15-6
351858-16-7 351858-17-8 351858-18-9 351858-19-0 351858-20-3
351858-21-4 351858-22-5 351858-23-6 351858-24-7 351858-25-8
351858-26-9 351858-27-0 351858-28-1 351858-29-2 351858-30-5
351858-31-6 351858-32-7 351858-33-8 351858-34-9 351858-35-0
351858-36-1 351858-37-2 351858-38-3 351858-39-4 351858-40-7
351858-41-8 351858-42-9 351858-43-0 351858-44-1 351858-45-2
351858-47-4 351858-48-5 351858-49-6 351858-50-9 351858-51-0
351858-52-1 351858-53-2 351858-54-3 351858-55-4 351858-56-5
351858-57-6 351858-58-7 351858-59-8 351858-60-1 351858-61-2
351858-62-3 351858-63-4 351858-64-5 351858-65-6 351858-66-7
351858-67-8 351858-68-9 351858-69-0 351858-70-3 351858-71-4
351858-72-5 351858-73-6 351858-74-7 351858-76-9 351858-81-6
351858-82-7 351858-84-9 351858-87-2 351858-92-9 351858-93-0
351859-05-7 351859-08-0 351859-09-1 351859-10-4 351859-11-5
351859-12-6 351859-13-7 351859-14-8 351859-15-9 351859-16-0
351859-17-1 351858-18-2 351859-19-3 351859-20-6 351859-21-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptidomimetic modulators of cell adhesion)

IT 143113-41-1, L-Valine, L-Histidyl-L-Alanyl
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(peptidomimetic modulators of cell adhesion)

IT 222311-36-6, 196-243-Occludin (human) 248248-46-6, Cadherin E (rat fragment) 255703-58-3 255703-59-4 255703-60-7 255703-61-8
316394-32-8 352207-86-4 352207-87-5 352207-89-7 352207-91-1
352207-94-4 352207-95-5 352207-97-7 352207-98-8
RL: PRP (Properties)
(unclaimed protein sequence; peptidomimetic modulators of cell adhesion)

IT 73205-86-4 110590-64-2 143304-79-4 170032-25-4 202527-94-4
202527-98-8 202528-00-5 202528-03-8 202528-07-2 202528-10-7
214684-50-1 214684-52-3 222169-86-0 222169-89-3 222169-90-6
229971-74-8 229971-80-6 231282-25-0 231282-43-2 231282-44-3
231282-45-4 231282-46-5 250268-78-1 250271-33-1 250271-34-2
250271-35-3 250271-36-4 250271-37-5 250271-39-7 250271-41-1
250271-42-2 255369-45-0 289914-94-9 313052-61-8 317320-19-7
331474-64-7 331474-65-8 331474-66-9 331474-67-0 331474-68-1
331474-69-2 331474-70-5 331474-71-6 331474-72-7 331474-73-8
331474-74-9 331474-75-0 331474-76-1 331474-77-2 331474-78-3
331474-79-4 331474-80-7 331474-81-8 331474-82-9 331474-83-0
331474-84-1 351974-94-2 351974-95-3 351974-96-4 351974-97-5
351974-98-6 351974-99-7 351975-00-3 351975-01-4 351975-02-5
351975-03-6 351975-04-7 351975-05-8 352000-58-9 352000-59-0
352000-60-3 352207-93-3 352208-00-5 352335-43-4 352335-47-8
352335-49-0 352335-51-4
RL: PRP (Properties)
(unclaimed sequence; peptidomimetic modulators of cell adhesion)

IT **351857-63-1 351857-64-2 351857-65-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(peptidomimetic modulators of cell adhesion)

RN 351857-63-1 HCAPLUS
CN Benzamide, N-[[[4-(5-oxazolyl)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 351857-64-2 HCAPLUS
CN Benzamide, 4-chloro-N-[[[4-(5-oxazolyl)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 351857-65-3 HCAPLUS
CN Benzamide, N-[[[4-(5-oxazolyl)phenyl]amino]carbonyl]-4-(trifluoromethyl)-
(9CI) (CA INDEX NAME)



L37 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:721433 HCAPLUS
DN 134:25114
ED Entered STN: 13 Oct 2000
TI Aryl ureas represent a new class of anti-trypanosomal agents
AU Du, Xiaohui; Hansell, Elizabeth; Engel, Juan C.; Caffrey, Conor R.; Cohen,
Fred E.; McKerrow, James H.
CS Department of Cellular and Molecular Pharmacology and Medicine, University

of California, San Francisco, CA, 94143-0450, USA
SO Chemistry & Biology (2000), 7(9), 733-742
CODEN: CBOLE2; ISSN: 1074-5521
PB Elsevier Science Ltd.
DT Journal
LA English
CC 1-3 (**Pharmacology**)
AB Background: The trypanosomal diseases including Changas' disease, African sleeping sickness and Nagana have a substantial impact on human and animal health worldwide. Classes of effective therapeutics are needed owing to the emergence of drug resistance as well as the toxicity of existing agents. The cysteine proteases of two trypanosomes, Trypanosoma cruzi (cruzain) and Trypanosoma brucei (rhodesain), have been targeted for a structure-based drug design program as mechanistic inhibitors that target these enzymes are effective in cell-based and animal models of trypanosomal infection. Results: We have used computational methods to identify new lead scaffolds for non-covalent inhibitors of cruzain and rhodesain, have demonstrated the efficacy of these compds. in cell-based and animal assays, and have synthesized analogs to explore structure activity relationships. Nine compds. with varied scaffolds identified by DOCK4.0.1 were found to be active at concns. below 10 μM against cruzain and rhodesain in enzymic studies. All hits were calculated to have substantial hydrophobic interactions with cruzain. Two of the scaffolds, the urea scaffold and the aroyl thiourea scaffold, exhibited activity against T. cruzi in vivo and both enzymes in vitro. They also have predicted pharmacokinetic properties that meet Lipinski's "rule of 5". These scaffolds are synthetically tractable and lend themselves to combinatorial chemical efforts. One of the compds., 5'(1-methyl-3-trifluoromethylpyrazol-5-yl)-thiophene 3'-trifluoromethylphenyl urea (D16) showed a 3.1 μM IC50 against cruzain and a 3 μM IC50 against rhodesain. Infected cells treated with D16 survived 22 days in culture compared with 6 days for their untreated counterparts. The mechanism of the inhibitors of these two scaffolds is confirmed to be competitive and reversible. Conclusions: The urea scaffold and the thiourea scaffold are promising leads for the development of new effective chemotherapy for trypanosomal diseases. Libraries of compds. of both scaffolds need to be synthesized and screened against a series of homologous parasitic cysteine proteases to optimize the potency of the initial leads.
ST trypanosomal disease aryl urea cruzain rhodesain
IT Molecular modeling
Pharmacophores
Trypanosoma brucei
Trypanosoma cruzi
Trypanosomicides
(aryl ureas, a new class of anti-trypanosomal agents)
IT Structure-activity relationship
(enzyme-inhibiting; aryl ureas, a new class of anti-trypanosomal agents)
IT Molecular structure-property relationship
(hydrophobicity; aryl ureas, a new class of anti-trypanosomal agents)
IT 57-13-6D, Urea, aryl derivs., biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(aryl ureas, a new class of anti-trypanosomal agents)
IT 257862-77-4 261966-29-4 312324-29-1 312324-36-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(aryl ureas, a new class of anti-trypanosomal agents)
IT 199180-13-7 288161-20-6 312324-31-5 312324-37-1 312324-38-2
312324-39-3 312324-40-6 312324-41-7 312324-42-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(aryl ureas, a new class of anti-trypanosomal agents)
IT 90371-53-2, Cruzain 312324-28-0, Trypanosoma brucei cysteine proteinase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(aryl ureas, a new class of anti-trypanosomal agents)
IT 113446-04-1 202827-87-0 216985-19-2 219139-94-3 219314-80-4
219314-82-6 **219864-88-7** 261510-74-1 312324-30-4
312324-32-6 312324-33-7 312324-34-8 312324-35-9
RL: PRP (Properties)
(aryl ureas, a new class of anti-trypanosomal agents)
IT 24016-03-3 86688-94-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(aryl ureas, a new class of anti-trypanosomal agents)
RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Bonaldo, M; Exp Parasitol 1981, V73, P44
(2) Brinen, L; unpublished results
(3) Caffrey; unpublished results
(4) Castro, J; J Med Chem 1996, V39, P842 HCAPLUS
(5) Connolly, M; J Appl Cryst 1983, V16, P548 HCAPLUS
(6) Connolly, M; Science 1983, V221, P709 HCAPLUS
(7) Croft, S; Trypanosomiasis and Leishmaniasis: Biology and Control 1997, P245 HCAPLUS
(8) Eakin, A; J Mol Biol 1995, V268, P6115
(9) Engel, J; J Exp Med 1998, V188, P725 HCAPLUS
(10) Ewing, T; J Comp Chem 1997, V18, P1175 HCAPLUS
(11) Ferrin, T; J Mol Graph 1988, V6, P13 HCAPLUS
(12) Flaherty, T; unpublished work
(13) Gillmor, S; Protein Sci 1997, V6, P1603 HCAPLUS
(14) Godal, T; WHO Division of Control in Tropical Diseases 1990, P12
(15) Gorla, N; Mutat Res 1988, V206, P217 MEDLINE
(16) Hansch, C; Substituent Constants for Correlation Analysis in Chemistry and Biology 1979
(17) Harth, G; Mol Biochem Parasitol 1993, V58, P17 HCAPLUS
(18) Hogberg, M; J Med Chem 1999, V42, P4150 MEDLINE
(19) Kirchhoff, L; New Engl J Med 1993, V329, P639 MEDLINE
(20) Lam, P; Science 1994, V263, P380 HCAPLUS
(21) Li, R; Biol Med Chem 1996, V4, P1421 HCAPLUS
(22) Libow, L; Cutis 1991, V48, P37 MEDLINE
(23) Lilly, E; Eli Lilly and Company Antibiotic Therapy: Sulfonamide Therapy 1953
(24) Lipinski, C; Adv Drug Deliv Rev 1997, V23, P3 HCAPLUS
(25) McKerrow, J; Annu Rev Microbiol 1993, V47, P821 HCAPLUS
(26) Mcgrath, M; J Mol Biol 1995, V247, P251 HCAPLUS
(27) Meirelles, M; Mol Biochem Parasitol 1992, V52, P175 HCAPLUS
(28) Molyneux, D; Trypanosomiasis and Leishmaniasis: Biology and Control 1997, P39
(29) Okada, M; Chem Pharm Bull 1996, V44, P1871 HCAPLUS
(30) Pearlman, D; Amber4.1 1995
(31) Perris, V; Proc Natl Acad Sci USA 2000, V97, P6073
(32) Rasmussen, C; Synthesis 1988, P456 HCAPLUS
(33) Rings, C; Proc Natl Acad Sci USA 1993, V90, P3583
(34) Scory, S; Exp Parasitol 1999, V91, P327 HCAPLUS
(35) Spink, W; Sulfanilamide and Related Compounds in General Practice 1942
(36) Tsuruoka, A; Chem Pharm Bull 1997, V45, P1169 HCAPLUS
(37) Ullman, J; J Assoc Comput Mach 1976, V23, P31
(38) Von Geldern, T; J Med Chem 1996, V39, P968 HCAPLUS
(39) WHO; World Health Org Tech Rep Ser 1998, V881
(40) Wallace, A; Protein Eng 1995, V8, P127 HCAPLUS
(41) Wallace, A; Protein Sci 1997, V6, P2308 HCAPLUS
(42) Wei, T; Synth Commun 1998, V28, P2851 HCAPLUS
(43) Williams, G; New Engl J Med 1988, V319, P1517 MEDLINE
(44) Zhang, Y; Synth Commun 1997, V27, P751 HCAPLUS

IT **219864-88-7**
RL: PRP (Properties)
(aryl ureas, a new class of anti-trypanosomal agents)
RN 219864-88-7 HCAPLUS
CN Benzamide, N-[[[2-[5-(2-bromo-5-methoxyphenyl)-1,3,4-oxadiazol-2-yl]phenyl]amino]carbonyl]-2-chloro- (9CI) (CA INDEX NAME)



L37 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:6982 HCAPLUS
DN 118:6982
ED Entered STN: 10 Jan 1993
TI Preparation of [(heterocyclyl)(alkyl)]phenyl amidines and guanidines as hypoglycemics.
IN Gopalan, Balasubramanian
PA Boots Co., PLC, UK
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 123 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
IC ICM C07D211-56
ICS C07D207-14; C07D233-02; C07D239-04; C07D265-30; C07D223-12
CC 28-13 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1**, **63**

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1057648	A	19920108	CN 1990-103295	19900629 <--
	CN 1037346	B	19980211		
PRAI	CN 1990-103295		19900629 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
CN 1057648	ICM	C07D211-56
	ICS	C07D207-14; C07D233-02; C07D239-04; C07D265-30; C07D223-12

OS CASREACT 118:6982; MARPAT 118:6982
GI



I

AB The title compds. [I; R1, R2 = (methoxy) aliphatic hydrocarbyl, cycloalkyl; or NR1R2 = N-containing heterocyclyl; R3 = alkyl, cycloalkyl, (substituted) amino; R5 = (methoxy) aliphatic hydrocarbyl; R6 = H, (substituted) alkyl, cycloalkyl; R7 = H,alkyl, halo, methoxy, CO2Me, SO2Me; R3R5 may form part of a ring; with provisos] are prepared E.g., 1-benzyl-3-methyl-2-pyrrolidinone in benzene containing POCl3 was heated with 4-(2-aminophenyl)morpholine at 70° for 24 h to give 4-[2-(1-benzyl-3-methyl-2-pyrrolidinylideneamino)phenyl]morpholine. This decreased the blood sugar level by ≥25% in rats 2 or 4 h after they were injected s.c. with glucose. Pharmaceuticals containing I were formulated.

ST amidine heterocyclylalkylphenyl prepn hypoglycemic; guanidine heterocyclylalkylphenyl prepn hypoglycemic; heterocyclylalkylphenyl amidine guanidine; hypoglycemic amidine guanidine

IT **Antidiabetics** and Hypoglycemics
([(heterocyclyl)(alkyl)]phenyl amidines and guanidines)

IT Amidines
RL: SPN (Synthetic preparation); PREP (Preparation)
(aryl, preparation of, as hypoglycemics)

IT 131679-02-2, N-(2-Morpholinomethylphenyl)morpholine-4-formamidine difumarate
RL: RCT (Reactant); RACT (Reactant or reagent)
(234prepn. of, as hypoglycemic)

IT 131675-72-4P, 4-[2-(2-Piperidinylideneamino)phenyl]morpholine
131675-74-6P, 4-[2-(1-Methyl-2-piperidinylideneamino)phenyl]morpholine
131675-75-7P 131675-76-8P 131675-77-9P 131675-78-0P 131675-80-4P
131675-81-5P 131675-82-6P 131675-83-7P, 4-[2-(1,3,3-Trimethyl-2-pyrrolidinylideneamino)phenyl]morpholine 131675-84-8P 131675-86-0P
131675-87-1P 131675-88-2P 131675-90-6P 131675-91-7P 131675-93-9P
131675-94-0P 131675-95-1P 131675-96-2P 131675-97-3P 131675-98-4P
131675-99-5P 131676-01-2P 131676-02-3P, 4-[4-Chloro-2-(2-piperidinylideneamino)phenyl]morpholine 131676-03-4P 131676-04-5P
131676-05-6P 131676-06-7P 131676-07-8P 131676-08-9P 131676-09-0P
131676-10-3P 131676-13-6P 131676-14-7P, 4-[2-(3-Methyl-2-pyrrolidinylideneamino)phenyl]morpholine fumarate 131676-15-8P
131676-16-9P 131676-17-0P, 1-Butyl-2-(2-morpholinophenyl)-3-acetamidine
131676-19-2P 131676-21-6P 131676-23-8P 131676-25-0P 131676-26-1P
131676-27-2P 131676-28-3P 131676-29-4P 131676-30-7P 131676-31-8P
131676-32-9P 131676-33-0P 131676-34-1P 131676-35-2P 131676-36-3P
131676-37-4P 131676-38-5P 131676-39-6P 131676-40-9P 131676-41-0P
131676-42-1P 131676-43-2P 131676-44-3P 131676-45-4P 131676-46-5P
131676-47-6P 131676-48-7P 131676-49-8P 131676-50-1P 131676-51-2P
131676-52-3P 131676-53-4P 131676-54-5P 131676-55-6P 131676-56-7P
131676-57-8P 131676-59-0P 131676-60-3P 131676-62-5P 131676-63-6P
131676-64-7P 131676-65-8P 131676-66-9P 131676-67-0P 131676-69-2P
131676-70-5P 131676-71-6P 131676-72-7P 131676-73-8P 131676-74-9P
131676-75-0P 131676-77-2P 131676-78-3P, N-(2-Morpholinophenyl)acetamidine 131676-79-4P, N-(5-Methyl-2-morpholinophenyl)acetamidine 131676-80-7P, N-(2-Morpholinophenyl)propionamidine 131676-81-8P, N-(2-Morpholinophenyl)butyramidine 131676-83-0P, N-(2-Morpholinophenyl)isobutyramidine 131676-85-2P, N-(5-Fluoro-2-morpholinophenyl)isobutyramidine 131676-86-3P, N-(2-Morpholinophenyl)pentanamidine 131676-87-4P, N-(2-Morpholinophenyl)neopentanamidine 131676-88-5P 131676-89-6P
131676-90-9P 131676-91-0P 131676-94-3P 131676-97-6P 131676-98-7P
131676-99-8P 131677-00-4P 131677-01-5P, 4-(2-[1-(2-Cyanoethyl)-2-piperidinylideneamino]phenyl)morpholine 131677-02-6P, 4-[2-(3-Morpholinylideneamino)phenyl]morpholine hydrochloride
131677-05-9P 131677-06-0P 131677-08-2P, 4-[2-(1,3-Dimethyl-2-imidazolidinylideneamino)phenyl]morpholine 131677-09-3P 131677-10-6P
131677-11-7P 131677-12-8P 131677-13-9P 131677-14-0P 131677-15-1P
131677-17-3P 131677-18-4P 131677-20-8P 131677-22-0P 131677-23-1P

131677-24-2P 131677-26-4P 131677-28-6P 131677-29-7P 131677-30-0P
131677-31-1P 131677-35-5P 131677-36-6P, 1-Ethyl-2-(2-morpholinophenyl)-
1,3,3-trimethylguanidine 131677-37-7P, 1-Allyl-2-(2-morpholinophenyl)-
1,3,3-trimethylguanidine 131677-38-8P, 1-Butyl-2-(2-morpholinophenyl)-
1,3,3-trimethylguanidine 131677-39-9P, 1-Pentyl-2-(2-morpholinophenyl)-
1,3,3-trimethylguanidine 131677-40-2P, 4-(2-[1-Methyl-3-(2-methoxyethyl)-
2-imidazolidinylideneamino]phenyl)morpholine 131677-41-3P,
4-(2-[1-Methyl-3-(2-methoxyethyl)-2-imidazolidinylideneamino]phenyl)morpho
line monofumarate 131677-42-4P, 4-(2-[1-Methyl-3-(2-hydroxyethyl)-2-
imidazolidinylideneamino]phenyl)morpholine 131677-43-5P,
N,N-Dimethyl-N'-(2-morpholinophenyl)morpholine-4-formamidine
131677-44-6P 131677-45-7P, 4-[2-(1,3-Dimethyl-2-
imidazolidinylideneamino)phenyl]thiamorpholine 1-oxide 131677-46-8P,
4-[2-(2-Imidazolidenylideneamino)phenyl]morpholine 131677-47-9P,
4-[2-(1-Methyl-2-imidazolidinylideneamino)phenyl]morpholine 131677-48-0P
131677-49-1P 131677-50-4P 131677-51-5P 131677-52-6P 131677-53-7P
131677-54-8P 131677-55-9P 131677-56-0P 131677-58-2P 131677-59-3P
131677-60-6P 131677-61-7P 131677-62-8P 131677-63-9P 131677-64-0P
131677-65-1P 131677-66-2P 131677-67-3P 131677-68-4P 131677-69-5P
131677-70-8P 131677-71-9P 131677-72-0P 131677-73-1P 131677-74-2P
131677-75-3P 131677-76-4P 131677-77-5P 131677-78-6P 131677-79-7P
131677-80-0P 131677-81-1P, 4-[2-(4-Methyl-2-
imidazolidinylideneamino)phenyl]morpholine 131677-82-2P,
4-[2-(4,5-Dimethyl-2-imidazolidinylideneamino)phenyl]morpholine
131677-83-3P, 4-[2-(4,5-Dimethyl-1-(2-hydroxyethyl)-2-
imidazolidinylideneamino)phenyl]morpholine 131677-84-4P,
4-[2-(1-Methylperhydropyrimidin-2-ylideneamino)phenyl]morpholine
131677-85-5P, 2-(2-Morpholinophenylimino)-1,3-diazacycloheptane
131677-86-6P, 1,1-Dimethyl-2-(morpholinophenyl)guanidine 131677-87-7P,
1,3-Dimethyl-2-(morpholinophenyl)guanidine 131677-88-8P,
1,3,3-Trimethyl-2-(2-morpholinophenyl)guanidine 131677-89-9P,
1-Ethyl-2-(2-morpholinophenyl)-3-methylguanidine 131677-90-2P,
1,3-Diethyl-2-(2-morpholinophenyl)guanidine 131677-91-3P,
4-(2-[1-(2-Acetoxyethyl)-2-imidazolidinylideneamino]phenyl)morpholine
131677-93-5P, 1-Butyl-2-(2-morpholinophenyl)-3-methylguanidine
131677-94-6P, 1-(2-Methoxyethyl)-2-(2-morpholinophenyl)guanidine
131677-96-8P, 1-(2-Methylthioethyl)-2-(2-morpholinophenyl)guanidine
131677-97-9P 131677-98-0P, 1-Propyl-2-morpholinophenyl-3-methylguanidine
monofumarate 131677-99-1P, 1-Methyl-2-(2-morpholinophenyl)-3-(2-
methoxyethyl)guanidine 131678-01-8P, 1-Cyclopentyl-2-(2-
morpholinophenyl)-3-methylguanidine 131678-02-9P, 1-Cyclopenyl-2-(2-
morpholinophenyl)-3-methylguanidine monofumarate 131678-03-0P,
N-Methyl-N'-(2-morpholinophenyl)pyrrolidine-1-formamidine 131678-08-5P,
1,3-Dimethyl-2-(5-methyl-2-morpholinophenyl)guanidine fumarate
131678-09-6P, 4-(2-[1-(2-Hydroxyethyl)-2-imidazolidinylideneamino]-4-
methylphenyl)morpholine 131678-12-1P, 1-Butyl-2-(5-methyl-2-
morpholinophenyl)-3-methylguanidine 131678-13-2P 131678-14-3P
131678-15-4P 131678-16-5P 131678-17-6P 131678-18-7P 131678-19-8P,
1,1-Dimethyl-2-(5-cyano-2-morpholinophenyl)guanidine 131678-20-1P,
1,3-Dipropyl-2-(2-morpholinophenyl)guanidine 131678-21-2P,
1,3-Dipropyl-2-(2-morpholinophenyl)guanidine hemifumarate 131678-22-3P
131678-23-4P 131678-24-5P 131678-25-6P 131678-26-7P 131678-27-8P
131678-28-9P 131678-29-0P 131678-30-3P 131678-31-4P 131678-32-5P
131678-33-6P 131678-35-8P 131678-36-9P 131678-38-1P 131678-39-2P
131678-40-5P 131678-41-6P 131678-43-8P 131678-44-9P 131678-45-0P
131678-46-1P, 1,1-Dimethyl-2-(5-methoxycarbonyl-2-
morpholinophenyl)guanidine 131678-47-2P 131678-48-3P 131678-49-4P
131678-50-7P 131678-51-8P 131678-52-9P 131678-53-0P 131678-54-1P
131678-55-2P 131678-56-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as hypoglycemic)

IT 131678-57-4P 131678-58-5P 131678-59-6P, 1,1-Dimethyl-2-(5-chloro-2-
morpholinophenyl)guanidine 131678-60-9P, 1,1-Dimethyl-2-(5-fluoro-2-

morpholinophenyl)guanidine 131678-61-0P, 1,1-Dimethyl-2-(3-methyl-2-morpholinophenyl)guanidine 131678-62-1P, 1,1-Dimethyl-2-(5-isobutyl-2-morpholinophenyl)guanidine 131678-63-2P, 1,1-Dimethyl-2-(5-methylsulfinyl-2-morpholinophenyl)guanidine 131678-64-3P 131678-65-4P 131678-66-5P 131678-67-6P 131678-70-1P 131678-71-2P 131678-72-3P, 4-(2-[1-(2-Hydroxyethyl)-2-imidazolidinylideneamino]phenyl)morpholine monotartrate 131678-74-5P, 1,1-Dimethyl-2-(2-morpholinophenyl)guanidine monotartrate 131678-75-6P, 1,1-Dimethyl-2-(5-methyl-2-morpholinophenyl)guanidine monohydrochloride 131678-76-7P, 1,1-Dimethyl-2-(2-morpholinophenyl)guanidine monohydrochloride 131678-78-9P, 4-[4-Chloro-2-(1,3-dimethyl-2-imidazolidinylideneamino)benzyl]morpholine 131678-79-0P, 4-[4-Chloro-2-(1,3-dimethyl-2-imidazolidinylideneamino)benzyl]morpholine monofumarate 131678-80-3P, N-(2-Morpholinomethylphenyl)morpholine-4-formamidine 131678-81-4P, N-(2-Morpholinophenyl)neopentanamidine monofumarate 131678-84-7P, N-Methyl-N'-(2-morpholinomethylphenyl)neopentanamidine 131678-85-8P, 4-(2-[1-(2-Benzoyloxyethyl)-3-methyl-2-imidazolidinylideneamino]phenyl)morpholine 131678-87-0P, 4-[2-(1-Isopropyl-4,4-dimethyl-2-imidazolidinylideneamino)phenyl]morpholine 131678-88-1P, 1-(2-Methoxyethyl)-2-(2-morpholinophenyl)guanidine fumarate 131678-89-2P, N-Methyl-N'-(2-morpholinophenyl)pyrrolidine-1-formamidine monofumarate 131678-90-5P, 1-Butyl-2-(2-morpholinophenyl)-3-ethylguanidine monofumarate 131678-92-7P, 1-Butyl-2-(5-methyl-2-morpholinophenyl)-3-methylguanidine monofumarate 131678-93-8P, 1-Butyl-2-(6-methyl-2-morpholinophenyl)-3-methylguanidine 131678-94-9P, 1-Butyl-2-(6-methyl-2-morpholinomethyl)-3-methylguanidine monofumarate 131678-95-0P, 1,1-Dimethyl-2-(2-morpholino-5-trifluoromethylphenyl)guanidine fumarate 131678-96-1P, 1,1-Dimethyl-2-(5-cyano-2-morpholinophenyl)guanidine monofumarate 131678-98-3P, 1,1-Dimethyl-2-(5-chloro-2-morpholinophenyl)guanidine monofumarate 131678-99-4P, 1,1-Dimethyl-2-(5-fluoro-2-morpholinophenyl)guanidine fumarate 131679-00-0P, 1,1-Dimethyl-2-(3-methyl-2-morpholinophenyl)guanidine fumarate 131679-01-1P, N,N-Dimethyl-N'-(2-morpholinomethylphenyl)guanidine 131679-03-3P, 4-[2-(1-Benzyl-3-methyl-2-pyrrolidinylideneamino)phenyl]morpholine 131679-07-7P, 4-(2-[1-Methyl-3-(2-acetoxyethyl)-2-imidazolidenylideneamino]phenyl)morpholine 131679-37-3P, 1-Butyl-3-(5-chloro-2-morpholinophenyl)thiourea 131679-38-4P 131679-40-8P 131679-42-0P 131679-45-3P, 1,1-Dimethyl-2-(2-morpholinophenyl)thiourea 131679-46-4P, 2-Methyl-1-(2-morpholinophenyl)-3,3-dimethyl-2-thiopseudourea 131697-93-3P 131697-94-4P 131697-95-5P 131697-96-6P 131697-97-7P 131697-98-8P 131697-99-9P, 4-[2-(1-Isopropyl-4,4-dimethyl-2-imidazolidenylideneamino)phenyl]morpholine monofumarate 131698-00-5P 131698-01-6P 131698-02-7P, 1,1-Dimethyl-2-(4-methoxy-2-morpholinophenyl)guanidine 143803-94-5P 143803-95-6P 143803-96-7P 143803-99-0P 143804-00-6P 143804-01-7P 143804-02-8P 143804-03-9P, N-(2-Morpholinomethyl)butyramidine 143804-04-0P, N-(5-Methylthio-2-morpholinophenyl)isobutyramidine 143804-05-1P, 4-[2-(3-Morpholinylideneamino)phenyl]morpholine 143804-06-2P 143804-07-3P 143804-08-4P, 2-(2-Morpholinomethyl)-1,1,3,3-tetramethylguanidine 143804-09-5P, 4-(2-[1-(2-Formyloxyethyl)-2-imidazolidinylideneamino]phenyl)morpholine 143804-10-8P, 1-(2-Methoxyethyl)-2-(2-piperidinylphenyl)guanidine 143804-11-9P, 1-Methyl-3-[2-(1-pyrrolidinyl)phenyl]urea 143804-12-0P, 1-Methyl-3-(5-methyl-2-morpholinophenyl)urea 143804-13-1P, 1-Methyl-2-(2-morpholinophenyl)-3-pentylguanidine 143804-14-2P 143804-15-3P 143804-16-4P, 4-[2-(1,3-Dimethyl-2-imidazolidinylideneamino)benzyl]morpholine 144187-06-4P, 4-[2-(2-Piperidinylideneamino)phenyl]morpholine maleate 144187-07-5P 144187-08-6P 144187-09-7P 144187-11-1P 144187-12-2P 144187-13-3P 144187-14-4P, 1,1-Dimethyl-2-(5-methyl-2-morpholinophenyl)guanidine monotartrate 144187-15-5P, 1,1-Dimethyl-2-(2-morpholinophenyl)guanidine hemisulfate 144187-16-6P, 1,1-Dimethyl-2-(2-morpholinophenyl)guanidine hemipamoate 144187-17-7P,

N-(2-Morpholinomethyl)butyramidine fumarate 144187-19-9P, N-Methyl-N'-(2-morpholinomethylbenzyl)neopentanamidine monofumarate 144187-20-2P, 4-(2-[1-(2-Benzoyloxyethyl)-3-methyl-2-imidazolidinylideneamino]phenyl)morpholine monofumarate 144187-21-3P 144187-22-4P, 1,3,3-Trimethyl-2-(2-morpholinophenyl)guanidine monofumarate 144187-23-5P, 1-Butyl-2-(2-morpholinophenyl)-3-methylguanidine monofumarate 144187-24-6P, 1-(2-Methoxyethyl)-2-(2-piperidinophenyl)guanidine hemifumarate 144187-25-7P, 1-Methyl-2-(2-morpholinophenyl)-3-(2-methoxyethyl)guanidine hemifumarate 144187-26-8P, 1-Allyl-2-[2-(1-pyrrolidinyl)phenyl]-3-methylguanidine monofumarate 144187-27-9P, 4-(2[-1-(2-Hydroxyethyl)-2-imidazolidinylideneamino]-4-methylphenyl)morpholine.2/3 fumarate 144187-28-0P, 1-Methyl-2-(2-morpholinophenyl)-3-valeramidine monofumarate 144187-29-1P, 2-Methyl-1-(6-methyl-2-morpholinophenyl)-3-methyl-2-thiopseudourea hydriodide 144187-32-6P, N,N-Dimethyl-N'-(2-morpholinomethylphenyl)guanidine monofumarate
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as hypoglycemic)

IT 80-73-9P, 1,3-Dimethyl-2-imidazolidinone 1530-89-8P, 4-Cyanomorpholine 3699-54-5P, 1-(2-Hydroxyethyl)-2-imidazolinone 51317-68-1P, 2-Piperidinophenyl isothiocyanate 67829-55-4P, 1-[2-(1-Pyrrolidinyl)phenyl]urea 95539-61-0P, 4-(2-Aminobenzyl)morpholine 131679-04-4P 131679-05-5P 131679-06-6P 131679-08-8P, 1-[2-(4-Morpholino)phenyl]thiourea 131679-09-9P 131679-12-4P 131679-13-5P, 2-[Bis(2-methoxyethyl)amino]phenyl isothiocyanate 131679-14-6P 131679-15-7P 131679-16-8P, 2-Thiamorpholinophenyl isothiocyanate 131679-18-0P 131679-21-5P 131679-22-6P, 5-Methyl-2-morpholinophenyl isothiocyanate 131679-23-7P, 1-(5-Methyl-2-morpholinophenyl)thiourea 131679-24-8P, 1-[2-(2-Methyl-1-pyrrolidinyl)phenyl]thiourea 131679-25-9P 131679-26-0P, 1-(2-Piperidinophenyl)thiourea 131679-27-1P 131679-28-2P, 6-Methyl-2-piperidinophenyl isocyanate 131679-29-3P 131679-30-6P, N-(2-Hydroxyethyl)-1,2-dimethyl-1,2-ethylenediamine 131679-31-7P, 1-(2-Morpholinophenyl)-3-methylthiourea 131679-32-8P, 2-Methyl-1-(2-morpholinophenyl)guanidine 131679-36-2P 131679-44-2P 131679-50-0P 131679-52-2P 131679-53-3P 131679-54-4P 131679-55-5P 131679-56-6P 131679-57-7P 131679-58-8P 131679-59-9P 131679-60-2P 131679-61-3P 131679-62-4P 131679-63-5P 131679-64-6P, N-(2-Morpholinophenyl)-N-cyanoamine 131679-65-7P, N-Methyl-N'-(2-morpholinophenyl)carbodiimide 131679-66-8P 131679-67-9P 131698-05-0P, 1-(6-Methyl-2-piperidinophenyl)thiourea 131698-06-1P 144187-33-7P, 6-Methyl-2-morpholinophenyl isothiocyanate 144187-34-8P, 1-(6-Methyl-2-morpholinophenyl)urea 144187-36-0P, 1-(2-Thiamorpholinophenyl)urea **144187-37-1P**, 3-Benzoyl-1-[2-(1-pyrrolidinyl)phenyl]urea 144187-38-2P 144187-39-3P, 1-Ethyl-3-(2-morpholinophenyl)urea 144187-40-6P 144187-41-7P, 1-Butyl-3-(2-morpholinophenyl)pseudourea 144187-58-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for hypoglycemics)

IT 57-13-6, Urea, reactions 74-88-4, Methyl iodide, reactions 75-21-8, Oxirane, reactions 78-82-0, Isobutyronitrile 80-48-8, Methyl p-toluenesulfonate 93-97-0, Benzoyl anhydride 107-15-3, 1,2-Ethanediamine, reactions 109-11-5, 3-Morpholinone 109-73-9, Butylamine, reactions 109-74-0, Butyronitrile 109-81-9 110-59-8, Valeronitrile 110-60-1, 1,4-Butanediamine 111-41-1, N-(2-Hydroxyethyl)-1,2-ethylenediamine 124-40-3, Dimethylamine, reactions 130-85-8, Pamoic acid 463-71-8, Thiophosgene 532-55-8, Benzoyl isothiocyanate 556-61-6, Methyl isothiocyanate 563-86-0, 1,2-Dimethylethylenediamine 592-82-5, Butyl isothiocyanate 630-18-2 632-22-4, Tetramethylurea 675-20-7, 2-Piperidinone 784-57-6, 2-Morpholino-5-(trifluoromethyl)aniline 872-50-4, 1-Methyl-2-pyrrolidinone, reactions 1003-03-8, Cyclopentylamine 1467-79-4, N,N-Dimethylcyanamide 5370-33-2, 1,3,3-Trimethyl-2-pyrrolidinone

5448-29-3, N'-Isopropyl-2-methyl-1,2-propanediamine 5585-33-1
6291-84-5, 3-(Methylamino)propylamine 6830-83-7 21627-58-7,
1-(2-Aminophenyl)pyrrolidine 22455-69-2 26586-18-5,
4-(2-Amino-4-methoxycarbonylphenyl)morpholine 39643-31-7,
2-Piperidinoaniline 39799-78-5, 1,3-Dimethyl-2-imidazolinone
50533-97-6, 4-(Dimethylamino)piperidine 51317-67-0 59504-49-3
84186-31-2, 6-Methyl-2-piperidinoaniline 90875-44-8,
4-(2-Amino-4-chlorophenyl)morpholine 91429-92-4, 4-(2-Amino-4-
methylphenyl)morpholine 108303-99-7, 1-Benzyl-3-methyl-2-pyrrolidinone
113502-25-3, 3-Ethyl-1,1,3-trimethylurea 131679-48-6,
2-Morpholino-5-(trimethylmethyl)phenyl isothiocyanate 131679-49-7
144187-42-8, 1-Methyl-3-(2-methoxyethyl)-2-piperidinone 144187-43-9,
5-(Methylthio)-2-morpholinoaniline 144187-44-0, 5-Fluoro-2-
morpholinoaniline 144187-45-1, 4-(2-Amino-4-chlorobenzyl)morpholine
144187-46-2, 3-Allyl-2-(2-morpholinophenyl)-1,3,3-trimethylurea
144187-47-3, 3-Butyl-1,1,3-trimethylurea 144187-48-4 144187-50-8,
6-Methyl-2-morpholinoaniline 144187-51-9, N,N-Bis(2-methoxyethyl)benzene-
1,2-diamine 144187-52-0, 2-Thiomorpholinoaniline 144187-53-1,
2-Methyl-1-(2-aminophenyl)pyrrolidine 144187-54-2 144187-55-3,
4-(2-Aminophenyl)morpholine hydrochloride 144187-56-4,
4-Methoxy-2-morpholinoaniline 144187-57-5, 5-Isobutyl-2-
morpholinoaniline hydrochloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of hypoglycemics)

IT **144187-37-1P**, 3-Benzoyl-1-[2-(1-pyrrolidinyl)phenyl]urea
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for hypoglycemics)

RN 144187-37-1 HCAPLUS

CN Benzamide, N-[[[2-(1-pyrrolidinyl)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



L37 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1990:132475 HCAPLUS

DN 112:132475

ED Entered STN: 13 Apr 1990

TI Preparation of urea derivatives for treating hematologic diseases

IN Jenkins, Vernon K.

PA Duphar International Research B. V., Neth.

SO Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW

DT Patent

LA English

IC ICM A61K031-17
ICS A61K031-165; A61K031-495; A61K031-445; A61K031-44; A61K031-40;
A61K031-41; C07C149-437; C07C127-22

CC 1-8 (**Pharmacology**)
Section cross-reference(s): 25

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 324521	A2	19890719	EP 1989-200030	19890106

EP 324521	A3	19911127			
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE					
DK 8900054	A	19890712	DK 1989-54		19890106
ZA 8900135	A	19891025	ZA 1989-135		19890106
JP 02000703	A2	19900105	JP 1989-2180		19890110
AU 8928408	A1	19890713	AU 1989-28408		19890111
AU 614012	B2	19910815			
US 5166180	A	19921124	US 1990-485822		19900227
PRAI US 1988-141848	A	19880111			
US 1989-295756	B1	19890111			

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 324521	ICM	A61K031-17
	ICS	A61K031-165; A61K031-495; A61K031-445; A61K031-44; A61K031-40; A61K031-41; C07C149-437; C07C127-22

OS MARPAT 112:132475

AB The urea derivs R1C(:X)NR3[C(:Y)NR4]nR2 (R1 = Ph, alkyl, cycloalkyl, styryl, etc.; R2 = H, alkyl, Ph, phenylalkyl, etc.; R3 = H, alkyl, alkoxyalyl; R4 = H, alkyl; X, Y = O, S; n = 0, 1) are prepared as drugs for the treatment of hematol. diseases, especially useful for hematopoietic stimulation. A suspension of 2-methylthiobenzamide and 4-chlorophenyl isocyanate in xylene was refluxed overnight, to give 1-(2-methylthiobenzoyl)-3-(4-chlorophenyl)urea (I). The hematopoietic activity of I (0.03 μg/mL) was shown on a murine bone marrow cell suspension, using the colony-forming technique.

ST urea deriv prepn hematopoietic drug

IT Radiation sickness
(hematopoietic disorders in, treatment of, with urea derivs.)

IT Blood
(disease, treatment of, with urea derivs.)

IT Hematopoiesis
(disorder, treatment of, with urea derivs.)

IT 124-40-3, Dimethylamine, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(amination by, of phenylurea derivative)

IT 96994-73-9
RL: BIOL (Biological study)
(hydration of)

IT 125931-38-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and amination of)

IT 51213-84-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenation of)

IT 125931-37-5P 125954-18-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)

IT 35367-23-8P 35367-38-5P 35367-40-9P 40109-86-2P 51213-97-9P
51213-99-1P 57160-46-0P 57160-48-2P 57160-69-7P 69441-50-5P
73609-43-5P 94661-56-0P 98784-84-0P 105353-47-7P 105353-50-2P
105353-52-4P 105353-62-6P 105353-63-7P 105353-68-2P 105353-77-3P
105353-92-2P 105353-97-7P 105354-06-1P 105354-07-2P 105354-08-3P
105354-11-8P 105354-28-7P 105354-43-6P 105354-48-1P 107485-44-9P
107485-61-0P 125930-97-4P 125930-98-5P 125930-99-6P 125931-00-2P
125931-01-3P 125931-02-4P 125931-03-5P 125931-04-6P 125931-05-7P
125931-06-8P 125931-07-9P 125931-08-0P 125931-09-1P 125931-10-4P
125931-11-5P 125931-12-6P 125931-13-7P 125931-14-8P 125931-15-9P
125931-16-0P 125931-17-1P 125931-18-2P 125931-19-3P 125931-20-6P
125931-21-7P 125931-22-8P 125931-23-9P 125931-24-0P 125931-25-1P

125931-26-2P 125931-27-3P 125931-28-4P 125931-29-5P 125931-30-8P
125931-31-9P 125931-32-0P 125931-33-1P 125931-34-2P 125931-35-3P
125954-13-4P **125954-14-5P** 125954-15-6P 125954-16-7P
125954-17-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as hematopoietic drug)

IT 69486-58-4 125931-36-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with chloroaniline)

IT 54705-16-7, 2-Methylthiobenzamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with chlorophenyl isocyanate)

IT 104-12-1, 4-Chlorophenyl isocyanate
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with methylthiobenzamide)

IT 106-47-8, 4-Chloroaniline, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with methylthiobenzoyl isocyanate)

IT **125954-14-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as hematopoietic drug)

RN 125954-14-5 HCAPLUS

CN 1-Piperazinecarboxamide, N-(4-chlorophenyl)-4-[4-[[[(2,6-difluorobenzoyl)amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




```
=> fil reg
FILE 'REGISTRY' ENTERED AT 18:39:05 ON 14 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   13 DEC 2004  HIGHEST RN 796963-46-7
DICTIONARY FILE UPDATES:  13 DEC 2004  HIGHEST RN 796963-46-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> => dhis l41-
DHIS IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d his l41-

     (FILE 'HCAPLUS' ENTERED AT 18:39:29 ON 14 DEC 2004)
               SET SMARTSELECT OFF

     FILE 'REGISTRY' ENTERED AT 18:39:30 ON 14 DEC 2004
L41          427 S L40
L42           73 S L41 AND L13

=> d scan l42

L42  73 ANSWERS   REGISTRY  COPYRIGHT 2004 ACS on STN
IN   Benzamide, 2-chloro-4,5-difluoro-N-[[[2-methoxy-4-(5-methyl-1H-1,2,4-
     triazol-3-yl)phenyl]amino]carbonyl]- (9CI)
MF   C18 H14 Cl F2 N5 O3
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):72

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-N-[[[2-chloro-4-(1H-tetrazol-5-yl)phenyl]amino]carbonyl]-4-fluoro- (9CI)
MF C15 H9 Cl2 F N6 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-N-[[[4-(4,5-dihydro-5-oxo-1,3,4-oxadiazol-2-yl)-2-methoxyphenyl]amino]carbonyl]-4,5-difluoro- (9CI)
MF C17 H11 Cl F2 N4 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-N-[[[2-chloro-4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]amino]carbonyl]-4-fluoro- (9CI)
MF C17 H11 Cl2 F N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, N-[[[2-(1H-benzimidazol-2-yl)phenyl]amino]carbonyl]-2-chloro-4,5-difluoro- (9CI)
MF C21 H13 Cl F2 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]- (9CI)
MF C20 H17 Cl F3 N3 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]- (9CI)

MF C20 H18 Cl F2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[4-chloro-2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]phenyl]-, methyl ester (9CI)
MF C21 H20 Cl2 F N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Piperidinecarboxamide, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]-N,N-diethyl- (9CI)
MF C24 H27 Cl F2 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-4-(methylsulfonyl)phenyl]-, methyl ester (9CI)
MF C22 H22 Cl F2 N3 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]phenyl]- (9CI)
MF C20 H18 Cl F2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-N-[[[5-[[(ethylamino)carbonyl]amino]-2-(1-pyrrolidinyl)phenyl]amino]carbonyl]-4,5-difluoro- (9CI)
MF C21 H22 Cl F2 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-4-fluoro-N-[[[2-methoxy-4-(5-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino]carbonyl]- (9CI)
MF C18 H15 Cl F N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-N-[[[4-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)-2-(trifluoromethoxy)phenyl]amino]carbonyl]-4,5-difluoro- (9CI)
MF C17 H9 Cl F5 N5 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-N-[[[2-(4,5-dihydro-5-oxo-1,3,4-oxadiazol-2-yl)phenyl]amino]carbonyl]-4-fluoro- (9CI)
MF C16 H10 Cl F N4 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-4-fluoro-N-[[[2-methyl-4-[5-(methylamino)-2-oxo-1,3,4-oxadiazol-3(2H)-yl]phenyl]amino]carbonyl]- (9CI)
MF C18 H15 Cl F N5 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-N-[[[4-(2,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)-2-methylphenyl]amino]carbonyl]-4-fluoro- (9CI)
MF C19 H16 Cl F N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Piperidinecarboxamide, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]- (9CI)
MF C20 H18 Cl F3 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Piperidinecarboxamide, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]- (9CI)
MF C20 H19 Cl F2 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[4-chloro-2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]phenyl]-, methyl ester (9CI)
MF C21 H19 Cl2 F2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]-, ethyl ester (9CI)
MF C22 H22 Cl F2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-(trifluoromethyl)phenyl]- (9CI)
MF C21 H18 Cl F4 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-5-fluorophenyl]-, monosodium salt (9CI)
MF C20 H17 Cl F3 N3 O4 . Na



● Na

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Piperidinecarboxamide, 1-[4-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-6-fluoro[1,1'-biphenyl]-3-yl]- (9CI)
MF C26 H22 Cl F3 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-4,5-difluoro-N-[[[2-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]amino]carbonyl]- (9CI)
MF C16 H9 Cl F3 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-N-[[[2-chloro-3-(1H-1,2,4-triazol-3-yl)phenyl]amino]carbonyl]-4,5-difluoro- (9CI)
MF C16 H9 Cl2 F2 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-N-[[[4-(4,5-dihydro-5-oxo-1,3,4-oxadiazol-2-yl)-2-methoxyphenyl]amino]carbonyl]-4-fluoro- (9CI)
MF C17 H12 Cl F N4 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-4-fluoro-N-[[[2-methoxy-4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3(2H)-yl)phenyl]amino]carbonyl]- (9CI)
MF C18 H14 Cl F N4 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-N-[[[2-chloro-4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)phenyl]amino]carbonyl]-4-fluoro- (9CI)
MF C16 H9 Cl2 F N4 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-N-[[[2-chloro-5-(5,6-dimethyl-1,2,4-triazin-3-yl)phenyl]amino]carbonyl]-4,5-difluoro- (9CI)
MF C19 H13 Cl2 F2 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]- (9CI)
MF C20 H18 Cl F2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-methylphenyl]- (9CI)
MF C21 H21 Cl F N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-(methoxycarbonyl)phenyl]- (9CI)
MF C22 H21 Cl F N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-(methoxycarbonyl)phenyl]-, methyl ester (9CI)
MF C23 H23 Cl F N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[5-carboxy-2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]phenyl]-, 4-methyl ester (9CI)
MF C22 H20 Cl F2 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[4-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-6-fluoro[1,1'-biphenyl]-3-yl]-, methyl ester (9CI)
MF C27 H23 Cl F3 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzoic acid, 4-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-3-(4-morpholinyl)- (9CI)
MF C19 H16 Cl F2 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-N-[[[2-chloro-5-(5-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino]carbonyl]-4,5-difluoro- (9CI)
MF C17 H11 Cl2 F2 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-4,5-difluoro-N-[[[4-(1H-tetrazol-5-yl)-2-(trifluoromethoxy)phenyl]amino]carbonyl]- (9CI)
MF C16 H8 Cl F5 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-4,5-difluoro-N-[[[2-(1,3,4-oxadiazol-2-yl)phenyl]amino]carbonyl]- (9CI)
MF C16 H9 Cl F2 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-N-[[[4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-2-(trifluoromethoxy)phenyl]amino]carbonyl]-4-fluoro- (9CI)
MF C17 H9 Cl F4 N4 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-N-[[[2-chloro-5-(2,5-dihydro-6-methyl-5-oxo-1,2,4-triazin-3-yl)phenyl]amino]carbonyl]-4,5-difluoro- (9CI)
MF C18 H11 Cl2 F2 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]- (9CI)
MF C20 H17 Cl F3 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-4-methylphenyl]- (9CI)
MF C21 H20 Cl F2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-4-(methoxycarbonyl)phenyl]- (9CI)
MF C22 H20 Cl F2 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-4-(methoxycarbonyl)phenyl]-, methyl ester (9CI)
MF C23 H22 Cl F2 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[4-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-6-fluoro[1,1'-biphenyl]-3-yl]- (9CI)
MF C26 H21 Cl F3 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-4-(trifluoromethyl)phenyl]-, ethyl ester (9CI)
MF C23 H21 Cl F5 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzoic acid, 4-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-3-(1-pyrrolidinyl)- (9CI)
MF C19 H16 Cl F2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzoic acid, 2-[3-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]phenyl]-5-methyl-4H-1,2,4-triazol-4-yl]- (9CI)
MF C24 H16 Cl F2 N5 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-4-fluoro-N-[[[4-(1H-tetrazol-5-yl)-2-(trifluoromethoxy)phenyl]amino]carbonyl]- (9CI)
MF C16 H9 Cl F4 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-4-fluoro-N-[[[2-(1,3,4-oxadiazol-2-yl)phenyl]amino]carbonyl]- (9CI)
MF C16 H10 Cl F N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-N-[[[4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-2-(trifluoromethoxy)phenyl]amino]carbonyl]-4,5-difluoro- (9CI)
MF C17 H8 Cl F5 N4 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Furancarboxylic acid, 5-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]phenyl]- (9CI)
MF C19 H12 Cl F N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[4-chloro-2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]phenyl]- (9CI)
MF C20 H17 Cl2 F2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-5-methylphenyl]- (9CI)
MF C21 H20 Cl F2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Piperidinecarboxylic acid, 1-[4-chloro-2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]phenyl]- (9CI)
MF C20 H18 Cl2 F N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]-, methyl ester (9CI)
MF C21 H20 Cl F2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Piperidinecarboxylic acid, 1-[4-carboxy-2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]phenyl]- (9CI)
MF C21 H18 Cl F2 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI)
MF C20 H17 Cl F3 N3 O4 . C4 H11 N O3

CM 1



CM 2



L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzoic acid, 4-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-3-(4-morpholinyl)- (9CI)
MF C19 H17 Cl F N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-1,2,4-Triazole-3-acetic acid, 5-[4-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-3-methoxyphenyl]- (9CI)
MF C19 H15 Cl F N5 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-N-[[[2-chloro-4-(1H-tetrazol-5-yl)phenyl]amino]carbonyl]-4,5-difluoro- (9CI)
MF C15 H8 Cl2 F2 N6 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 2-chloro-N-[[[2-(4,5-dihydro-5-oxo-1,3,4-oxadiazol-2-yl)phenyl]amino]carbonyl]-4,5-difluoro- (9CI)
MF C16 H9 Cl F2 N4 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, N-[[[2-(5-amino-1,3,4-oxadiazol-2-yl)phenyl]amino]carbonyl]-2-chloro-4,5-difluoro- (9CI)
MF C16 H10 Cl F2 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Furancarboxylic acid, 5-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]phenyl]- (9CI)
MF C19 H11 Cl F2 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]-, monosodium salt (9CI)

MF C20 H17 Cl F3 N3 O4 . Na



● Na

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-5-methylphenyl]- (9CI)
MF C21 H21 Cl F N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Piperidinecarboxylic acid, 1-[4-chloro-2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]phenyl]- (9CI)
MF C20 H17 Cl2 F2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]-, methyl ester (9CI)
MF C21 H19 Cl F3 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-(methylsulfonyl)phenyl]-, methyl ester (9CI)
MF C22 H23 Cl F N3 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]phenyl]- (9CI)
MF C20 H19 Cl F N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L42 73 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzoic acid, 4-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-3-(1-pyrrolidinyl)- (9CI)
MF C19 H17 Cl F N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> => d ide can tot

L43 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN
RN 123-75-1 REGISTRY
CN **Pyrrolidine (8CI, 9CI)** (CA INDEX NAME)
OTHER NAMES:
CN Azacyclopentane
CN Azolidine
CN Butylenimine
CN NSC 62781
CN Perhydropyrrole
CN Prolamine
CN Pyrrole, tetrahydro-
CN Pyrrolidine ring
CN Tetrahydropyrrole
CN Tetramethylenimine

FS 3D CONCORD
MF C4 H9 N
CI COM, RPS
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIPPR*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USPAT2, USPATFULL, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Book; Conference; Dissertation; Journal; Patent; Preprint; Report
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); CMBI (Combinatorial study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); CMBI (Combinatorial study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10355 REFERENCES IN FILE CA (1907 TO DATE)
379 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
10379 REFERENCES IN FILE CAPLUS (1907 TO DATE)
60 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 141:419645

REFERENCE 2: 141:411116

REFERENCE 3: 141:410955

REFERENCE 4: 141:410954

REFERENCE 5: 141:410946

REFERENCE 6: 141:410940

REFERENCE 7: 141:410931

REFERENCE 8: 141:410925

REFERENCE 9: 141:410924

REFERENCE 10: 141:410822

L43 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN
RN 109-97-7 REGISTRY
CN 1H-Pyrrole (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Pyrrole (8CI)**
OTHER NAMES:
CN 1-Aza-2,4-cyclopentadiene
CN Azole
CN Divinylenimine
CN Imidole
CN Monopyrrole
CN NSC 62777
CN Pyrrol
FS 3D CONCORD
DR 21995-14-2, 45361-50-0
MF C4 H5 N
CI COM, RPS
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DETHERM*, DIPPR*, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USPAT2, USPATFULL, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Book; Conference; Dissertation; Journal; Patent; Report
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9767 REFERENCES IN FILE CA (1907 TO DATE)

1236 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
9789 REFERENCES IN FILE CAPLUS (1907 TO DATE)
5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 141:416008

REFERENCE 2: 141:414786

REFERENCE 3: 141:414464

REFERENCE 4: 141:413666

REFERENCE 5: 141:411435

REFERENCE 6: 141:411161

REFERENCE 7: 141:411135

REFERENCE 8: 141:410949

REFERENCE 9: 141:410734

REFERENCE 10: 141:410733

=> d his

(FILE 'HOME' ENTERED AT 18:17:29 ON 14 DEC 2004)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 18:20:29 ON 14 DEC 2004
L1 STR
L2 50 S L1
L3 10484 S L1 FUL
SAV TEMP L3 ZINNA617/A
L4 STR L1
L5 28 S L4 SAM SUB=L3
L6 553 S L4 FUL SUB=L3
SAV L6 ZINNA617A/A
L7 STR L4
L8 62 S L7 FUL SUB=L6
SAV L8 ZINNA617B/A
L9 46 S L8 AND 16.136.9/RID
L10 16 S L8 NOT L9
L11 507 S L6 NOT L9
L12 STR L1
L13 488 S L12 FUL SUB=L11
SAV L13 ZINNA617C/A
L14 19 S L11 NOT L13

FILE 'HCAOLD' ENTERED AT 18:25:52 ON 14 DEC 2004
L15 0 S L13

FILE 'HCAPLUS' ENTERED AT 18:25:56 ON 14 DEC 2004
L16 29 S L13
L17 3 S L16 AND (SCHOENAFINGER ? OR SCHONAFINGER ? OR DEFOSSA ? OR DE
L18 3 S L16 AND AVENTI?/PA,CS
L19 3 S L17,L18
L20 26 S L16 NOT L19
L21 25 S L20 AND (PD<=20020712 OR PRD<=20020712 OR AD<=20020712)
SEL HIT RN

FILE 'REGISTRY' ENTERED AT 18:30:27 ON 14 DEC 2004

```
L22          393 S E1-E393
L23              STR L7
L24           21 S L23 SAM SUB=L13
L25          451 S L23 FUL SUB=L13
                 SAV L25 ZINNA617D/A
L26           37 S L13 NOT L25
L27          362 S L25 AND L22

     FILE 'HCAPLUS' ENTERED AT 18:33:47 ON 14 DEC 2004
L28           24 S L27
L29           24 S L28 AND (PD<=20020712 OR PRD<=20020712 OR AD<=20020712)
L30            5 S L27 (L) (THU OR PKT OR PAC OR DMA)/RL
L31            8 S L27 AND (PHARMACEUT? OR PHARMACOL?)/SC,SX
L32            8 S L30,L31
L33            1 S L29 AND ?DIABET?
                 E DIABETES/CT
                 E E3+ALL
L34        83761 S E1+OLD,NT,PFT,RT OR E2+OLD,NT,PFT,RT OR E3+OLD,NT,PFT,RT
L35         4543 S NIDDM
L36            0 S L29 AND L34,L35
L37            8 S L32,L33
L38           16 S L29 NOT L37
L39            0 S L38 NOT AGROCHEM?/SC,SX

     FILE 'REGISTRY' ENTERED AT 18:36:27 ON 14 DEC 2004

     FILE 'HCAPLUS' ENTERED AT 18:36:44 ON 14 DEC 2004

     FILE 'REGISTRY' ENTERED AT 18:39:05 ON 14 DEC 2004

     FILE 'HCAPLUS' ENTERED AT 18:39:29 ON 14 DEC 2004
                 SET SMARTSELECT ON
L40          SEL L19 1- RN :     427 TERMS
                 SET SMARTSELECT OFF

     FILE 'REGISTRY' ENTERED AT 18:39:30 ON 14 DEC 2004
L41           427 S L40
L42            73 S L41 AND L13
L43             2 S PYRROLE/CN OR PYRROLIDINE/CN

=>
```